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1. INTRODUCTION AND BACKGROUND FOR THE 
PROPOSED RESEARCH 
 
1.1 Global impact of HCV infection 
 
Infection by the hepatitis C virus (HCV) is a global health problem (1). Since its 
discovery in 1989, HCV is one of the leading causes of acute and chronic hepatitis, liver 
cirrhosis and hepatocellular carcinoma (2, 3). Up to September 2016, the global 
prevalence of HCV infection was estimated to be between 2–3%, ranging from 1.3% in 
Americas up to 2.9% in Africa (4). According to prevalence estimates based on a 
comprehensive modelling study, the global prevalence of viremic HCV was estimated 
to be 1.0% in 2015, corresponding to 71.1 million (62.5–79.4) people with viremic 
infection (5). It was estimated that HCV caused 86,000 deaths in the World Health 
Organization (WHO) European Region and it was accounted for 35% of cirrhosis and 
32% of liver cancer deaths (6).  
 
HCV infection is unevenly distributed in the world. In the European Union, the 
prevalence of HCV infection among general population varies from 0.1% in the 
Western Europe (Belgium, Ireland, and the Netherlands) to 3.2% in Romania, and going 
up to 5.9% in some HCV hyper-endemic regions in Italy (7). In a number of 
Mediterranean countries, the HCV prevalence is around 3% and well over 10% in some 
regions of Asia and Africa, including Egypt with the highest prevalence of HCV in the 
world, estimated nationally at 14.7% (4, 8).  
 
Infection with HCV most commonly happens through exposure to blood of HCV 
infected person. This could happen through transfusion of blood and its products, 
injecting drug use, hemodialysis, unsafe injection practices and surgical interventions, 
mother-to-fetus transmission, and among those with high-risk sexual behaviors. 
Transmission through sexual intercourse, though, is less likely and most commonly 
occurs among men who have sex with men and among people living with HIV (9).  
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Injection drug use and unsafe health-care procedures were the leading causes of new 
HCV infections, accounting for most of the 1.75 million new infections in 2015 (10).  
 
Globally, 10 million injecting drug users (IDUs) are estimated to be infected with HCV, 
corresponding to a midpoint prevalence of 67% (11). It is estimated that IDUs have 47 
times higher antibodies against hepatitis C virus (anti-HCV) prevalence compared to the 
general population (12). The HCV prevalence among IDUs in the European Union 
countries ranges from 13.8% in Malta to 84.3% in Portugal (6). The prevalence rate of 
HCV infection among IDUs in the USA aged 40–65 years was found to be 43.1%, 
whereas up to 90% of IDUs have been exposed to HCV in the past and 70–85% of those 
are estimated to be chronically infected and able to transmit HCV to others (13–15). 
Anti-HCV screening was positive for 54.6% of clients enrolled in the National 
Methadone Maintaince program in China (16).  In Zanzibar, 33.5% of IDUs were found 
to be infected with HCV, with longer duration of drug injection and older age being 
independently associated with HCV infection (17). 
 
Worldwide HCV prevalence varies also among patients on hemodialysis, ranging from 
1.9% in Slovenia, 3.4% in the Netherlands, 4.7% in Lebanon, 5.6% in Senegal, 6.1% in 
Bejing, China, 7.7% in France, 8.4% in Brazil, 23.7% in Khartum, Sudan, 27.3% in 
Romania, 31.1% in Libya, and up to 60% in Morocco (18–28).  
 
Patients on dialysis were recognized as a high risk group for hepatitis C virus (HCV) 
infection almost immediately after the identification of HCV in 1989. Both transfusional 
and nosocomial transmission of HCV were relatively frequent in dialysis units (29, 30). 
Correlation between HCV infection, blood transfusion and time duration on dialysis was 
noticed more than twenty years ago (31). In addition, higher prevalence in hemodialysis 
than peritoneal dialysis or home hemodialysis, and the highly variable prevalence from 
unit to unit, all suggested that nosocomial transmission has contributed to the high HCV 
prevalence (32).   
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HCV transmission in the hemodialysis environment still remains a substantial problem 
in low-resource countries compared to developed countries in which isolated small-
scale HCV outbreaks in hemodialysis units are reported only occasionally (33–35).  
 
 
1.2 Main features of HCV 
 
HCV is an enveloped, single-stranded, positive-sense RNA virus (36). The virus is a 
member of the Hepacivirus genus in the virus family of Flaviviridae. The HCV genome 
with its 9.6 kb size, encodes a single polyprotein which is cleaved by cellular and viral 
proteases into at least ten different proteins: the structural proteins core, E1, E2, the ion 
channel p7 and the non-structural proteins NS2, NS3, NS4A, NS4B, NS5A, and NS5B 
(37). They act with host proteins to mediate virus entry and to coordinate RNA 
replication and virus production (38). The hepatitis C genome has high genetic 
divergence, and the superfacing E1 and E2 proteins have the most changes (39). Not 
being a DNA virus, hepatitis C virus cannot enter the host genome, therefore does not 
proliferate with DNA; its half-life is around 2.5 hours (40). Genetically diverse variants 
of HCV seem to have circulated for hundreds of years in Central and West sub-Saharan 
Africa and South and South East Asia, where the origin of HCV could be traced (41).  
 
There are 7 genotypes and 67 subtypes of hepatitis C virus (42, 43). In 2014, genotype 7 
of HCV was identfied in four subjects originating from the Democratic Republic of 
Congo (44). It is estimated that HCV genotype 1 is most prevalent worldwide (approx. 
46% of all HCV cases), followed by genotype 3 (with approx. 30%) and genotypes 2, 4, 
and 6 (with approx. 22.8%). HCV genotype 5 comprises less than 1% of global 
prevalence (45). Some subtypes of HCV (1a, 1b, 2a, 2b, and 3a) are widely distributed 
all over the world. Others have a more restricted distribution, such as genotype 4 in the 
Middle East and central Africa, subtype 5a in southern Africa, and genotype 6 in 
Southeast Asia (46). Infections with HCV subtype 1a and 3a have been shown to be 
significantly associated with injecting drugs (47-49). In the Netherlands, among patients 
with HCV subtype 1b, transfusion of blood/blood products was found to be the main 
route of transmission (50).    
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1.3. HCV infection and disease progression 
 
In most cases, acute HCV infection remains without symptoms or with only unspecific 
symptoms such as fatigue, low-grade fever, myalgia or nausea. Jaundice appears only in 
20% to 30% of the cases. On average, 26% of patients with acute hepatitis C infection 
experience spontaneous clearance of the virus, an event that occurs primarily during the 
first 3 months after clinical onset of disease and depends on several host and viral 
factors (51, 52). Individuals may remain asymptomatic for many years in case they fail 
to clear their HCV infection in this manner, entering into chronic infection and facing 
considerable risk of liver disease (53). Regardless of HCV genotype and of viral load, 
hepatic inflammation and fibrosis progression follow chronic infection (54). Death 
related to the complications of cirrhosis may occur, at an incidence of approximately 
4% per year, whereas hepatocellular carcinoma (HCC) occurs in this population at an 
estimated incidence of 1–5% per year (55). Patients diagnosed with HCC have a 33% 
probability of death during the first year (56, 57). 
 
1.4 HCV treatment 
 
Until the introduction of direct acting antivirals (DAAs), the standard of care for HCV 
infection was based on pegylated interferon-α and ribavirin combination therapy (58). 
Currently, combination of DAAs, with/without ribavirin and/or interferon and treatment 
duration depends, in addition to clinical stage of HCV infection, also on HCV genotype 
(59).  
 
Since 2011, the first DAAs, boceprevir and telaprevir, have been approved for use in the 
United States (60). DAAs are molecules that target specific nonstructural proteins of the 
virus, which results in disruption of viral replication and infection. Currently, there are 
four classes of DAAs, which are defined by their mechanism of action and therapeutic 
target. The four classes are: nonstructural proteins 3/4A (NS3/4A) protease inhibitors 
(PIs), NS5B nucleoside polymerase inhibitors (NPIs), NS5B non-nucleoside polymerase 
inhibitors (NNPIs), and NS5A inhibitors (61).  
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Availability of DAAs has transformed HCV treatment, enabling regimens that can be 
administered orally, with shorter duration (as short as eight weeks), resulting in cure 
rates higher than 90%, and being associated with fewer serious adverse events than the 
previous interferon containing regimens (62). 
 
A number of studies have reported a genetic polymorphism near the interleukin (IL) 
28B gene, encoding interferon-λ-3 (IFN-λ-3) associated with an approximately two-fold 
change in response to treatment with pegylated interferon (IFN) and ribavirin among 
patients with chronic hepatitis C, genotype 1 (63–65). Also, IL28B polymorphism 
(rs12979860 CC genotype) was associated with a sustained virological response in 
patients infected with HCV genotype 2 or 3 who did not achieve a rapid virological 
response (66). Therefore, information on the presence of IL28B polymorphism gives 
both patients and clinicians a possibility to make more informed decisions regarding the 
risk-benefit of treatment, raising the likelihood of success for any given individual (67). 
However, this test is not helpful in predicting response to DAA-based therapy, and thus 
is no longer one of the components of the pre-treatment evaluation in countries where 
these drugs are available for patients infected with HCV (62). 
 
 
1.5 Kosovo and HCV infection 
 
Kosovo is a small country (10908 km2) in South Eastern Europe with approximately 1.8 
million people. Administratively, it is divided into 7 regions, among them the Region of 
Prishtina being the largest with 27.5% of the total population (68).  
 
Current information on HCV in Kosovo is scarce. There are no comprehensive data 
available or published on HCV prevalence among the general population, specific 
groups of population, and groups at a higher risk for exposure to HCV or genotype 
distribution among these groups. A few studies, with limited number of study 
participants or with limited geographical coverage for Kosovo, show the prevalence of 
HCV among the general population to be 0.5% – 0.7% (69, 70).  
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Blood donation in Kosovo is based on voluntary (approx. 80%) and family basis 
(approx. 20%), with approximately 23,000 donations per year. All blood donors are 
tested mandatorily on the presence of antibodies against HCV, human 
immunodeficiency virus (HIV), syphilis and hepatitis B surface antigen (HBsAg). 
Laboratory testing is centralized; blood donations given all around Kosovo are being 
tested only at the laboratory of the National Blood Transfusion Center of Kosovo 
(NBTCK) in Prishtina. Data from 70,438 blood donors at the NBTCK in the period 
2000–2003 show the presence of HCV antibodies of 0.29% (71). An unpublished report 
from the NBTCK shows that there were 23,120 blood donations in 2011, of which 
15,099 (65.3%) in Prishtina. There were 73,295 blood donations in Kosovo in the 
period 2011-2013, of which only 29 resulted anti-HCV positive, giving anti-HCV 
prevalence among blood donors of 0.04% (unpublished data from the National Blood 
Transfusion Center of Kosovo). 
 
Labyrinth, a non-governmental organization working with drug users in Kosovo, 
reported an increase of drug use and estimated there were 3,000 IDUs in Kosovo in 
2007, with half of them located in Prishtina. A biological behavioral surveillance study 
among IDUs in Prishtina and Prizren, conducted in 2014, showed anti-HCV prevalence 
of 27% among 300 IDUs in Prishtina and 12% among 199 IDUs in Prizren. The 
programatic mapping and size estimation of key populations in Kosovo with regard to 
HIV program, conducted in 2016, estimated 4,973 IDUs in Kosovo, of which 1,217 
(range 966–1468) or 24.5% were from the municipality of Prishtina (72).  
 
Hemodialysis in Kosovo is provided at 7 regional centers, with approximately 700 
patients, among them 170-180 being located in the Region of Prishtina, Kosovo. A 
study by Telaku et al., based on data from 2008, shows anti-HCV prevalence of 42.9% 
among all Kosovo patients on hemodialysis (73). Also, Quaglio et al. reported anti-
HCV prevalence at Peja dialysis center in 2005 to be 87% (69). 
 
The treatment with pegylated interferon and ribavirin within the public health sector of 
Kosovo started in 2011, and it is still provided in one location only, at the Infectious 
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Disease Clinic, University Clinical Center of Kosovo in Prishtina. DAAs are not 
available through public funding (74). Due to lack of funds, a very limited number of 
people with chronic HCV infection are currently in the treatment program (approx. 10–
15 new cases of HCV chronic patients per year). 
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2. HYPOTHESIS 
 
1. HCV genotypes 1 and 3 are the most prevalent HCV genotypes in the Prishtina 
Region of Kosovo; 
2. Phylogenetic analysis of HCV strains will reveal significant transmission 
clusters within different groups of population living in Prishtina, Kosovo. 
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3. AIMS AND PURPOSE OF THE RESEARCH 
 
GENERAL AIM:  
To determine genetic diversity of hepatitis C virus among different population groups in 
the Prishtina Region of Kosovo. 
 
SPECIFIC AIMS:  
To determine the distribution of HCV genotypes in different groups of population in 
Prishtina, Kosovo; 
To assess IL28B genetic variations in HCV positive patients in Kosovo and their 
relationship to virus clearance outcome. 
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4. MATERIALS AND METHODOLOGY  
 
With the purpose to reach goal of the study and considering the fact that we were 
dealing with different groups of population in Prishtina and overall in Kosovo, 
following approval by the Ethics Board of the Medical Faculty, University of Prishtina 
“Hasan Prishtina” in Kosovo, we have used materials and methodologies described 
below.  
 
4.1 Hemodialysis patients  
 
Blood samples of all 668 dialysis patients at Prishtina dialysis center and all other six 
regional dialysis centers of Kosovo, obtained between January–March 2013, were 
included in the study. We expanded the range of inclusion of dialysis patients beyond 
Prishtina dialysis center with all patients of regional dialysis centers of Kosovo to gain 
the overall picture of HCV infection at dialysis centers of Kosovo and to compare the 
situation in Prishtina dialysis center and other centers in Kosovo. Blood samples were 
initially tested on the presence of antibodies against hepatitis C virus (anti-HCV). The 
anti-HCV testing was conducted at the National Institute of Public Health of Kosovo in 
Prishtina with ELISA anti-HCV test (Axiom, Germany) on ELISA washer 2600 and 
ELISA reader 2100 (Awareness Technologies, USA) following the manufacturers’ 
instructions. Positive anti-HCV samples were further tested for HCV RNA, HCV 
genotype, and HCV NS5B region sequenced for phylogenetic analyses. Additionally, in 
order to better understand the situation with HCV infection at dialysis units in Prishtina 
and overall in Kosovo, we implemented a questionnaire through face-to-face interviews 
with 618 out of 708 dialysis patients undergoing hemodialysis in Kosovo in December 
2015. The questionnaire consisted of questions about the main demographic data of the 
patients undergoing dialysis in Kosovo, their knowledge about HCV, their anti-HCV 
status, the information on possible factors which could have played a role in HCV 
infection, and the information on inclusion within the treatment program. One part of 
the questionnaire was directed towards managers of the dialysis units in Kosovo, with 
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the aim to collect information about the issues related to management of the dialysis 
units.  
 
4.2. Injecting drug users  
 
We used 99 anti-HCV positive serum samples and data collected from interviews with 
205 IDUs within the Biological and Behavioral Surveillance Study (BIOBSS) in the 
Prishtina Region of Kosovo. The BIOBSS was implemented in 2011 under the auspices 
of the Ministry of Health and funded by the Global Fund for AIDS, Tuberculosis and 
Malaria project in Kosovo using respondent-driven sampling methodology but there 
was no HCV genotyping or phylogenetic analysis conducted nor behavioral data 
analyzed with the focus on HCV infection. BIOBSS inclusion criteria were: (a) age 18–
50; (b) fluency in Albanian language; (c) drugs injected at least once in the past month; 
and (d) living and/or working in Prishtina (or having injected drugs regularly for at least 
three months in the past year in Prishtina). Blood samples from IDUs were collected by 
staff of the non-governmental organization 'Labyrinth', at their premises in Prishtina, 
following the study protocol. This organization is known among IDUs since it provides 
on regular basis the methadone substitution therapy and needle exchange program for 
IDUs in the Prishtina Region. All eligible individuals were informed about the nature 
and requirements of the study and asked for informed consent. Following verbal 
consent, participants were interviewed and briefed about the biological testing (pre-test 
counseling). After blood drawing, participants received a primary incentive (10 €) and 
three coupons for peer recruitment. During the second visit, the participants were given 
post-test counseling, during which test results were communicated. A secondary 
incentive was given pending the successful recruitment of other participants (max. 3 x 2 
€). Samples were tested at the Department of Microbiology, National Institute of Public 
Health of Kosovo using HCV Ab Sensitive ELISA test (Dialab, Austria) for the 
presence of antibodies against HCV, following the manufacturer’s instructions as part of 
the initial BIOBSS study. Positive anti-HCV samples were further tested for HCV 
RNA, HCV genotype, and HCV NS5B region sequenced for phylogenetic analyses. The 
behavioral component of the study included a questionnaire on drug use practices, 
sexual behavior, imprisonment and treatment information. 
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4.3. Chronic HCV patients and blood donors 
 
We also included 50 blood samples from chronic HCV patients. As a part of treatment 
monitoring, samples were collected during the months January–June 2013, at the 
Infectious Disease Clinic of the University Clinical Center of Kosovo in Prishtina, the 
only institution that provides treatment to HCV infected patients in Kosovo. Those 
samples were further tested for HCV RNA, HCV genotype, and HCV NS5B region 
sequenced for phylogenetic analyses. Additionally, we implemented a questionnaire 
with 35 out of those 50 HCV chronic patients who agreed to be interviewed. The 
questionnaire included questions similar to the ones used with dialysis patients 
described above. 
 
There were 73,295 blood donations in Kosovo in the period 2011–2013, of which 29 
resulted anti-HCV positive through regular screening of blood for HCV infection at the 
Blood Transfusion Center of Kosovo. Only ten of those anti-HCV positive blood donors 
agreed to participate in the study. Due to the low number of anti-HCV positive blood 
donors agreeing to participate in the study, their data were analyzed in the same section 
with chronic HCV patients. 
 
4.4 Molecular and phylogenetic testing 
 
In total, 514 anti-HCV positive serum samples from all four study groups were further 
tested at the Institute of Microbiology and Immunology, Faculty of Medicine, 
University of Ljubljana, Slovenia, for HCV RNA detection, HCV genotyping, and 
sequencing of NS5B region of HCV for phylogenetic analysis. In addition, 
identification of genetic polymorphism of IL28B was conducted among all study 
groups, except for dialysis patients.  
 
The presence of HCV RNA was tested using COBAS® AmpliPrep/COBAS® 
TaqMan® HCV Qualitative Test, v2.0 (Roche Molecular Diagnostics, France). 
Viral RNA was extracted from 200-400 µl of plasma, using the MagnaPure Compact 
Nucleic Acid Isolation kit (Roche Diagnostics, Germany) on MagNA Pure Compact 
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nucleic acid extraction instrument (Roche Diagnostics, Germany) yielding 50 µl of final 
eluate. The PCR was performed using SuperScriptTM III One-Step RT-PCR System with 
Platinum® Taq High Fidelity (Invitrogen, USA) and primers Sc2/Ac2, as described 
previously (75). If no amplicon was obtained, nested PCR with S7/A5 primers (75) and 
FastStart High Fidelity PCR System (Roche Diagnostics, Germany) was employed. The 
acquired 441 bp or 355 bp amplicons of the core region of HCV genome were purified 
with the addition of enzymes Exonuclease I and FastAP (Thermo Fisher Scientific, 
USA) and sequenced using BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied 
Biosystems, USA) with the nested S7 primer. A BigDyeXTerminator Purification Kit 
(Applied Biosystems) was used for the removal of unincorporated dye terminators from 
the sequencing reactions and after successfully obtaining the sequences on the 3500 
Genetic Analyzer (Applied Biosystems, USA), HCV genotype was determined with the 
NCBI Genotyping tool (76) with the addition of the genotype reference set 2012 of the 
core region retrieved from HCV Sequence Alignments (77), since the default reference 
set, which did not include all subtypes, wrongly subtyped 4d sequences as subtypes 4a, 
1c or 1c/4a.  
 
For the purpose of investigating molecular epidemiology and transmission routes of 
HCV among patients in Kosovo, the NS5B region of the viral genome was sequenced as 
described for the core region. Samples that were determined as subtypes 1a and 1b, 3a 
and 4d were further analyzed with primers A1b/F1b and B1b/E1b for subtypes 1a and 
1b, primers A3a/F3a and B3a/E3a for subtype 3a, and primers 4HCV-OS/4HCV-OA 
and 4HCV-IS/E1B for subtype 4d (78). Separate alignments of the obtained sequences 
of subtype 1a, 1b, 3a, and 4d sequences were made using ClustalW available in the 
BioEdit package (79). Quick neighbor joining tree was created using Mega 5.05 with 
100 bootstrap replicates (80). Major clusters were identified and HCV control sequences 
were selected among GenBank available sequences, found most similar to the clustered 
sequences and also other more divergent sequences from Kosovo by employing HCV 
BLAST search tool (81–83). Find Best DNA/Protein Models tool in Mega 5.05 (80) 
was employed for the selection of the best fitted evolutionary model. Finally, maximum 
likelihood phylogenetic trees were constructed using PhyML 3.0 (84) and obtained 
phylogeny viewed with FigTree v1.4.3. Transmission clusters were identified according 
to approximate likelihood ratio test (aLRT) branch support values obtained. 
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The HCV positive samples were tested for the presence of IL28 polymorphism with 
LightMix kit IL28B (TIB MOLBIOL, Germany) and LightCycler® FastStart DNA 
Master HybProbe version 15 (Roche Diagnostics, Germany) on LightCycler® 480 
Instrument (Roche), following the manufacturers’ instructions.  
 
 
4.5. Statistical analysis 
 
The statistical analyses were performed using SPSS software, version 17.0. Data 
obtained from questionnaires were analyzed with the main focus on factors that could 
have had an impact on HCV infection. 
 
Data are expressed as mean±SD, median and inter-quartile range, or frequencies, as 
appropriate. Differences between subgroups were assessed by χ2 (chi-squared) test, 
Fisher’s exact test, Student’s t-test and Analysis of Variance test. The Backward 
Poisson regression was used to assess the independent effect of a variable, and the 
prevalence ratios and their respective robust 95% confidence intervals were calculated. 
The Wald test was used as a statistical test.  
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5. RESULTS 
5.1 HCV INFECTION AMONG DIALYSIS PATIENTS IN 
PRISHTINA AND OVERALL IN KOSOVO 
5.1.1 Anti-HCV prevalence, HCV genotypes and phylogenetic analysis 
among dialysis patients  
 
The study results showed that the mean prevalence of the antibodies against HCV (anti-
HCV positive) in patients on dialysis in Kosovo was 53%. Prishtina dialysis center had 
the lowest anti-HCV prevalence (22.3%) among all dialysis centers of Kosovo. The 
highest percentage of anti-HCV positive patients on dialysis was recorded in Gjakova 
(91.1%), followed by Prizren, Peja, and Mitrovica, with very similar percentages 
(68.7%, 68.0%, and 67.6%, respectively). Almost half of the dialysis patients in Gjilan 
(49.4%) where anti-HCV positive as well as one third of patients at dialysis centers in 
Ferizaj (33.3%) (Table 1).  
 
Table 1. Prevalence of antibodies against HCV among patients at dialysis centers 
of Kosovo in 2013 
Dialysis center Patients 
(n) 
Anti-HCV positive 
(n) 
Anti-HCV 
positivity (%) 
Prishtina 188 42 22.3 
Mitrovica  68 46 67.6 
Peja  75 51 68.0 
Prizren 163 112 68.7 
Ferizaj 39 13 33.3 
Gjilan  79 39 49.4 
Gjakova 56 51 91.1 
Total  668 354 53.0 
 
The core region of HCV genome was detected among 275/354 (77.7%) anti-HCV 
positive dialysis patients in Kosovo. The highest percentage was observed among 
samples of Gjakova patients with 86.3%, followed by Gjilan patients with 84.6%. Very 
similar percentages of HCV core positive were detected among dialysis patients at 
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Prishtina, Prizren, Peja, and Mitrovica dialysis centers (76.2%, 77.7%, 80.4%, and 
71.7%, respectively). The lowest percentage was found among anti-HCV positive 
patients at dialysis center in Ferizaj (38.5%) (Table 2).  
 
Table 2. Anti-HCV positive patients at dialysis centers of Kosovo with presence of 
HCV core region and NS5B sequencing 
Dialysis center Anti-HCVpositive 
n 
HCV core positive  
n (%) 
NS5B sequenced 
n (%) 
Prishtina 42 32 (76.2%) 29 (90.6%) 
Mitrovica  46 33 (71.7%) 31 (93.9%) 
Peja  51 41 (80.4%) 40 (97.6%) 
Prizren 112 87 (77.7%) 80 (92.0%) 
Ferizaj 13 5 (38.5%) 5 (100%) 
Gjilan  39 33 (84.6%) 30 (90.9%) 
Gjakova  51 44 (86.3%) 42 (95.5%) 
Total  354 275 (77.7%) 257 (93.5%) 
 
The HCV genotype was determined in 275 out of the total of 354 anti-HCV positive 
dialysis patients in Kosovo (Table 3). 
 
The results showed that subtype 1a was the most frequent among patients on dialysis in 
Kosovo, with 62.2%; with the greatest frequency of occurrence at Ferizaj dialysis center 
(100%), followed by Gjakova (79.5%), Gjilan (78.8%), Mitrovica (75.8%), Prizren 
(63.2%), Prishtina (46.9%), and the lowest percentages of samples with subtype 1a were 
detected at Peja dialysis center (24.4%). 
 
HCV subtype 4d was the second most frequent genotype among HCV patients at 
dialysis centers of Kosovo, with 33.1%. The frequency of occurrence of this subtype at 
the dialysis centers was: 73.2% in Peja, 43.8% in Prishtina, 34.5% in Prizren, 21.2% in 
Mitrovica. The lowest percentages of HCV subtype 4d were registered in Gjakova and 
Gjilan with 18.2% and 6.1%, respectively. HCV  subtype 4d was not registered at 
Ferizaj dialysis center. 
There were 10 samples with HCV subtype 1b, four in Gjilan (12.1%), followed by three 
(9.4%) in Prishtina, and one at each of the centers of Mitrovica, Peja, Prizren, and 
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Gjakova. Additionally, two patients had HCV genotype 2, one from Gjilan and one 
from Prizren (Table 3).  
 
Table 3. HCV genotypes among patients at dialysis centers in Kosovo 
Region HCV genotype 
Number of 
genotyped 
n 
1a 
n (%) 
1b 
n (%) 
2 
n (%) 
4d 
n (%) 
Prishtina 32 15 (46.9) 3 (9.4) 0  14 (43.8) 
Mitrovica  33 25 (75.8) 1 (3.0) 0 7 (21.2) 
Peja  41 10 (24.4) 1 (2.4) 0 30 (73.2) 
Prizren 87 55 (63.2) 1 (1.1) 1 (1.1) 30 (34.5)   
Ferizaj 5 5 (100) 0 0 0 
Gjilan  33 26 (78.8)   4 (12.1) 1 (3.0) 2 (6.1) 
Gjakova  44 35 (79.5) 1 (2.3) 0 8 (18.2) 
Total  275 171 (62.2) 11 (4.0) 2 (0.7) 91 (33.1) 
 
Out of 275 anti-HCV positive patients with sequenced HCV core region, we were able 
to obtain HCV NS5B region from 257 (93.5%) (Table 2). We obtained the following 
number of NS5B sequences: 162 sequences of subtype 1a (63.0%), 84 of subtype 4d 
(32.8%), and 11 of subtype 1b (4.3%) (Table 4). 
 
Table 4. NS5B sequenced samples by dialysis center and HCV genotype 
Region Number of NS5B sequenced samples by HCV genotype 
Number of 
NS5B 
sequences 
n 
1a 
n (%) 
1b 
n (%) 
4d 
n (%) 
Prishtina 29 14 (48.3) 3 (10.3) 12 (41.4) 
Mitrovica  31 25 (80.6) 1 (3.2) 5 (16.1) 
Peja  40 9 (22.5) 1 (2.5) 30 (75.0) 
Prizren 80 51 (63,8) 1 (1.3) 28 (35.0) 
Ferizaj 5 5 (100.0) 0 0 
Gjilan  30 24 (80.0) 4 (13.3) 2 (6.7) 
Gjakova  42 34 (81.0) 1 (2.4) 7 (16.7) 
Total  257 162 (63.0) 11 (4.3) 84 (32.7) 
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The cladogram phylogenetic tree of the sequences gained from the NS5B region of the 
HCV subtypes 1a, 1b and 4d isolates from dialysis units in Kosovo showed a number of 
clusters which were mainly related to specific dialysis centers where dialysis patients 
had utilized the services.  
 
Phylogenetic tree developed by the dialysis sample sequences of HCV subtype 1a 
showed three large clusters with aLRT>0.9. In the largest cluster (with aLRT>0.9) were 
74 dialysis samples (74/162; 45.7%), of which 5 were from Prishtina dialysis center, 29 
from Prizren, 25 from Gjakova, 8 from Peja, 4 sample sequences from Mitrovica 
dialysis center, and 3 from Gjilan. The second cluster (with aLRT>0.9) included 46 
dialysis samples (46/162; 28.4%), of which 3 were from Prishtina dialysis center, 21 
from Mitrovica, 20 from Prizren, 1 from Gjakova, and 1 from Gjilan dialysis center. 
The third cluster of dialysis samples with aLRT>0.9 inside cladogram of HCV subtype 
1a consisted of 22 samples (22/162; 13.6%), of which 5 were from Prishtina dialysis 
center, 15 from Gjilan, and 2 from Ferizaj (Fig. 1).  In general, all dialysis samples 
(100%) with HCV subtype 1a showed phylogenetic clustering with aLRT>0.9. 
 
With regard to cladogram phylogenetic tree of the HCV isolates with subtype 1b at 
dialysis centers of Kosovo (n=11), there was one cluster of sample sequences with 
aLRT>0.9 consisted of 7 samples (7/11; 63.6%), of which 3 were from Prishtina 
dialysis center, 2 from Gjilan, and 1 from Prizren and Gjakova dialysis centers (Fig. 2). 
Almost 2/3 (63.6%) of sample sequences from dialysis patients with HCV subtype 1b 
showed phylogenetic clustering. 
 
Phylogenetic tree developed by the NS5B sequences of the HCV subtype 4d isolated 
from dialysis patients showed three clusters with aLRT>0.9, 2 clusters with aLRT >0.8, 
and three clusters with aLRT<0.8. The largest cluster with aLRT>0.9 consisted of 13 
sample sequences (13/84; 15.5%), of which 11 were from Peja, 1 from Prishtina, and 1 
from Prizren dialysis center. The second cluster with aLRT>0.9 consisted of 11 sample 
sequences from Prizren dialysis center (11/84; 13.1%). The third cluster with 
aLRT>0.9, as part of the sample sequences from HCV subtype 4d, also consisted of 6 
samples from Prizren dialysis center (6/84; 9.5%). Those sequences were part of a 
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larger cluster with aLRT>0.8, which additionally included 20 sample sequences from 
dialysis patients (20/84; 23.8%). Among them 9 were from Prishtina dialysis center, 2 
from Gjilan, 4 from Prizren, and 5 from Mitrovica dialysis center. The second cluster 
with aLRT>0.8, as part of this cladogram, consisted of 15 dialysis samples (15/84; 
17.8%), of which 6 were from Prizren, 5 from Peja, and 4 from Gjakova dialysis center 
(Fig. 3). In fact, 77.4% (65/84) of sample sequences from dialysis patients with HCV 
subtype 4d showed phylogenetic clustering with aLRT>0.8. If we add to this calculation 
also the samples with aLRT<0.8, then we have 96.4% (81/84) of sample sequences of 
HCV subtype 4d showing phylogenetic clustering. 
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Figure 1. The maximum likelihood phylogenetic tree of HCV subtype 1a. Sequences 
from different groups (including different dialysis centers) are colored differently. 
Clusters with aLRT>0.9 are highlighted in green and clusters with aLRT>0.8 are 
highlighted in yellow. 
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Figure 2. The maximum likelihood phylogenetic tree of HCV subtype 1b. Sequences 
from different groups (including different dialysis centers) are colored differently. 
Clusters with aLRT>0.9 are highlighted in green and clusters with aLRT>0.8 are 
highlighted in yellow. 
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Figure 3. The maximum likelihood phylogenetic tree of HCV subtype 4d. Sequences 
from different groups (including different dialysis centers) are colored differently. 
Clusters with aLRT>0.9 are highlighted in green and clusters with aLRT>0.8 are 
highlighted in yellow. 
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5.1.2 Results from interviews with dialysis patients 
 
Out of a total of 708 patients on dialysis at the dialysis centers in Kosovo in December 
2015, 618 (87.2%) agreed to be interviewed and to participate in this study. Among 
them, 477 (77.1%) had been subjects of the initial study conducted in 2013. 
Distribution of the examinees by regional dialysis centers showed that most patients 
were from Prishtina and Prizren dialysis centers (27% and 24.8%, respectively) (Fig. 4). 
 
Figure 4. Distribution of dialysis patients by dialysis center in Kosovo 
 
 
 
5.1.2.1 Socio-demographic data of dialysis patients in Kosovo 
 
Among the study population, there were 299 (48.4%) females and 319 (51.6%) males, 
with a mean age of 57.7 ± 12.6 years (minimum age 20 years, maximum age 84 years). 
Most patients were aged 50–59 years, with 178 (28.8%) patients, and 60–69 years, with 
180 (29.1%) patients. There were 52 patients aged up to 39 years (8.4%). As for marital 
status, married patients dominated – 508 (83.2%). As for educational level, there were 
96 (15.5%) patients without formal education, 245 (39.6%) with primary education, 200 
(32.3%) with secondary education, and the lowest number of patients with higher 
education – 60 (9.7%).  
 
Among the study population, there were only 9 (1.5%) health workers, more than 50% 
of the examinees were unemployed – 337 (54.5%), and 212 (34.%) had a status of 
retired persons (Table 5).  
Total; examinees 
N = 618 
Mitrovica 
N= 63 (10.2%) 
Prishtina 
N= 167 (27%) 
 
Peja 
N= 78 (12.6%) 
Prizren 
N= 153 (24.8%) 
Ferizaj 
N= 45 (7.3%) 
Gjilan 
N= 48 (7.8%) 
Gjakova 
N= 64 (10.4%) 
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Table 5. Demographic characteristics of dialysis patients in Kosovo 
Variable N (%) 
Gender female 299 (48.4) 
male 319 (51.6) 
 
 
Age group 
 ≤ 39 52 (8.4) 
40 – 49 96 (15.5) 
50 – 59 178 (28.8) 
60 – 69 180 (29.1) 
70 > 112 (18.1) 
 
 
Marital 
status 
single 49 (7.9) 
engaged 1 (0.2) 
married 508 (82.2) 
widow/er 59 (9.5) 
divorced 1 (0.2) 
 
 
Education 
no formal education 96 (15.5) 
primary school 245 (39.6) 
secondary school 200 (32.4) 
university 60 (9.7) 
other 17 (2.8) 
 
 
 
 
Occupation 
housewife 257 (41.6) 
farmer 76 (12.3) 
physical worker 55 (8.9) 
teacher 29 (4.7) 
engineer 6 (0.9) 
economist 17 (2.8) 
lawyer 6 (0.9) 
health worker 9 (1.5) 
other 163 (26.4) 
 
 
Employment 
unemployed 337 (54.5) 
employed in public sector 38 (6.1) 
employed in private sector 28 (4.5) 
employed in public sector, private sector 1 (0.2) 
retired 212 (34.3) 
missing 2 (0.3) 
 
The gender structure at dialysis centers showed the highest numbers of females at 
Ferizaj (60%) dialysis center followed by the centers in Mitrovica, Gjakova, Prishtina, 
and Gjilan (55.6%, 53.1%, 52.1%, and 52.1%, respectively). In both regional centers, 
 - 25 - 
Peja and Prizren, male patients were in majority (56.4% and 62.8%, respectively) (Table 
6). 
 
Table 6. Distribution of patients at dialysis centers by gender  
Dialysis center Gender 
female n (%) male n (%) 
Prishtina               n = 167 87 (52.1) 80 (47.9) 
Mitrovica              n = 63 35 (55.6) 28 (44.4) 
Peja                       n = 78 34 (43.6) 44 (56.4) 
Prizren                  n = 153 57 (37.3) 96 (62.7) 
Ferizaj                   n = 45                27 (60.0)                18 (40.0) 
Gjilan                    n = 48 25 (52.1) 23 (47.9) 
Gjakova                n = 64 34 (53.1) 30 (46.9) 
Total                     N = 618 299 (48.4)              319 (51.6) 
 
The average age was the lowest in the group of patients from Mitrovica (56.2 ± 12.6 
years) and Prizren (56.2 ± 13.1 years) dialysis center, whereas patients from Ferizaj 
were the oldest, on average (62.4 ± 8.5 years). Age of Prishtina dialysis patients was 
similar to average age of dialysis patients in Kosovo (57.4 vs 57.7 years) (Table 7a). 
 
Table 7a. Distribution of dialysis patients by age 
Dialysis center Age group (years) Age 
(mean ± SD; 
min–max) 
Up to 59 
n (%) 
60 or older 
n (%) 
Prishtina 88 (52.7) 79 (47.3) 57.4 ± 14.3 (20–83) 
Mitrovica 34 (54.0) 29 (46.0) 56.2 ± 12.6 (23–80) 
Peja 39 (50.0) 39 (50.0) 58.9 ± 11.6 (27–84) 
Prizren 92 (60.1) 61 (39.6) 56.2 ± 13.1 (23–81) 
Ferizaj 15 (33.3) 30 (66.7) 62.4 ±   8.5 (41–79) 
Gjilan 25 (52.1) 23 (47.9) 58.5 ± 11.9 (27–78) 
Gjakova 33 (51.6) 31 (48.4) 58.6 ±   9.9 (29–80) 
Total 326 (52.8) 292 (47.2) 57.7 ± 12.6 (20–84) 
 
For study purposes, we divided patients from dialysis centers into 5 age groups: (1) up 
to 39 years; (2) 40 to 49 years; (3) 50 to 59 years; (4) 60 to 69 years; and (5) 70 years 
and older. 
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There were no patients in the youngest age group at Ferizaj dialysis center, while the 
greatest percentage of patients in this category (13.2%) was observed at Prishtina 
dialysis center. The lowest percentage of patients in age group 40 to 49 years was 
observed at Ferizaj dialysis center (6.7%), and the highest (22.2%) at Prizren dialysis 
center; the lowest percentage of patients in age group 50 to 59 years was observed at 
dialysis centers in Ferizaj and Mitrovica (26.8% and 27%, respectively), and the highest 
at Gjilan dialysis center (35.4%). The lowest percentage of patients in age group 60 to 
69 years was found at Prizren dialysis center (21.6%), and the highest at Ferizaj center 
(46.7%). The lowest percentage of patients in the oldest age group was found among 
dialysis patients in Gjakova (10.9%), and the highest in Prishtina (22.2%) (Table 7b).    
 
Table 7b. Distribution of dialysis patients by specific age groups 
Dialysis 
center 
Age group (years) 
≤ 39 
n (%) 
40 – 49 
n (%) 
50 – 59 
n (%) 
60 – 69 
n (%) 
>70  
n (%) 
Prishtina 22 (13.2) 20 (12.0) 46 (27.5) 42 (25.1) 37 (22.2) 
Mitrovica 6 (9.5) 11 (17.5) 17 (27.0) 20 (31.7) 9 (14.3) 
Peja 4 (5.1) 11 (14.1) 24 (30.8) 26 (33.3) 13 (16.7) 
Prizren 14 (9.2) 34 (22.2) 44 (28.8) 33 (21.6) 28 (18.3) 
Ferizaj 0 3 (6.7)    12 (26.7) 21 (46.7) 9 (20.0) 
Gjilan 4 (8.3) 4 (8.3) 17 (35.4) 14 (29.2) 9 (18.8) 
Gjakova 2 (3.1) 13 (20.3) 18 (28.1) 24 (37.5) 7 (10.9) 
Total 52 (8.4) 96 (15.5) 178 (28.8) 180 (29.1) 112 (18.1) 
 
All 45 patients at Ferizaj dialysis center were married, as well as most patients at other 
regional dialysis centers (Table 8).  
 
Table 8. Distribution of patients at dialysis centers by marital status 
Dialysis 
center 
Marital status 
single 
n (%) 
engaged 
n (%) 
married 
n (%) 
widow/er 
n (%) 
divorced 
n (%) 
Prishtina 17 (10.2) 0 139 (83.2) 11 (6.6) 0 
Mitrovica 3 (4.8) 1 (1.6) 55 (87.3) 4 (6.3) 0 
Peja 7 (9.0) 0 59 (75.6) 12 (15.4) 0 
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Prizren 15 (9.8) 0 118 (77.1) 19 (12.4) 1 (0.7) 
Ferizaj 0 0 45 (100) 0 0 
Gjilan 4 (8.3) 0 36 (75.0) 8 (16.7) 0 
Gjakova 3 (4.7) 0 56 (87.5) 5 (7.8) 0 
Total 49 (7.9) 1 (0.2) 508  (82.2) 59 (9.5) 1 (0.2) 
 
The highest percentage of patients without formal education was observed at Ferizaj 
center (26.7%), with primary education in Prizren (52.3%), with completed secondary 
education in Prishtina (37.7%), and with higher education at Peja dialysis center 
(17.9%) (Table 9). 
 
Table 9. Distribution of patients at dialysis centers by educational level 
Dialysis 
center 
Educational level 
no formal 
education 
n (%) 
primary 
school 
n (%) 
secondary 
school 
n (%) 
university 
n (%) 
other 
n (%) 
Prishtina 32 (19.2) 50 (29.9) 63 (37.7) 19 (11.4) 3 (1.8) 
Mitrovica 12 (19.0) 23 (36.5) 17 (27.0) 8 (12.7) 3 (4.8) 
Peja 11 (14.1) 30 (38.5) 21 (26.9) 14 (17.9) 2 (2.6) 
Prizren 12 (7.8) 80 (52.3) 53 (34.6) 6 (3.9) 2 (1.3) 
Ferizaj 12 (26.7) 16 (35.6) 15 (33.3) 2 (4.4) 0 
Gjilan 4 (8.3) 20 (41.7) 14 (29.2) 3 (6.3) 7 (14.6) 
Gjakova 13 (20.3) 26 (40.6) 17 (26.6) 8 (12.5) 0 
Total 96 (15.5) 245 (39.6) 200 (32.4) 60 (9.7) 17 (2.8) 
 
The regional distribution by patients’ occupation showed a great number of housewives 
at all centers. Out of 9 health workers who participated in the study, 5 were from 
Prishtina, 2 from Mitrovica, and 1 health worker from Peja and Gjakova each (Table 
10). 
Table 10. Distribution of patients at dialysis centers by occupation 
Dialysis 
centre 
Occupation 
Housewife  
n (%) 
Farmer      
n (%) 
Physical 
worker        
n (%)  
Teacher    
n (%) 
Engineer   
n (%)  
Economist  
n (%) 
Lawyer       
n (%) 
Health 
worker      
n (%) 
Other        
n (%) 
Prishtina 75 (44.9) 9 (5.4) 8 (4.8) 10 
(6.0) 
2 (1.2) 6 (3.6) 3 (1.8) 5 (3.0) 49 
(29.3) 
Mitrovica 32 (50.8) 8 
(12.7) 
0 0 1(1.6) 2 (3.2.) 0 2 (3.2) 18 
(28.6) 
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Peja 28 (35.9) 13 
(16.7) 
7 (9.0) 9 
(11.5) 
2 (2.6) 2 (2.6) 1 (1.3) 1 (1.3) 15 
(19.2) 
Prizren 54 (35.3) 27 
(17.6) 
22 
(14.4) 
5 (3.3) 0 0 2 (1.3) 0 43 
(28.1) 
Ferizaj 25 (55.6) 8 
(17.8) 
10 
(22.2) 
2 (4.4) 0 0 0 0 0 
Gjilan 20 (41.7) 7 
(14.6) 
2 (4.2.) 1 (2.1.) 0 3 (6.2) 0 0 15 
(31.2) 
Gjakova 23 (35.9) 4 (6.2) 6 (9.4) 2 (3.1.) 1 (1.6) 4 (6.3) 0 1 (1.6) 23 
(35.9) 
Total 257 76 55 29 6 17 6 9 163 
 
As for employment status, the lowest percentage of the unemployed was observed in 
Peja (39.5%), the highest in Mitrovica (69.8%). There were no patients employed in 
public and private sectors at Ferizaj dialysis center; the greatest percentage of the 
employed in public sector were from Peja (9.2%), and in the private sector from Gjilan 
(8.3%). The lowest percentage of the retired patients was found in Mitrovica (19.0%) 
and the greatest in Ferizaj (60.0%) (Table 11).   
 
Table 11. Distribution of patients at dialysis centers by employment 
Dialysis 
center 
Employment status 
Unemployed 
n (%) 
Employed in 
public sector  
n (%) 
Employed in 
private sector  
n (%) 
Retired 
n (%) 
Prishtina 90 (54.2) 12 (7.2) 8 (4.8) 56 (33.7) 
Mitrovica 44 (69.8) 5 (7.9) 2 (3.2) 12 (19.0) 
Peja 30 (39.5) 7 (9.2) 5 (6.6) 34 (44.7) 
Prizren 94 (61.4) 7 (4.6) 7 (4.6) 45 (29.4) 
Ferizaj 18 (40.0) 0 0 27 (60.0) 
Gjilan 24 (50.0) 4 (8.3) 4 (8.3) 16 (33.3) 
Gjakova 37 (57.8) 3 (4.7) 2 (3.1) 22 (34.4) 
Total 337 (54.8) 38 (6.2) 28 (4.5) 212 (34.5) 
 
Among the patients having antibodies against HCV, 52.5% were females, 78.7% had a 
partner (wife/husband), the majority (43.4%) had primary education, 2.0% were  health 
workers, 61.5% were unemployed at the time of the study implementation, 57.0% were 
younger than 59 years. 
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Female patients on dialysis had non-significantly higher prevalence of antibodies 
against HCV compared to males (42.8% vs 36.4%). 
 
The prevalence of antibodies against HCV of 42.6% was observed in the age group of 
patients up to 59 years, and it was non-significantly higher than in the group of patients 
older than 60 years, among whom 36.0% had antibodies against HCV. As for 
distribution by age groups: the prevalence of anti-HCV antibodies was 51.9% in the 
group of patients up to 39 years of age, 41.7% in the age group 40 to 49 years, 40.4% in 
the age group 50 to 59 years, 38.9% in the age group 60 to 69 years, and 31.2% in the 
group of patients aged 70 years and older. Statistically significant difference in the 
prevalence of anti HCV antibodies among the analyzed age groups (p=0.15) was not 
found.  
 
In the groups of patients with and without a partner, the prevalence of antibodies against 
HCV differed non-significantly (47.7% and 37.7%, respectively). 
 
Patients with different educational levels had non-significantly different prevalence of 
antibodies against HCV (p=0.3). The highest percentage of HCV positive patients was 
recorded among those with completed primary education (43.4%).  
 
Patient's occupation was significantly correlated with the prevalence of antibodies 
against HCV (p=0.047). The presence of antibodies against HCV was found in 5 
(55.6%) out of 9 health workers. The lowest prevalence of antibodies was found in the 
group of patients with higher education (teachers, lawyers, engineers, economists) at 
34.5%.  
 
The prevalence of antibodies against HCV significantly correlated with the employment 
status of patients on dialysis. The percentage of HCV positive patients was 44.5%, 
34.3%, and 33.5%, in the groups of unemployed, employed and retired, respectively 
(Table 12). 
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Table 12. Demographic data of anti-HCV positive dialysis patients in Kosovo  
Variable anti-HCV 
positive 
n (%) 
% of 
positivity 
p-value 
Gender female 128 (52.5%) 42.8 0.1 
male 116 (47.5%) 36.4 
 
Age group 
≤ 59 139 (57.0%) 42.6 0.09 
60 > 105 (43.0%) 36.0 
Age group 
≤ 39 27 (11.1%) 51.9 
0.15 
40 – 49 40 (16.4%) 41.7 
50 – 59 72 (29.5%) 40.4 
60 – 69 70 (28.7%) 38.9 
70 > 35 (14.3%) 31.2 
 
Marital 
status 
without partner 52 (21.3%) 47.7 
0.4 with partner 192 (78.7%) 37.7 
 
 
Education 
no formal education  41 (16.8%) 42.7 
0.3 
primary school 106 (43.4%) 43.3 
secondary school   70 (28.7%) 35.0 
university 22 (9.0%) 36.7 
other  5 (2.0%) 29.4 
 
 
Occupation 
housewife 113 (46.3%) 44.0 
0.047* 
farmer 29 (11.9%)  38.2 
physical worker 27 (11.1%) 49.1 
teacher, engineer, 
economist, lawyer 
20 (8.2%) 34.5 
health worker 5 (2.0%) 55.6 
other 50 (20.5%) 30.7 
 
Employment 
unemployed 150 (61.5%) 44.5 0.024* 
employed  23 (9.4%)  34.3 
retired 71 (29.1%) 33.5 
p (Chi-square)    *p<0.05 
 
 
 
5.1.2.2 Knowledge about HCV among dialysis patients in Kosovo 
 
Results of this study showed that the anti-HCV positive patients on dialysis significantly 
more frequently heard about HCV infection than the anti-HCV negative patients 
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(p=0.001). Almost 65% of HCV positive patients heard about HCV infection vs. half of 
HCV negative patients. 
 
The HCV infected and the noninfected patients on dialysis significantly differed in 
knowledge about HCV spread (p=0.02). Affirmative response to the question 'Do you 
know how the HCV is spread?' was given by 65.7% of HCV positive patients compared 
to 51.5% of HCV negative patients, and negative response by 18.6% of HCV positive 
versus 27% of HCV negative patients.  
 
Surprisingly, 41.4% of laboratory confirmed HCV cases, responded 'No' to the question 
if they had been diagnosed with HCV, and in the same group 11.9% answered 'Don’t 
know'. In addition, 7.5% of HCV negative patients said they were HCV positive.  
 
Affirmative response to the question 'Have you ever had skin jaundice?' was given by 
36.6% of HCV positive and 9.8% of HCV negative patients, and negative response by 
59.3% of HCV positive and 89.6% of HCV negative patients, while 4.1% of HCV 
positive and 0.5% of HCV negative patients did not know if such a situation happened 
to them. The difference in the distribution of responses between HCV positive and HCV 
negative patients with regard to this variable was shown to be statistically significant 
(p<0.0001). 
 
Family history revealed family members infected with HCV among 10.2% of HCV 
positive and 8.0% of HCV negative patients. The HCV positive and negative patients on 
dialysis gave non-significantly different information for family history with HCV 
(p=0.17) (Table 13). Information on HCV infection of a mother or a father was given by 
8 HCV positive and 5 HCV negative patients, of a wife or a husband by 2 HCV positive 
and 3 HCV negative patients, of a daughter or a son by 4 HCV positive and 10 HCV 
negative patients, of a brother or a sister by 5 HCV positive and 6 HCV negative 
patients. 
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Table 13. Knowledge of HCV positive and HCV negative patients about HCV 
Variable HCV positive 
n (%) 
HCV negative 
n (%) 
p-value 
Heard about hepatitis C virus 
Yes   n = 348 158 (64.8) 190 (50.8) 0. 001 
yes vs no  0.0003 No    n = 256   79 (32.4) 177 (47.3) 
Don`t know  n = 14  7 (2.9) 7 (1.9) 
Knew how hepatitis C virus is spread 
Yes   n = 216 113 (65.7) 103 (51.5) 0.02 
yes vs no  0.018 
yes vs don`t know  0.046 
No    n = 86 32 (18.6) 54 (27.0) 
Don`t know  n = 70 27 (15.7) 43 (21.5) 
Missing      n = 246 72 174 
Diagnosed with hepatitis C infection 
Yes    n = 142 114 (46.7) 28 (7.5) < 0.0001 
yes vs no  < 0.0001 
yes vs don`t know  
0.000003 
No     n = 415 101 (41.4) 314 (84.0) 
Don`t know  n = 61 29 (11.9) 32 (8.5) 
Skin jaundice 
Yes   n = 125 89 (36.6) 36 (9.8) < 0.0001 
yes vs no  < 0.0001 
yes vs don`t know  0.0001 
No     n = 473 144 (59.3) 329 (89.6) 
Don`t know  n =12 10 (4.1) 2 (0.5) 
Missing         n = 8 1 7 
Family members infected with hepatitis C virus 
Yes   n = 55 25 (10.2) 30 (8.0)  
0.17 No     n = 544 215 (88.1) 329 (88.0) 
Don`t know  n =19 4 (1.6) 15 (4.0) 
p (Chi-square test) 
 
Information on the time when HCV infection was diagnosed was given by 112 patients 
on dialysis. Diagnosis of HCV infection had been established in those patients, on 
average, 8.7 ± 11.3 years earlier (Fig. 5). 
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Figure 5. Distribution of anti-HCV positive dialysis patients by year of infection 
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5.1.2.3 Risk factors for HCV infection among dialysis patients in 
Kosovo 
 
5.1.2.3.1 Blood transfusion as a risk factor for HCV infection 
 
Patients on dialysis infected with HCV had received blood transfusion significantly 
more frequently compared to the noninfected ones (p<0.0001). The percentage of 
patients on dialysis who had received blood was 87.3% in the group of HCV positive 
and 70.3% in the group of HCV negative patients.  
The University Clinical Center of Kosovo in Prishtina was the most frequent health 
institution where the dialysis patients from Kosovo had received blood transfusion 
(Table 14).   
 
Table 14. Results of questionnaire about blood transfusion  
Variable HCV positive 
n (%) 
HCV negative 
n (%) 
p-value 
Blood transfusion 
Yes    n = 476 213 (87.3) 263 (70.3)  
0.000001 No     n = 142  31 (12.7) 111 (29.7) 
Medical institution(s) where blood transfusion was performed 
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University Clinical Center of 
Kosovo  
n = 198 
80 (37.6) 118 (44.9)   
Regional hospital  n = 164 67 (31.4) 97 (36.9)  
Private hospital     n = 1 0 1 (0.4) 
Other                      n = 27 16 (6.6) 11 (4.2)  
University Clinical Center of 
Kosovo,  
Regional hospital     n = 78 
43 (20.2) 35 (13.3) 
Regional hospital, Other   n = 8 7 (3.3) 1 (0.4) 
p (Chi-square test) 
 
The number of blood transfusions received was significantly greater in the group of 
HCV positive patients vs. HCV negative patients (p=0.0013). Maximum number of 
blood transfusions received was 50 in the group of HCV positive, and 20 in the group of 
HCV negative patients. The average number of blood transfusions received in the HCV 
infected group was 4 (rank 2–6), and 3 in the noninfected group (rank 2–4) (Fig. 6). 
 
Figure 6. Number of blood transfusions 
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Significant difference in the time of the first blood transfusion (p<0.0001) was observed 
between HCV infected and noninfected patients. HCV positive patients had their first 
blood transfusion earlier, on average 9.6 ± 7.6 years, compared to HCV negative 
patients, with 5.1 ± 6.5 years on average (rank 2–6) (Table 15). 
 - 35 - 
 
Table 15. Year of first blood transfusion  
Anti-HCV test 
result 
N Year of first blood transfusion 
mean ± SD min - max median (IQR) 
HCV positive 203 9.6 ± 7.6 1 - 50 7 (4 – 14) 
HCV negative 248 5.1 ± 6.5 1 - 45 3 (2 – 6) 
  p < 0.0001 
p (Mann-Whitney U test) 
 
 
5.1.2.3.2 Dental services as a risk factor for HCV infection  
 
The anti-HCV positive patients on dialysis used non-significantly more frequently 
dental services than the anti-HCV negative patients (p=0.36). Most patients in both 
groups had dental interventions (85.7% and 82.9%, respectively). The type of dental 
services and health institutions where they were provided are listed in Table 16. The 
HCV positive patients more frequently than the HCV negative patients underwent teeth 
extraction (49.9% vs 32.6%) and prosthetic interventions (12% vs 7.4%). Family 
Medicine Centers were the medical institutions in which most HCV positive patients 
utilized dental services (41.6%), whereas most HCV negative patients indicated private 
dentistry centers (47.1%) (Table 16).  
 
Table 16. Use of dental services between HCV positive and HCV negative patients 
on dialysis  
Variable HCV positive 
n (%) 
HCV 
negative 
n (%) 
p-value 
Dental services 
Yes   n = 519 209 (85.7) 310 (82.9)  
0.36 No     n = 99  35 (14.3)  64 (17.1) 
Type of dental service 
Filling  n = 28  8 (3.8) 20 (6.5)  
Extraction   n = 204 103 (49.3) 101 (32.6) 
Prosthetics  n = 48 25 (12.0) 23 (7.4) 
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Other            n = 11   7 (3.3) 4 (1.3) 
Filling, extraction    n = 102  27 (12.9) 75 (24.2) 
Filling, prosthetics  n = 5 1 (0.5) 4 (1.3) 
Filling, other            n = 1 1 (0.5) 0 
Extraction, prosthetics  n = 63 21 (10.0) 42 (13.5) 
Extraction, other            n = 2 2 (1.0) 0 
Filling, extraction, prosthetics  n = 55 14 (6.7) 41 (13.2) 
Medical institution where dental services were performed 
Family Medicine Center      n = 182 87 (41.6) 95 (30.6)  
Private dentistry center        n = 217 71 (34.0) 146 (47.1) 
University Clinical Center for Dentistry 
of Kosovo          n = 13 
4 (1.9) 10 (3.2) 
Other         n = 41 21 (10.0) 20 (6.5) 
Family Medicine Center, Private 
dentistry center        n = 61 
24 (11.5) 37 (11.9) 
Family Medicine Center, University 
Clinical Center for Dentistry of Kosovo         
n = 2  
2 (1.0) 0 
Family Medicine Center, University 
Clinical Center for Dentistry of Kosovo, 
Other   n =2 
0 2 (0.6) 
p (Chi-square test) 
 
5.1.2.3.3 Surgical interventions as a risk factor for HCV infection  
 
All patients on dialysis had a type of fistula placed. Beside this procedure, 36.1% of 
HCV positive and 36.6% of HCV negative patients on dialysis had other types of 
surgical interventions. Statistical analysis showed that patients on dialysis infected with 
HCV and the noninfected ones did not significantly differ in relation to surgical 
interventions (p=0.98).  
Abdominal surgeries were the most frequent surgical interventions performed in both 
groups of patients (11.5% and 10.7%, respectively). Kidney transplantations were 
performed on 7 patients, 5 of which belonged to the group of HCV positive, and 2 to the 
group of HCV negative patients. In more than 50% of both HCV positive and HCV 
negative patients, surgical interventions were performed at the University Clinical 
Center of Kosovo in Prishtina (57.8% and 59.4%, respectively) (Table 17).  
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Table 17. Surgical interventions among HCV positive and HCV negative patients 
on dialysis 
Variable HCV positive 
n (%) 
HCV 
negative 
n (%) 
p-value 
Surgical intervention 
Yes   n = 225  88 (36.1) 137 (36.6)  
0.98 No     n = 393 156 (63.9) 237 (63.4) 
Type of surgical intervention 
Abdominal 28 (11.5) 40 (10.7)  
Orthopedics 6 (2.5) 14 (3.7) 
Ophthalmological 4 (1.6) 12 (3.2) 
Throat 3 (1.2) 1 (0.3) 
Urological 14 (5.7) 16 (4.3) 
Cardiovascular 3 (1.2) 14 (3.7) 
Gynecological 7 (2.9) 8 (2.1) 
Kidney transplant 4 (1.6) 2 (0.5) 
Thoracic  4 (1.1) 
Abdominal, orthopedics 1 (0.4) 1 (0.3) 
Abdominal, ophthalmological  2 (0.8) 2 (0.5) 
Abdominal, throat  1 (0.4)  
Abdominal, urological 2 (0.8) 2 (0.5) 
Abdominal, cardiovascular  2 (0.8) 3 (0.8) 
Abdominal, gynecological 1 (0.4) 1 (0.3) 
Abdominal, thoracic  1 (0.3) 
Orthopedics, ophthalmological  2 (0.8) 1 (0.3) 
Orthopedics, urological 2 (0.8) 1 (0.3) 
Orthopedics, cardiovascular  1 (0.3) 
Orthopedics, gynecological  1 (0.4) 1 (0.3) 
Orthopedics, kidney transplant 1 (0.4)  
Ophthalmological, throat  2 (0.5) 
Ophthalmological, urological  1 (0.3) 
Ophthalmological, cardiovascular  2 (0.5) 
Urological, cardiovascular   1 (0.3) 
Throat, gynecological 1 (0.4) 1 (0.3) 
Urological, gynecological 3 (1.2) 1 (0.3) 
Gynecological, kidney transplant  1 (0.4)  
Missing  3 (0.8)  
Medical institution where surgical intervention was performed 
University Clinical Center of Kosovo   141 (57.8) 222 (59.4)  
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n = 363 
Regional hospital n = 62 24 (9.8) 38 (10.2)  
Private hospital     n = 17 6 (2.5) 11 (2.9)  
Other    n = 54 27 (11.1) 27 (7.2)  
University Clinical Center of Kosovo,   
Regional hospital   n = 40 
17 (7) 23 (6.1)  
University Clinical Center of Kosovo,   
Private hospital     n = 14 
8 (3.3) 6 (1.6)  
University Clinical Center of Kosovo,   
Other    n = 47 
15 (6.1) 32 (8.6)  
Regional hospital, Private hospital    n = 3   3 (0.8)  
Regional hospital, other   n = 9 3 (1.2) 6 (1.6)  
Private hospital, other n = 1 0 1 (0.3)  
Missing  1 (3.1) 4 (1.1)  
p (Chi-square test) 
 
 
 
5.1.2.3.4 Tattoo, ear piercing, using others' shaving kit, 
imprisonment, and hemophilia as risk factors for HCV infection 
in dialysis patients 
 
The HCV positive patients on dialysis non-significantly more frequently had had some 
of the following risk procedures: tattoo, ear/body piercing, injected drugs, used shaving 
kit belonging to someone else, and had been non-significantly more frequently 
imprisoned, or had hemophilia (p=0.37). The observed percentages of HCV positive and 
HCV negative patients with a registered high-risk procedure were 41.4% and 34.2%, 
respectively. Tattoo was registered in 2.9% of HCV positive and 4.3% of HCV negative 
patients; ear or other body piercing in 37.3% of HCV positive and 28.1% of HCV 
negative patients; used shaving kit belonging to someone else in 1.2% of HCV negative 
and 1.9% of HCV negative patients on dialysis. Experience as prisoners was registered 
in 4.9% of HCV positive and 8% of HCV negative patients, and the history of 
hemophilia was reported by 2.5% of HCV positive and 6.7% of HCV negative patients 
(Table 18).   
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Table 18. Tattoo, ear piercing, using others’ shaving kit, imprisonment and 
hemophilia as risk factors for HCV infection in dialysis patients 
Variable HCV positive 
n (%) 
HCV 
negative 
n (%) 
p-value 
Had tattoo, ear piercing, used shaving kit, imprisonment, hemophilia 
Yes    n = 229 101 (41.4) 128 (34.2)  
0.37 No     n = 389 143 (58.6) 246 (65.8) 
High-risk behaviour 
Tattoo                                     Yes    n = 23 
                                                No     n = 595 
7 (2.9) 
237 (97.1) 
16 (4.3) 
358 (95.7) 
0.06 
Ear or other body piercing     Yes     n = 196 
                                                No     n = 422 
 
  91 (37.3) 
153 (62.7) 
105 (28.1) 
269 (71.9) 
0.016* 
Used shaving kit belonging to someone else 
                                              Yes  n = 10 
                                              No   n = 608 
 
3 (1.2) 
241 (98.8) 
7 (1.9) 
367 (98.1) 
0.78 
 
Ever imprisoned 
Yes   n = 42 12 (4.9) 30 (8.0) 0.13 
No     n = 574 232 (95.1) 344 (92.0) 
Hemophilia 
Yes   n = 31 6 (2.5) 25 (6.7) 0.058 
No     n = 565 230 (94.3) 335 (89.6) 
Don`t know = 22 8 (3.3) 14 (3.7) 
p (Chi-square test)  *p<0.05 
 
 
5.1.2.3.5 Risk factor – Dialysis 
 
Results of this study showed that the history of dialysis was significantly longer in 
patients with the presence of anti-HCV vs. the negative ones (p<0.001). The mean 
history of dialysis was 8.8 ± 5.7 years in the group of anti-HCV positive patients, and 
3.4 ± 2.9 years in the group of anti-HCV negative patients. The median history of 
dialysis in the group of infected patients was 8 years (interquartile range 4–12 years), 
and 3 years in the noninfected group (interquartile range 1–4 years) (Table 19).  
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Table 19. History of dialysis in anti-HCV positive and anti-HCV negative patients 
Group History of dialysis 
mean ± SD min – max median (IQR) 
Anti-HCV positive 8.8 ± 5.7 1 – 30 8 (4 – 12) 
Anti-HCV negative  3.4 ± 2.9 1 – 22 3 (1 – 4) 
 p<0.001 
p (Mann-Whitney U test) 
 
Figure 7. Start of dialysis treatment 
0
20
40
60
80
100
120
1
9
8
6
1
9
8
8
1
9
8
9
1
9
9
1
1
9
9
2
1
9
9
3
1
9
9
4
1
9
9
5
1
9
9
6
1
9
9
7
1
9
9
8
1
9
9
9
2
0
0
0
2
0
0
1
2
0
0
2
2
0
0
3
2
0
0
4
2
0
0
5
2
0
0
6
2
0
0
7
2
0
0
8
2
0
0
9
2
0
1
0
2
0
1
1
2
0
1
2
2
0
1
3
2
0
1
4
2
0
1
5
HCV positive HCV negative
N
years
 
 
Eleven patients with terminal chronic kidney insufficiency were started on dialysis 
between 1986 and 1995, of whom 10 (90.9%) patients were found anti-HCV positive in 
this study. Between 1996 and 2005, 83 patients were started on dialysis, 69 (83.1%) of 
whom were anti-HCV positive. Most patients were started on dialysis between 2006 to 
2015, among whom the prevalence of anti HCV antibodies was 31.5% (164/520). There 
was no information on the start of dialysis for 4 patients who agreed to participate in 
this study. Difference in the start of dialysis between HCV positive and HCV negative 
patients was shown to be statisticaly significant (Table 20a). 
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Table 20a. Distribution of anti-HCV positive and anti-HCV negative patients 
based on the year of dialysis initiation 
Year of dialysis initiation HCV positive 
n (%) 
HCV negative 
n (%) 
p-value 
1986–1995     n = 11 10 (90.9) 1 (9.1) 0.0001 
1996–2005     n = 83 69 (83.1) 14 (16.9) 
2006–2015    n = 520        164 (31.5)     356 (68.5) 
Total 243 371 614 
p (Chi-square test)   
 
Data on dialysis initiation were available for 144 HCV positive patients with the HCV 
genotype determined. Seven HCV positive samples of patients who were started on 
dialysis between 1986 and 1995 had HCV genotype determined, four of whom had  
subtype 1a, one had subtype 1b, and two had subtype 4d. Among 54 patients with 
determined HCV subtype who were started on dialysis between 1996 and 2005, 26 
(48.1%) samples were of subtype 1a, one sample of subtype 1b, and 27 samples of 
subtype 4d. Among 83 patients with determined HCV subtype who were started on 
dialysis between 2006 and 2015, 62 (74.7%) had subtype 1a, 2 (2.4%) had subtype 1b, 
one sample was genotype 2, and 18 (21.7%) samples were subtype 4d (Table 20b). 
 
Table 20b. HCV genotype based on the year of dialysis initiation 
Region HCV Genotype 
Total 
n 
Genotype 
1a 
n (%) 
Genotype 
1b 
n (%) 
Genotype  
2 
n (%) 
Genotype 
4d 
n (%) 
1986–1995 7 4 (57.1) 1 (14.3) 0    2 (28.6) 
1996–2005 54 26 (48.1) 1 (1.9) 0  27 (50.0) 
2006–2015 83 62 (74.7) 2 (2.4) 1 (1.2) 18 (21.7) 
Total  144 92  4  1  47  
 
The anti-HCV positive patients underwent significantly more frequently dialysis than 
the HCV negative patients (p=0.03). There were no HCV positive patients who 
underwent dialysis once a week vs. 1.1% of HCV negative patients. There were 4.5% of 
HCV positive patients undergoing dialysis twice a week vs. 8.8% of HCV negative 
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patients, while 95.5% and 89.8% of HCV positive and negative patients, respectively, 
underwent dialysis three times a week (Table 21).   
 
Table 21. Frequency of dialysis in HCV positive and HCV negative patients  
Frequency of dialysis HCV positive 
n (%) 
HCV negative 
n (%) 
p-value 
Once a week 0 4 (1.1) 0.03* 
Twice a week 11 (4.5) 33 (8.8) 
Three times a week 233 (95.5) 336 (89.8) 
Missing 0 1 (0.3) 
Total 244 374 618 
p (Chi-square test)  p<0.05 
 
Most patients on dialysis, both in the HCV infected and noninfected group, were started 
on dialysis at dialysis center in Prishtina (73.8% and 72.9%, respectively). Then, 
dialysis center in Peja followed, in which 7.0% of HCV positive and 10.4% of HCV 
negative patients were started on dialysis; 12.7% of HCV positive and 6.4% of HCV 
negative patients were started on dialysis outside Kosovo. In Mitrovica and Prizren, the 
greatest percentage of HCV positive patients (15.6% and 14.7%, respectively) 
continued to undergo dialysis, while at dialysis center in Prishtina the greatest 
percentage of HCV negative patients (34.5%) continued with their dialysis. At dialysis 
centers outside Kosovo, 15.6% of HCV positive and 8.6% of HCV negative patients 
continued to undergo dialysis.    
In this analysis, a comparison was made between HCV positive and HCV negative 
patients in relation to the number of dialysis centers in which the dialysis was provided. 
Results showed that HCV positive patients were on dialysis significantly more 
frequently in more than one center than HCV negative patients (79.5% vs 49.3%, 
p<0.0001) (Table 22).  
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Table 22. Distribution of HCV positive and HCV negative patients based on 
dialysis center at which dialysis was started and continued  
Variable HCV positive 
n (%) 
HCV negative 
n (%) 
Dialysis center where dialysis was started  
Prishtina         n = 454 178 (72.9) 276 (73.8) 
Mitrovica       n = 7 4 (1.6) 3 (0.8) 
Peja                n = 56 17 (7.0) 39 (10.4) 
Gjakova         n = 11 3 (1.2) 8 (2.1) 
Prizren           n = 28 8 (3.3) 20 (5.3) 
Ferizaj            n = 1 1 (0.4) 0 
Gjilan             n = 6 2 (0.8) 4 (1.1) 
Other              n = 55 31 (12.7) 24 (6.4) 
Dialysis center where dialysis was continued 
Prishtina 29 (11.9) 129 (34.6) 
Mitrovica 38 (15.6) 19 (5.1) 
Peja 15 (6.1) 44 (11.8) 
Gjakova 25 (10.2) 28 (7.5) 
Prizren 36 (14.7) 43 (11.5) 
Ferizaj 1 (0.4)  
Gjilan 1 (0.4) 4 (1.1) 
Prishtina, Mitrovica 5 (2.1)  
Prishtina, Peja   7 (2.9) 5 (1.3) 
Prishtina, Prizren 29 (11.9) 18 (4.8) 
Prishtina, Ferizaj 4 (1.6) 29 (7.8) 
Prishtina, Gjilan 10 (4.1) 22 (5.9) 
Peja, Gjakova 5 (2.1)  
Prizren, Gjilan 1 (0.4)  
Other 38 (15.6) 32 (8.6) 
Dialysis at more than one dialysis center 
No 50 (20.5) 189 (50.7) 
Yes 194 (79.5) 184 (49.3) 
 p<0.0001 
p (Chi-square test) 
 
The association of the HCV infection with gender and age of the study patients, the 
centers where the dialysis was provided, the dialysis provided at more than one center, 
as well as the association of the HCV infection with blood transfusion, medical 
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interventions (dental, surgical), other high-risk behaviours, and with the level of 
knowledge of dialysis patients about HCV were analysed by Poisson analysis.   
 
The unadjusted Poisson analysis for all dialysis centers of Kosovo showed that  factors 
significantly associated with the anti-HCV positivity were the age of patients on 
dialysis (PR = 0.955, CI 0.972–0.998, p=0.021), longer duration of dialysis (PR = 
1.032, CI 1.02–1.044, p<0.0001), dialysis at more than one center (PR = 1.251, CI 
1.086–1.42, p=0.002), and blood transfusion (PR = 1.188, CI 1.006–1.404, p=0.043) 
(Table 23a).  
 
Table 23a. Unadjusted Poisson analysis of factors associated with anti-HCV 
positivity for all Kosovo dialysis centers (n = 618) 
Variable  N (%) 
 
PR 
 
CI 95% p-value 
Gender 
female 
male 
 
128 (42.8) 
116 (36.4) 
 
ref (1) 
0.955 
 
 
0.836 – 1.91 
0.498 
Age (years) 
mean=56.3 ± 12.7 
  
0.985 
 
0.972 – 0.998 
 
0.021* 
Duration of dialysis 
(years) 
mean=8.8 ± 5.7 
  
 
1.032 
 
 
1.02 – 1.044  
 
 
< 0.0001 
Region 
Prishtina 
Mitrovica 
Peja 
Prizren 
Ferizaj 
Gjilan 
Gjakova 
 
     30 (18.0) 
44 (69.8) 
26 (33.3) 
77 (50.3) 
16 (35.6) 
17 (35.4) 
34 (53.1) 
 
ref (1) 
1.44 
1.13 
1.274 
1.149 
1.148 
1.298 
 
 
1.138 – 1.822 
0.891 – 1.433 
1.054 – 1.541 
0.862 – 1.531 
0.867 – 1.519 
1.019 – 1.654 
0.06 
Dialysis at more than 
one center 
No 
Yes 
 
 
50 (20.9) 
  194 (51.3) 
 
 
ref (1) 
1.251 
 
 
 
1.086 – 1.442 
0.002** 
Blood transfusion 
No 
Yes 
 
31 (21.8) 
  213 (44.7) 
 
ref (1) 
1.188 
 
 
1.006 – 1.404 
0.043* 
Dental services 
No 
 
35 (35.3) 
 
ref (1) 
 
 
0.704 
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Yes   209 (40.3) 1.036 0.862 – 1.246 
Surgical intervention 
No 
Yes 
 
156 (39.7) 
  88 (39.1) 
 
ref (1) 
1.001 
 
 
0.871 – 1.15 
0.991 
Other risk behaviour 
No 
Yes 
 
143 (36.8) 
101 (44.1) 
 
ref (1) 
1.054 
 
 
0.918 – 1.209 
0.67 
Knowledge about 
HCV infection 
Yes 
No 
Don`t know 
 
 
158 (45.4) 
  79 (30.9) 
 7 (50.0) 
 
 
ref (1) 
0.9 
1.032 
 
 
 
0.784 – 1.033 
0.667 – 1.596 
   0.309 
PR (unadjusted prevalence rate)  *p<0.05   **p<0.01; p (Wald test) 
 
Specifically for Prishtina dialysis center, the unadjusted Poisson analysis showed that 
factors significantly associated with the anti-HCV positivity were longer duration of 
dialysis (PR = 1.235 CI, 1.128 – 1.351, p<0.0001), and blood transfusion (PR = 3.762, 
CI 1.452 – 9.746, p=0.006) (Table 23b). 
 
Table 23b. Unadjusted Poisson analysis of factors associated with anti-HCV 
positivity at Prishtina dialysis center (n = 167) 
Variable  N (%) 
 
PR 
 
CI 95% p-value 
Gender 
female 
male 
 
87 (52.1) 
80 (47.9) 
 
ref (1) 
1.009 
 
 
0.462 – 2.2 
 
 
0.983 
Age (years) 
mean=57.4 ± 14.2 
  
0.979 
 
0.953 – 1.005 
 
0.111 
Duration of dialysis 
(years) 
mean=5.4 ± 4.5 
  
 
1.235 
 
 
1.128 – 1.351  
 
 
< 0.0001* 
Dialysis at more than 
one center 
No 
Yes 
 
 
152 (90.48) 
15 (8.93) 
 
 
ref (1) 
1.107 
 
 
 
0.293 – 4.186 
 
 
 
0.881 
Blood transfusion 
No 
Yes 
 
71 (42.52) 
96 (57.48)) 
 
ref (1) 
3.762 
 
 
1.452 – 9.746 
 
 
 0.006* 
Dental services 
No 
 
  25 (14.97) 
 
ref (1) 
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Yes 142 (85.03) 1.404 0.512 – 3.852 0.704 
Surgical intervention 
No 
Yes 
 
103 (61.68) 
  64 (38.32) 
 
ref (1) 
1.001 
 
 
0.871 – 1.15 
 
 
   0.51 
Other risk behaviour 
No 
Yes 
 
89 (53.29) 
78 (46.71) 
 
ref (1) 
1.049 
 
 
0.71 – 1.55 
 
 
   0.809 
Knowledge about 
HCV infection 
Yes 
No 
Don`t know 
 
 
     54 (32.33) 
113 (67.67) 
 
 
ref (1) 
        1.79 
 
 
 
0.719 – 4.461 
 
 
 
   0.211 
PR (unadjusted prevalence rate)  *p<0.01; p (Wald test) 
 
In the multivariate analysis for all dialysis centers of Kosovo, duration of dialysis and 
dialysis at more than one center were shown as independent significant factors, 
associated with anti-HCV positivity (APR = 1.032, CI 1.017–1.042, p<0.0001; APR = 
1.18, CI 1.02–1.365, p=0.026) (Table 24a). 
 
Table 24a. Adjusted Poisson analysis of factors associated with anti-HCV positivity 
for all dialysis centers of Kosovo (n = 618) 
Variable  APR CI 95% p-value 
Gender 
female 
male 
 
ref (1) 
0.978 
 
 
0.818 – 1.17 
 
 
0.48 
Age (years)  0.997 0.992 – 1.003 0.327 
Duration of dialysis (years)  
1.032 
 
1.017 – 1.042 
 
< 0.0001* 
Region 
Prishtina 
Mitrovica 
Peja 
Prizren 
Ferizaj 
Gjilan 
Gjakova 
 
ref (1) 
1.436 
1.134 
1.271 
1.163 
1.151 
1.302 
 
 
1.135 – 1.817 
0.894 – 1.439 
1.051 – 1.537 
0.871 – 1.552 
0.87  – 1.524 
1.022 – 1.659 
 
 
 
 
 
 
0.065 
Dialysis at more than one 
center 
No 
Yes 
 
ref (1) 
1.18 
 
 
1.02 – 1.365 
 
 
0.026* 
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Blood transfusion 
No 
Yes 
 
ref (1) 
0.92 
 
 
0.817 – 1.041 
 
 
0.341 
Dental services 
No 
Yes 
 
ref (1) 
1.039 
 
 
0.864 – 1.249 
 
 
0.685 
Surgical intervention 
No 
Yes 
 
ref (1) 
1.002 
 
 
0.872 – 1.151 
 
 
0.978 
Other risk behaviour 
No 
Yes 
 
ref (1) 
0.949 
 
 
0.827 – 1.088 
 
 
0.453 
Knowledge about HCV 
infection  
Yes 
No 
Don`t know 
 
ref (1) 
1.055 
0.908 
 
 
0.679 – 1.639 
0.853 – 1.156 
 
 
 
0.362 
APR (Adjusted prevalence rate)  *p<0.05; p (Wald test) 
 
 
Analyzing data for Prishtina dialysis center specifically, the multivariate analysis 
showed the following as independent significant factors associated with the anti-HCV 
positivity: age (APR = 0.96, CI 0.926–0.994, p=0.023), longer duration of dialysis 
(APR = 1.258, CI 1.132–1.398, p<0.0001), blood transfusion (APR = 3.077 CI, 1.129–
8.384, p=0.028), and knowledge about HCV (APR = 1.395 CI, 1.071–1.763, p=0.038) 
(Table 24b). 
 
Table 24b. Adjusted Poisson analysis of factors associated with anti-HCV positivity 
for Prishtina dialysis center (n = 167) 
Variable  APR CI 95% p-value 
Gender 
female 
male 
 
ref (1) 
0.42 
 
 
0.089 – 1.98 
 
 
0.27 
Age (years)  0.96 0.926 – 0.994 0.023* 
Duration of dialysis (years)  
1.258 
 
1.132 – 1.398 
 
< 0.0001 
Dialysis at more than one 
center 
No 
Yes 
 
 
ref (1) 
1.225 
 
 
 
0.255 – 5.886 
 
 
 
0.800 
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Blood transfusion 
No 
Yes 
 
ref (1) 
3.077 
 
 
1.129 – 8.384 
 
 
0.028* 
Dental services 
No 
Yes 
 
ref (1) 
0.915 
 
 
0.245 – 3.413 
 
 
0.894 
Surgical intervention 
No 
Yes 
 
ref (1) 
1.46 
 
 
0.532 – 4.004 
 
 
0.462 
Other risk behaviour 
No 
Yes 
 
ref (1) 
0.953 
 
 
0.195 – 4.657 
 
 
0.953 
Knowledge about HCV 
infection 
Yes 
No 
Don`t know 
 
 
ref (1) 
1.395 
 
 
 
1.071 – 1.763 
 
 
 
0.038* 
APR (Adjusted prevalence rate)  *p<0.05; p (Wald test) 
 
 
 
5.1.2.4 Treatment of HCV infection among dialysis patients 
 
Only 18 out of 244 (7.4%) dialysis patients infected with HCV received therapy with 
pegylated interferon and ribavirin at the Clinic for Infectious Diseases, University 
Clinical Center of Kosovo. Most anti-HCV positive patients on dialysis (77.0%) did not 
know about any reasons for not being enrolled in the HCV treatment program.  
 
The treatment was completed for 12 (66.6%) patients, one patient discontinued the 
treatment due to side effects (abdominal pain), while the reason for discontinuation of 
the therapy by other patients was not stated. Six (33.3%) of the treated patients had no 
side effects related to the treatment. The remaining anti-HCV positive dialysis patients 
who received treatment mentioned several complaints as presented in Table 25.   
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Table 25. Information related to the treatment of anti-HCV positive patients on 
dialysis 
Variable N (%) 
Treated with 
interferon/ribavirin 
Yes    18 (2.9) 
No      600 (97.1) 
Treatment completed Yes     12 (66.7) 
No         5 (27.8) 
Missing  1 (5.5) 
Reason/s for not being enrolled 
in the treatment with 
interferon/ribavirin   
I didn’t want to receive 
treatment 
0 
No place available in the 
treatment program 
0 
No financial possibilities to 
personally finance the treatment 
1 (0.4) 
Didn’t have information that 
treatment for hepatitis C 
infection exists 
2 (0.8) 
Don`t know 188 (77.0) 
Missing data   53 (21.7) 
Complaints related to 
interferon/ribavirin treatment 
No complaints   6 (33.3) 
Vomiting 1 (5.5) 
Fever   3 (16.7) 
Anemia 1 (5.5) 
Diabetes  1 (5.5) 
Fatigue 1 (5.5) 
Knee pain 1 (5.5) 
Frequent interventions 1 (5.5) 
Missing data   3 (16.7) 
 
 
5.1.3 Management information from hemodialysis units 
 
A total of 708 patients with chronic kidney insufficiency were on dialysis in the 
Republic of Kosovo in December 2015, with the greatest percentage at dialysis centers 
in Prishtina (26.1%) and Prizren (24.9%), and the lowest percentage at the dialysis 
center in Ferizaj (7.1%). 
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At dialysis centers of Kosovo, 18 doctors were employed, 5 of them at the dialysis 
center in Prishtina, and only one doctor at the centers of Mitrovica, Ferizaj, and 
Gjakova. On average, one doctor provided care for 39 patients, and per region, the 
dialysis center in  Gjilan was shown the best staffed with doctors (16 patients per 
doctor), and the worst situation concerning the number of doctors was in Mitrovica and 
Gjakova, where the number of the patients per doctor was 70 and 69, respectively. 
 
At dialysis centers in Kosovo, 129 nurses were employed, mostly at the dialysis center 
in Prishtina (32), with the lowest number at the center of Ferizaj (10). One nurse, on 
average, provided care for 5 to 6 patients on dialysis in Kosovo.  One nurse provided 
care for the lowest number of patients (4) in Gjakova, whereas at dialysis centers in 
Prizren and Peja, one nurse provided care for 6 to 7 patients.  
 
A total of 189 dialysis machines were operational, the greatest number at the center of 
Prishtina (56), the lowest number at the center of Mitrovica (18). On average, 4 patients 
were using one dialysis machine, or per region, the lowest number of patients (2) were 
using one machine at Ferizaj center, whereas at the center in Prizren 5 patients were on 
dialysis on one machine.  
 
The surface area of premises reserved for dialysis ranged between 250–300 square 
meters in Gjakova, up to 1,000 in Prishtina. There was regular maintenance of dialysis 
machines, trained staff provided care for HCV positive patients only, and at the centers 
of Peja and Prizren the premises for HCV positive and negative patients were not 
separated as they were in other centers of Kosovo. 
 
At the dialysis center in Prizren, there was insufficient supply of disposable single-use 
gloves, at the centers in Mitrovica and Gjilan the staff complained about the poor 
quality of gloves. There were no sterile gauzes for daily work at dialysis centers in Peja, 
Prizren and Gjakova, while the centers in Prizren, Gjilan and Gjakova did not have 
sufficient disinfection material for daily work. 
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Only dialysis centers in Ferizaj and Gjilan received regularly the anti-HCV test results 
before they placed the patient on dialysis machine. The most common sources of the 
anti-HCV test results were the National Institute of Public Health of Kosovo and 
different private biochemical laboratories. 
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Table 26. Human resources and infrastructure at dialysis centers of Kosovo in December 2015 
Dialysis 
center 
No. of 
MDs 
No. of 
nurses 
No. of 
patients 
No. of dialysis 
machines 
Surface 
area 
(m2) 
Regular 
maintenance 
Separate 
dialysis 
machines for 
HCV positive 
patients 
Separate 
premises for 
HCV positive 
patients 
Staff 
dedicated  
for HCV 
positive  
patients 
only 
Prishtina 5/37 32/5.8 185 (26.1%) 56/3.3 1000 yes yes yes yes 
Mitrovica 1/70 12/5.8 70 (9. 9%) 18/3.9 350 – 400 yes yes yes yes 
Peja 2/47 15/6.3 94 (13.3%) 22/4.3 600 yes yes no yes 
Prizren 4/44 27/6.5 176 (24.9%) 37/4.8 800 yes yes no yes 
Ferizaj 1/50 10/5 50 (7.1%) 30/1.7 300 yes yes yes yes 
Gjilan 4/16 15/4.3 64 (9.0%) 20/3.2 280 yes yes yes yes 
Gjakova 1/69 18/3.8 69 (9.7%) 22/3.1 250 – 300 yes yes yes yes 
Total 18/39 a 129/5.5 b 708 205/3.5 c      
a  Number of patients per doctor      b Number of patients per nurse    c  Number of  patients per machine  
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Table 27. Availability of consumables and anti-HCV testing at dialysis centers of Kosovo in December 2015 
Dialysis 
center 
Sufficient 
supply of 
gloves  
Sufficient 
supply of 
sterile 
gauzes  
Sufficient 
supply of 
disinfection 
material  
Anti-HCV test 
result before 
patient is 
admited to 
dialysis  
Laboratory that performs testing for 
anti-HCV  
Manager opinion – reasons for 
high prevalence of HCV infection 
in your dialysis unit  
Prishtina yes yes yes no 
National Institute of Public Health of 
Kosovo, private laboratories 
- 
Mitrovica 
yes in last year, 
poor quality 
yes yes no Private laboratories 
Human factor, surgical 
interventions, many transfusions 
Peja yes no yes no Private laboratories 
Human factor, surgical 
interventions, many transfusions 
Prizren no no no no 
National Institute of Public Health of 
Kosovo, private laboratories 
Lack of appropriate premises; after 
the war a situation when even 
gloves were missing 
Ferizaj yes yes yes yes 
National Institute of Public Health of 
Kosovo, private laboratories 
Lack of on-time detection of HCV 
infection 
Gjilan yes yes no yes 
National Institute of Public Health of 
Kosovo, private laboratories 
Lack of HCV testing capacities; 
human mistakes; machine not 
properly disinfected 
Gjakova 
yes in last year, 
poor quality 
no no no 
National Institute of Public Health of 
Kosovo, private laboratories 
Inherited problem; lack of 
appropriate premises; in the past all 
patients were in the same premises; 
no regular testing 
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5.2 HCV INFECTION AMONG INJECTING DRUG USERS IN 
PRISHTINA, KOSOVO 
 
5.2.1 Laboratory data 
 
Ninety nine (48.3%) out of a total of 205 IDUs participating in the study were anti-HCV 
positive. There were no HIV positive cases among the study population of IDUs. In four 
subjects, the presence of antibodies against Treponema pallidum (2.0%) was detected, 
and 18 (8.8%) were HBsAg positive. 
The presence of HCV RNA was detected in 70 (70.7%) anti-HCV positive IDUs. HCV 
genotyping was possible among all HCV RNA positive IDUs (70), and the following 
subtypes were determined: subtype 1a (45/70; 64.3%), subtype 3a (24/70; 34.3%), and 
subtype 2k (1/70; 1.4%).  
IL28 genotype was determined among 98 out of 99 anti-HCV positive IDUs. Allele CC 
was the most prevalent, determined in 47 (47.9%), followed by CT and TT genotypes 
with 37 and 14 samples (37.8%, 14.3%), respectively (Table 28). 
 
Table 28.   Results of laboratory tests on IDUs in 
Prishtina Region of Kosovo 
Variable N (%) 
Anti-HIV 0 
Anti-Treponema pallidum 4 (2.0) 
HBsAg 18 (8. 8) 
Anti-HCV 99 (48.3) 
HCV core region 
sequenced 
70 (70.7) 
HCV subtype 
1a 
3a 
2k 
70 
45 (64.3) 
24 (34.3) 
1 (1.4) 
IL28B 
CT 
CC 
TT 
98 
37 (37.8) 
47 (47.9) 
14 (14.3) 
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Figure 8. Presence of antibodies against HCV among IDUs in Prishtina Region, 
Kosovo 
Anti-HCV positive 
48.3%
Anti-HCV 
negative 51.7%
 
 
Figure 9. Distribution of HCV genotypes among IDUs in Prishtina Region, Kosovo 
1a
64.3%
3a
34.3%
2k
1.4%
% HCV-genotype
 
Figure 10. Distribution of IL28 polymorphism among anti-HCV positive IDUs in 
Prishtina Region, Kosovo 
CT
37.8%
CC
47.9%
TT
14.3%
% IL28B genotype
 
 - 56 - 
IL28 polymorphism CC was present more frequently than CT and TT in anti-HCV 
positive IDUs, either being HCV RNA positive  (43.5%, 39.1%, and 17.4%, 
respectively) or negative (58.6%, 34.5%, and 6.9%, respectively). However, those 
differences were not statistically significant (p=0.26) (Table 29).  
 
Table 29. IL28B polymorphism among anti-HCV positive IDUs in Prishtina 
Region of Kosovo 
IL28B polymorphism  HCV RNA p-value 
negative positive 
n (%) n (%) 
CT 10 (34.5) 27 (39.1) 0.26 
CC 17 (58.6) 30 (43.5) 
TT 2 (6.9) 12 (17.4) 
p (Chi-square test) 
 
Significant differences  in the distribution of CT, CC and TT of the IL28B among anti-
HCV positive IDUs infected with HCV genotypes 1a and 3a (p=0.74) were not found 
(Table 30). 
 
Table 30. IL28B polymorphism among anti-HCV positive IDUs in Prishtina 
Region of Kosovo with HCV genotype 1a and 3a 
IL28B polymorphism among anti- 
HCV positive 
HCV genotype p-value 
1a 3a 
n (%) n (%) 
CT 16 (59.3) 11 (40.7) 0.74 
CC 20 (69.0) 9 (31.0) 
TT 8 (66.7) 4 (33.3) 
p (Chi-square test) 
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Cladogram phylogenetic trees for HCV subtypes 1a and 3a were constructed with 
sequences of the NS5B region isolated from IDUs (Figures 1 and 11, respectively). 
 
Among the cladogram phylogenetic tree consisted of 39 sequences of HCV subtypes 1a 
isolated from IDUs in Prishtina, two clusters were revealed with aLRT>0.9, one with 5 
sequences and another with 3 sequences. Those two clusters were part of a larger cluster 
with aLRT>0.8 consisted in total of 26 sample sequences of IDUs. These findings show 
that among IDU samples belonging to HCV subtype 1a isolated in this study, 66.7% 
(26/39) were observed with a phylogenetic link (Fig. 1).  
 
With regard to cladogram phylogenetic tree constructed with sequences of the HCV 
subtype 3a (n=21), there was a presence of one large cluster with aLRT>0.9 with 12 
sequences, and another cluster with aLRT>0.8 with 3 samples from IDUs and one 
transmission pair. In total, 71.4% (15/21) of samples belonging to the HCV subtype 3a 
isolated from IDUs in Prishtina Region of Kosovo showed phylogenetic clustering (Fig. 
11).  
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Figure 11. The maximum likelihood phylogenetic tree of HCV subtype 3a. Sequences 
from IDUs and chronic HCV pateints are colored differently. Clusters with aLRT>0.9 
are highlighted in green and clusters with aLRT>0.8 are highlighted in yellow.  
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5.2.2 Demographic characteristics of IDUs  
 
Among 205 IDUs from the Prishtina Region of Kosovo, most were men (183/204 – 
89.7%), with a mean age of 36.2 years (range 24–59 years), and in the age group 30–39 
(50.7%). Male IDUs were found older than the female but the difference was not 
significant (36.4 ± 7.2 vs 34.4 ± 6.1). Almost half of the recruited IDUs had completed 
secondary education (101/205; 49.3%). During study implementation, most subjects 
were single (49.8%; 102/205), while 30.7% (63/205) were married. Most IDUs, in the 
past three months, lived in their own house/apartment (42.9%; 88/205) or lived together 
with their parents (32.7%; 67/205). Four subjects responded they were in prison at that 
time. About 9% of the IDUs had no income in the past month, most of them were 
financially supported by their family (39.5%), and approximately one third was 
permanently employed (29.8%) (Table 31).   
 
Table 31. Demographic characteristics of IDUs in Prishtina Region of Kosovo  
Variable N (%) 
Gender Male 183 (89.3) 
Female 21 (10.2) 
Missing 1 (0.5) 
Age group (years) 19 – 29 37 (18.1) 
30 – 39 104 (50.7) 
≥ 40 64 (31.2) 
Education No formal education 2 (1.0) 
Some primary 5 (2.4) 
Primary 43 (21.0) 
Some secondary  19 (9.3) 
Secondary 101 (49.3) 
Some college 29 (14.1) 
College / university 6 (2.9) 
Marital status 
 
Married 63 (30.7) 
Divorced 28 (13.6) 
Widowed 3 (1.5) 
In a steady relationship 9 (4.4) 
Single 102 (49.8) 
 
Place of residence in 
the past three months 
In your house or apartment  88 (42.9) 
In a rented house or apartment 38 (18.5) 
In your parents' house or apartment 67 (32.7) 
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In someone else's house or apartment 4 (1.9) 
No permanent location 1 (0.5) 
Prison 4 (1.9) 
Other  3 (1.5) 
Main source of income 
in the past month 
No income in the past month 19 (9.3) 
Permanent employment 61 (29.8) 
Temporary job/part time job 23 (11.2) 
Family support 81 (39.5) 
Selling drugs / 
Stealing and/or begging 5 (2.4) 
Other  16 (7.8) 
 
 
Results from the survey showed that the anti-HCV positive IDUs were most frequently 
men (92.9%), and mainly aged from 30 to 39 years (48.5%). As for marital status, 
single and married were the most frequent categories of anti-HCV positive IDUs 
(41.4% and 37.4%, respectively). Most of them (34.3% and 56.6%, respectively) had 
completed primary and secondary education. In the past three months, the anti-HCV 
positive IDUs lived most frequently in their own house/apartment (43.4%), or in the 
house of their parents (28.3%), and three of them were in prison. 
 
There were 7 (7.1%) IDUs infected with hepatitis C virus without any income in the 
past month, 25 (25.3%) were permanently employed, most of them were financially 
supported by their families – 40 (40.4%), three subjects said they were stealing or 
begging in order to provide for their living. None of them reported to be engaged in 
selling drugs.  
    
In the group of male IDUs, the prevalence of antibodies against HCV was non-
significantly higher compared to the female IDUs (49.7% vs 33.3%, p=0.15). 
HCV prevalence among IDUs correlated significantly with their age (t=5.07 
p=0.000001). The age of the IDUs infected with hepatitis C virus was, on average, 38.6 
± 6.9 years, and of the noninfected 33.9 ± 6.5 years. When age was stratified, the 
greatest percentage of the infected subjects belonged to the age group older than 40 
years (65.6%), followed by the age group 30–39 years (46.2%), and the age group 19–
29 years, in which 24.3% had antibodies against HCV (p=0.00027). 
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When comparing married to nonmarried IDUs, a significantly different prevalence of 
the antibodies against HCV (58.7% and 43.7%, respectively; p=0.046) was observed. In 
the group with different marital status, the highest HCV prevalence was found of IDUs 
being divorced, followed by those being married, and without a partner (64.3%, 58.7%, 
and 40.2%, respectively). The difference in HCV prevalence among the analyzed 
categories of marital status was also statistically significant (p=0.02).    
  
The participants' educational level had a significant impact on HCV prevalence 
(p=0.0005). Anti-HCV positive IDUs had more frequently primary or lower education 
compared to anti-HCV negative IDUs.  
 
The prevalence of antibodies against HCV depended neither on where the IDUs lived 
(p=0.58) nor on their employment status (p=0.17). Infection with HCV was present in 
three out of four IDUs that were in prison in the past three months. Unemployed IDUs 
were non-significantly more frequently anti-HCV positive (51.4% vs 41.0%) than the 
employed IDUs (Table 32). 
 
Table 32.    Demographic data of IDUs in Prishtina Region by anti-HCV status 
Variable 
 
Total 
Anti-HCV 
positive 
n (%) 
Anti-
HCV 
negative 
n (%) 
p-value 
Gender 
Male 183 91 (49.7) 92 (50.3)  a0.15 
  Female   21   7  (33.3) 14 (66.7) 
Age group 
19–29  37  9 (24.3) 28 (75.7)  a0.00027* 
  
  
30–39 104 48 (46.2) 56 (53.8) 
≥ 40  64 42 (65.6) 22 (34.4) 
Marital 
status 
Married  63 37 (58.7) 26 (41.3) 
  b0.02* 
  
  
Divorced  28 18 (64.3) 10 (35.7) 
Widowed    3 1 (33.3) 2 (66.7) 
In a steady relationship    9 2 (22.2) 7 (77.8) 
Single 102 41 (40.2) 61 (59.8) 
Married/not 
married 
Married   63 37 (58.7) 26 (41.3) 
a0.046* Not married 142 62 (43.7) 80 (56.3) 
Education ≤ Primary    50 34 (68.0) 16 (32.0)   
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Secondary  120 56 (46.7) 64 (53.3)  
a0.0005** 
  Higher   35 9 (25.7) 26 (74.3) 
Place of 
living 
In own house   88 43 (48.9) 45 (51.1) 
  
 b0.58 
  
In a rented house or apartment   38 17 (44.7) 21 (55.3) 
In your parents' house or apartment   67  28 (41.8%) 39 (58.2) 
In someone else's house or apartment     4 4(100%) 0 
No permanent location     1 1 (100%) 0 
In someone else’s house     3 3 (100%) 0) 
Prison     4 3 (75.0) 1 (25.0) 
Employment 
Employed   61 25 (41.0) 36 (59.0) 
 a0.17 Unemployed 144 74 (51.4) 70 (48.6) 
a(Chi-square test)  b(Fisher's exact test)  *p<0.05   **p<0.01 
 
Figure 12. Prevalence of anti-HCV among IDUs by age groups  
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Figure 13. Prevalence of anti-HCV among IDUs by marital status  
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Figure 14. Prevalence of anti-HCV among IDUs by educational level 
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5.2.3 Drug use practices  
 
Significant difference in duration of injection drug use was observed between anti-HCV 
positive and anti-HCV negative IDUs (p=0.0016). Longer duration of drug injection 
was observed in the group of anti-HCV positive IDUs compared to anti-HCV negative 
IDUs (15.2 ± 6.3 vs 12.3 ± 6.7 years) (Table 33). 
However, in the group of IDUs who were anti-HCV positive, there was no significant 
difference in the duration of drug injection between 1a and 3a HCV genotypes (p=0.22), 
and among CT, CC and TT genotypes of IL28B (p=0.32). 
Table 33.   Duration of injection drug use in relation to anti-HCV presence, HCV 
genotype and IL28B polymorphism of IDUs in Prishtina Region of Kosovo 
Variable Result 
Duration of drug use in years 
p-value 
mean ± SD min – max 
HCV Positive 15.2 ± 6.3 5 – 35 c0.0016** 
Negative 12.3 ± 6.7 5 – 37 
 
HCV GN 
1a 16 ± 6.7 5 – 35  
c0.22 3a 13.9 ± 6.6 6 – 37 
2k 11  
 
IL28B 
CT 16.5± 7.2 6 – 37  
d0.32 CC 14.3 ± 6.2 6 – 31 
TT 15.9 ± 6.9 8 – 32 
c (Student’s  t test)  d (Analysis of Variance)  **p<0.01 
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Figure 15. Mean duration of injection drug use among anti-HCV positive and 
negative IDUs 
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HCV prevalence among IDUs correlated significantly with the duration of the drug use 
(p=0.031). When duration of injection drug use was stratified, the highest prevalence of 
the antibodies against HCV was found in the group of IDUs who injected drugs for 25 
to 29 years (75.0%), followed by lower anti-HCV prevalence in the groups of IDUs 
having shorter history of drug injection (Table 34).  
 
The frequency of drug injection had a significant impact on the HCV prevalence among 
IDUs (p<0.0001). The IDUs who injected drugs more frequently had a higher 
prevalence of antibodies against HCV. The HCV infection was detected in all 10 IDUs 
who reported drug injection four or more times a day. The lowest prevalence of 
infection was found among IDUs who injected drugs only once, or 2–3 times per month 
(31.3% and 27.8%, respectively). 
 
As for the impact of the place of drug injection on HCV prevalence, the results showed 
a significant impact of the so called 'shooting galleries' or similar places where IDUs 
gather (p=0.0006). Two thirds (67.2%) of anti-HCV positive IDUs had injected drugs in 
shooting galleries (or similar places where IDUs gather) compared to 32.8% of anti-
HCV negative IDUs.  
 
As for the type of drugs injected, anti-HCV positive IDUs were using statistically 
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significantly more heroin and cocaine combined (p=0.011), amphetamine (p=0.002), 
morphine (p=0.007), and methadone (p<0.001), compared to anti-HCV negative IDUs. 
 
There was no significant difference between anti-HCV positive and anti-HCV negative 
IDUs with regard to injection with already used needles and syringes (p=0.055), use of 
sterile needles and syringes (p=0.056), frequency of using sterile needles and syringes, 
and applied method for cleaning needles (p=0.23).  
 
The anti-HCV positive IDUs significantly more commonly obtained sterile syringes and 
needles from the non-governmental organizations than the HCV negative IDUs (58.8% 
vs  41.2% p=0.00002) (Table 34). 
 
Table 34.    Drug use practices of IDUs in Prishtina Region of Kosovo 
Variable 
 
Total 
Anti-HCV 
positive 
n(%) 
Anti-HCV 
negative 
n (%) 
p-value 
 
Duration of drug 
use (years) 
5–9 69 23 (33.3) 46 (66.7)  
 
b0.031* 
10–14 52 25 (48.1) 27 (51.9) 
15–19 45 27 (60.0) 18 (40.0) 
20–24 28 17 (60.7) 11 (39.3) 
25–29 4 3 (75.0) 1 (25.0) 
30> 7 4 (57.1) 3 (42.9) 
Duration of drug 
use (years) 
= 5 years  5 1 (20.0) 4 (80.0) a0.2 
> 5 years 200 98 (49.0) 102 (51.0) 
Frequency of 
injection drug use 
Once a month 67 21 (31.3) 46 (68.7)  
b< 0.001 2–3 times a 
month 
36 10 (27.8) 26 (72.2) 
1–3 times a 
week 
43 24 (55.8) 19 (44.2) 
4–6 times a 
week 
6 5 (83.3) 1 (16.7) 
1–3 times a 
day 
43 29 (67.4) 14 (32.6) 
4 or more 
times a day 
10 10 (100) 0 
 
 
At  home 161 77 (47.8) 84 (52.2) a0.8 
In a private 
house or 
4 2 (50.0) 2 (50.0) b1.0 
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Place of drug use 
apartment 
In a public 
place, e.g. a 
bar, shop, 
toilet 
5  
3 (60.0) 
 
2 (40.0) 
b0.67 
 
In a dealer's 
house or 
apartment 
4  
1 (25.0) 
 
3 (75.0) 
b0.62 
 
On the street 
or in the park 
17  
7 (41.2) 
 
10 (58.8) 
a0.54 
 
In a shooting 
gallery or in 
another place 
where IDUs 
gather 
58  
39 (67.2) 
 
19 (32.8) 
a0.0006** 
 
In prison 1 1  0  
Other  18 9 (50.0) 9 (50.0) a0.88 
 
Type of drugs 
injected 
Heroin 201 98 (48.8) 103 (51.2) a0.35 
Cocaine 55 30 (54.5) 25 (45.5) a0.28 
Heroin and 
cocaine 
combined 
52 33 (63.5) 19 (36.5) a0.011* 
Amphetamine 12 11 (91.7) 1 (8.3) a0.002** 
Morphine 21 16 (76.2) 5 (23.8) a0.007** 
Opium 11 8 (72.7) 3 (27.3)    a0.095 
Methadone 143 89 (62.2) 54 (37.8) a< 0.0001 
Use of used  
needles/syringes 
Yes 24 16 (66.7) 8 (33.3) a0.055 
No 181 83 (45.9) 98 (54.1) 
Use of sterile 
needles/syringes 
Yes 202 98 (48.5) 104 (51.5) b0.052 
No 3 1 (33.3) 2 (66.7) 
Somebody else 
used your 
needle/syringe 
afterwards 
Yes 190 94 (49.5) 96 (50.5) a0.13 
No 14 4 (28.6) 10 (71.4) 
 
Frequency of 
using sterile 
needles/syringes  
Always 
(100%) 
163 79 (48.5) 84 (51.5)  
 
 
b1.0 
Most of the 
time (75%) 
39 19 (48.7) 20 (51.3) 
About every 
second time 
(50%) 
2 1 (50.0) 1 (50.0) 
Sometimes 
(25%) 
 / / 
Rarely (about  / / 
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10%) 
Never or 
almost never  
 / / 
 
 
Method of 
cleaning of used 
needle/syringes  
With cold 
water 
20 12 (60.0) 8 (40.0)  
 
 
 
b0.23 
With warm 
water 
3 1 (33.3) 2 (66.7) 
With hot 
water 
14 11 (78.6) 3 (21.4) 
With boiling 
water 
30 14 (46.7) 16 (53.3) 
With soap or 
detergent 
 / / 
With bleach  / / 
With alcohol 15 6 (40.0) 9 (60.0) 
Other  4 3 (75.0) 1 (25.0) 
Place of 
obtaining sterile 
needles/syringes 
Pharmacy or 
hospital 
204 99 (48.5) 105 (51.5) b1.0 
I buy them in 
the street 
1 0 1 
 
From a non-
governmental 
organization  
 
136 
 
80 (58.8) 
 
56 (41.2) 
a0.00002** 
a(Chi-square test)  b(Fisher's exact test)  *p<0.05   **p<0.01 
 
Figure 16. Prevalence of anti-HCV among IDUs by duration of drug use 
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Figure 17. Prevalence of anti-HCV among IDUs by frequency of drug injection 
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Table 35 shows the distribution of HCV genotypes by duration of drug use, frequency 
of injection, place of injection, type of drug, usage of used or sterile needles and 
syringes. All these characteristics related to the usage of drugs differed non-significantly 
between 1a and 3a HCV subtypes of IDUs. 
 
Table 35. HCV Genotypes and drug use practices among IDUs in  
Prishtina Region of Kosovo 
Variable 
HCV Genotype 
p-
value 
 1a 
n (%) 
 3a 
n (%) 
 2k 
n (%) 
Duration of drug 
use (years) 
5–9 7 (50.0) 7 (50.0) 0  
b0.24 10–14 12 (66.7) 5 (27.8) 1 (5.5) 
15–19 13 (56.5) 10 (43.5) 0 
20–24 10 (90.9) 1 (9.1) 0 
25–29 1  0 0 
30> 2  1  0 
 = 5 years  1  0 0  
b1.0 > 5 years 44 (63.8) 24 (34.8) 1 (1.45) 
Frequency of 
injection drug use 
Once 8 (61.5) 5 (38.5) 0  
 
 
b0.16 
 
2–3 times 4 (80.0) 1 (20.0) 0 
1–3 times a week 16 (80.0) 4 (20.0) 0 
4–6 times a week 1  2  0 
1–3 times a day 14 (66.7) 7 (33.3) 0 
4 or more times a 2 (25.0) 5 (62.5) 1 (12.5) 
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day 
 
 
 
 
Place of drug use 
At  home 38 (65.5) 19 (32.8) 1 (1.7) b0.74 
In a private 
house or 
apartment 
2  0 0  
In a public place, 
e.g. a bar, shop, 
toilet 
2  0 0  
In a dealer's 
house or 
apartment 
0 0 0  
On the street or 
in the park 
3  0 0  
In a shooting 
gallery or in 
another place 
where IDUs 
gather 
16 (64.0) 8 (32.0) 1(4.0)  a0.85 
In prison 0 1  0  
Other  3  2  0 b1.0 
 
Type of drugs 
injected 
Heroin 45 (65.2) 23 (33.3) 1 (1.5) b0.35 
Cocaine 15 (68.2) 7 (31.8) 0 a0.72 
Heroin and 
cocaine 
combined 
18 (72.0) 7 (28.0) 0 a0.37 
Amphetamine 6 (100) 0 0  
Morphine 11 (73.3) 4 (26.7) 0 a0.46 
Opium 3  2  0 b1.0 
Methadone 38 (60.3) 24 (38.1) 1 (1.6) b0.087 
Use of used 
needles/syringes 
Yes 5 (45.5) 5 (45.4) 1 (9.1) b0.3 
No 40 (67.8) 19 (32.2) 0 
Use of sterile 
needles/syringes 
Yes 44 (63.8) 24 (34.8) 1 (1.4) b1.0 
No 1  0 0 
Somebody else 
used your 
needle/syringe 
afterwards 
Yes 3  0 0 b0.55 
No 41 (62.1) 24 (36.4) 1 (1.5) 
 
Frequency of use 
of sterile 
needles/syringes 
Always (100%) 37 (66.1) 19 (33.9) 0  
 
b0.56 
Most of the time 
(75%) 
8 (61.5) 4 (30.8) 1 (7.7) 
About every 
second time 
(50%) 
0 1  0 
 With cold water 5 (55.6) 3 (33.3) 1 (11.1)  
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Method of 
cleaning used 
needles/syringes  
With warm water 1    
With hot water 6 (75.0) 2 (25.0) 0 
With boiling 
water 
8 (72.7) 3 (27.3) 0 
With soap or 
detergent 
/   
With bleach /   
With alcohol 3  1  0 
Other  1  1  0 
Place of 
obtaining sterile 
needles/syringes 
A pharmacy or 
hospital 
10 (76.9) 3 (23.1) 0 
b0.6 Non-
governmental 
organization 
35 (61.4) 21 (36.8) 1 (1.8) 
a(Chi-square test)  b(Fisher's exact test) 
 
5.2.4 Experience with the police and prison 
 
Results of the analysis about the experience of IDUs with the police showed that 103 
(50.2%) of them were arrested for drug use. Significantly more anti-HCV positive IDUs 
were arested (p=0.02). More than half (110/205; 53.7%) of IDUs reported ever being 
imprisoned. Anti-HCV positive IDUs significantly more frequently reported ever being 
in prison (60.9%, p=0.0001). However, there was no significant difference among anti-
HCV positive and negative IDUs with regard to injecting drugs during imprisonment 
(Table 36). 
 
Table 36. Experience with police and prison of IDUs in Prishtina Region of Kosovo 
Variable Total 
Anti-HCV 
positive 
Anti-HCV 
negative 
p-value 
Arrested for drug use 
Yes  103 58 (56.3) 45 (43.7)  
a0.02* No  102 41 (40.2) 61 (59.8) 
Imprisoned Yes  110 67 (60.9) 43 (39.1)  
a0.0001** No  95 32 (33.7) 63 (66.3) 
Injected drugs during 
imprisonment 
Yes  6 4 (66.7) 2 (33.3)  
b1.0 No 104 63 (60.58) 41 (39.42) 
a(Chi-square test)  b(Fisher's exact test)  *p<0.05  **p<0.01 
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Figure 18. Prevalence of anti-HCV among IDUs with regard to being ever arrested 
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Figure 19. Prevalence of anti-HCV among IDUs with regard to ever being in 
prison
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5.2.5 Sexual practices 
 
A total of 149 (72.7%) IDUs had a sexual intercourse within the month prior to 
participation in the study. IDUs who had sexual intercourse within the past month were 
infected by HCV non-significantly more frequently than the IDUs who denied this 
practice (50.3% vs 44.4%; p=0.46). 
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Most IDUs who had sexual intercourse in the past month (71.8%) had one sexual 
partner within the past month. All the three IDUs who had sexual intercourse with 4 
different persons in the past month were HCV positive. The prevalence of antibodies 
against HCV was also high in the group of IDUs who, within the period of the past 
month, had sexual intercourse with three different individuals (64.3%). Difference in the 
number of sexual partners in the past month between HCV positive and HCV negative 
IDUs was not statistically significant (p=0.23).  
 
Forty-eight IDUs that had sexual intercourse in the past month reported always using 
condoms (31.8%). The prevalence of HCV infection was not statistically significantly 
different among the IDUs who used condoms all the time when they had a sexual 
intercourse in the past month and those who did not (p=0.26). The HCV positive and the 
HCV negative IDUs differed significantly by the use of condoms during their last 
sexual intercourse with their marital partner or permanent partner (p=0.037), i.e. 58.3% 
of IDUs who used condoms during their last sexual intercourse with their marital or 
permanent partner were anti-HCV positive vs 41.7% who were anti-HCV negative.  
In this study population of IDUs, 18 (9.1%) had a regular sexual partner who injected 
drugs, eight of which (44.4%) also had hepatitis C; four IDUs had a regular sexual 
partner who previously injected drugs, two of whom were HCV positive. There were no 
statistically significant differences in the prevalence of antibodies against HCV among 
IDUs with a permanent sexual partner who injected drugs, IDUs with a permanent 
sexual partner who did not inject drugs, and IDUs with a permanent sexual partner who 
used to inject drugs previously (p=0.93).  
 
A total of 120 (61.9%) IDUs used a condom during their last sexual intercourse with a 
casual partner. Among them, 60 (50.0%) had HCV infection, while in the group of 74 
IDUs who did not use a condom, 47.3% had HCV infection (p=0.7).  
 
Twelve (6.0%) IDUs had sexual intercourse in the past month with a non-regular 
partner who injected drugs, six of whom were HCV positive. No significant difference 
was observed between anti-HCV positive and anti-HCV negative patients related to 
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having sexual intercourse with a non-regular partner who injected drugs in the past 
month (p=0.9).   
 
The prevalence of antibodies against HCV differed non-significantly among the groups 
who used a condom the last time they had sexual intercourse with a casual partner 
injecting drugs and who did not use a condom or did not remember using a condom 
(p=0.7). 
 
Statistically significant difference was not found for the infection frequency with HCV 
among the IDUs who had anal sex (47.7%), had no anal sex (52.9%), and those who 
refused to answer this question (41.2%) (p=0.47). Also, non-significant difference was 
found in the frequency of HCV infection among the IDUs who used or did not use a 
condom during anal sex (48.5% vs 45.5%) (p=0.8) (Table 37). 
 
Table 37. Sexual practices and HCV infection among IDUs in Prishtina Region of 
Kosovo 
Variable 
  
Total 
n 
Anti-
HCV 
positive 
n (%) 
Anti-
HCV 
negatives 
n (%) 
p-
value 
Sexual 
intercourse in 
the past month 
Yes 149 75 (50.3) 74 (49.7)  
a0.46 No 
54 
24 (44.4) 30 (55.6) 
Number of 
sexual partners 
in the past 
month 
1 107 52 (48.6) 55 (51.4)  
 
b0.23 
2 25 11 (44.0) 14 (56.0) 
3 14 9 (64.3) 5 (35.7) 
4 3 3 (100) 0 
Condom use 
during each 
sexual 
intercourse in 
the past month 
Yes 48 28 (58.3) 20 (41.7)  
b0.2 No 100 47 (47) 53 (53) 
Don't remember 
1 
0 1 
Condom use 
during each 
sexual 
intercourse with  
regular partner 
or spouse 
Yes 72 42 (58.3) 30 (41.7)  
a0.037*  
No 
128 
 
55 (43.0) 
 
73 (57.0) 
Regular sex Yes 18 8 (44.4) 10 (55.6)  
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partner injects 
drugs 
No 179 88 (49.2) 91 (50.8) 
b0.93 
No, but he/she used to inject 4 2 2 
Condom use 
during the last 
sexual 
intercourse with 
casual partner 
Yes 120 60 (50.0) 60 (50.0) a0.7 
No 
74 
35 (47.3) 39 (52.7) 
Sexual 
intercourse in 
the past month 
with a non-
regular partner 
who also 
injected drugs  
Yes 12 6 (50.0) 6 (50.0) a0.9 
No 
188 
92 (48.9) 96 (51.1) 
Condom use 
during  the last 
sexual 
intercourse with  
casual partner 
who injected 
drugs 
Yes 45 23 (51.1) 22 (48.9) a0.7 
No 38 20 (52.6) 18 (47.4) 
Don't remember 
25 
11 (44.0) 14 (56.0) 
Anal sex Yes 65 31 (47.7) 34 (52.3) a0.47 
No 102 54 (52.9) 48 (47.1) 
Refused to answer 34 14 (41.2) 20 (58.8) 
Anal sex with: Only women     64 30 (46.9) 34 (53.1)  
b1.0 Only men 1 0 1 
Condom use 
during the last 
anal sex 
Yes 33 16 (48.5) 17 (51.5) a0.8 
No 
33 
15 (45.5) 18 (54.5) 
a(Chi-square test)  b(Fisher's exact test)  *p<0.05   
 
Distribution of HCV genotypes was not significantly correlated with any of the IDUs 
sexual practices, in the Prishtina Region (Table 38). 
 
Table 38. HCV genotypes among IDUs in Prishtina Region of Kosovo  
and their sexual practices  
Variable HCV Genotype p-value 
 1a 
n (%) 
 3a 
n (%) 
 2k 
n (%) 
Sexual intercourse in 
the past month 
Yes 37 (68.5) 16 (29.6) 1 (1.9) a0.8 
No 8 (50) 8 (50) 0 
Number of sexual 1 27 (77.1) 8 (22.9) 0  
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partners in the past 
month 
2 6 (66.7) 2 (22.2) 1 (11.1) 
b0.105 
3 4 (44.4) 5 (55.6) 0 
4 0 1 0 
Condom use during 
each sexual intercourse 
in the past month 
Yes 13 (65) 7 (35) 0  
a0.79 No 24 (66.7) 11 (30.5) 1 (2.8) 
Condom use during the 
last sexual intercourse 
with regular partner  
yes 20 (71.4) 8 (28.6) 0  
a0.53 no 25 (62.5) 14 (35) 1 (2.5) 
Regular sex partner 
injects drugs 
Yes 0 2 (66.7) 1 (33.3)  
 
b0.21 
No 43 (67.2) 21 (32.8) 0 
No, but 
he/she used 
to inject 
2 0 0 
Condom use during the 
last sexual intercourse 
with casual partner 
Yes 27 (69.2) 12 (30.8) 0  
a0.31 No 16 (55.2) 12 (41.4) 1 (3.4) 
Sexual intercourse in 
the past month with 
non-regular partner 
who also injected drugs 
Yes 0 3 0  
a0.015* No 45 (67.2) 21 (31.3) 1 (1.5) 
Condom use during the 
last sexual intercourse 
with casual partner 
who injected drugs 
Yes 13 (72.2) 5 (27.8) 0  
 
b0.5 
No 8 (50) 7 (43.8) 1 (6.2) 
Don't 
remember 
4 (57.1) 3 (42) 0 
Anal sex Yes 11 (52.4) 9 (42.9) 1 (4.7)  
a0.41 No 28 (71.8) 11 (28.2) 0 
Refused to 
answer 
6 (60) 4 (40) 0 
Anal sex with: Women 
only 
11 (55) 9 (45)   
Condom use during the 
last anal sex 
Yes 6 (50) 6 (50) 0 a0.58 
No 5 (55.6) 3 (33.3) 1 (11.1) 
a(Chi-square test)  b(Fisher's exact test)  *p<0.05   
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5.2.6 Sex work 
 
Eleven (5.4%) IDUs reported getting paid for sex in the past month. The prevalence of 
antibodies against HCV in those IDUs was 63.6%, vs. 48.2% in the group of IDUs who 
did not get paid for sexual intercourse in the past month. Association of sexual 
intercourse for money and HCV infection was not statistically significant (p=0.32). A 
similar situation was observed with regard to the use of condom during the last paid 
sexual intecourse. 
 
In the past 12 months, 9 (4.5%) IDUs paid or gave drugs for sex, and seven (70.0%) 
reported using a condom the last time they were paying for sex. Nevertheless, none of 
those sexual behaviors was significantly different between anti-HCV positive and anti-
HCV negative IDUs (Table 39). 
 
Table 39. Sex work and HCV infection among IDUs in Prishtina Region of Kosovo 
Variable 
Total 
n 
Anti-HCV 
positive 
n (%) 
Anti-
HCV 
negative 
n (%) 
p-value 
Got paid for sexual intercourse 
in the past month 
Yes  11 7 (63.6) 4 (36.4)  
a0.32 No 191 92 (48.2) 99 (51.8) 
Condom use during the last 
sexual intercourse that got paid 
for 
Yes   4 3 (75) 1 (25)  
 
No   4 3 (75) 1 (25) 
Paid/gave goods/drugs to have 
sexual intercourse in the past 
12 months  
Yes   9 5 (55.6) 4 (44.4)  
b0.74 
No 193 94 (48.7) 99 (51.3) 
Condom use during the last 
paid (for money or drugs) 
sexual intercourse 
Yes 7 4 (57.1) 3 (42.9)  
b0.2 
No 2 0 2 (100) 
a(Chi-square test)  b(Fisher's exact test)   
 
5.2.7 Treatment for drug addiction 
 
A total of 161 (78.5%) IDUs used NGO Labyrinth services in the previous year, 71 
(44.1%) of whom were anti-HCV positive. The statistical analysis showed that the IDUs 
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who were not using Labyrinth services were significantly more commonly infected with 
HCV (79.1% vs 44.1%; p=0.000046). 
 
Half of IDUs (50.1%) entered the treatment program in order to reduce or quit drug use, 
with statistically significantly more anti-HCV positive IDUs in the treatment program 
(57.7% vs 38.0%; p=0.000048).  
 
Information about the type of treatment was obtained from 105 IDUs, and 73 (69.5%) 
of them most frequently visited the rehabilitation program in a medical treatment 
facility. The type of treatment received had no significant impact on the frequency of 
infection with HCV (p=0.5) (Table 40).     
 
Table 40. Treatment for drug addiction and HCV infection among IDUs in Prishtina 
Region of Kosovo 
Variable 
  
Total 
Anti-HCV 
positive 
Anti-
HCV 
negative 
p-value 
Have you used 
Labirint services in 
the past year 
 
Yes 161 71 (44.1) 90 (55.9) 
a0.000046** 
No 43 34 (79.1) 9 (20.9) 
Treatment to 
reduce or quit use 
of drugs 
Yes 104 60 (57.7) 44 (42.3) 
 
a0.000048** 
No 100 38 (38.0) 62 (62) 
Type of treatment  Rehabilitation 
program  run by an 
NGO 
13 7 (53.9) 6 (46.1) 
 
 
 
 
b0.5 
Rehabilitation 
program in a 
medical treatment 
facility 
73 46 (63) 27 (37) 
Rehabilitation 
program in prison 
6 4 (66.7) 2 (33.3) 
Detoxication 
treatment by my 
family 
2 1 1 
Self-help  5 1 (20) 4 (80) 
Other 6 3 (50) 3 (50) 
a(Chi-square test)  b(Fisher's exact test);  **p<0.01 
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The average age at which HCV positive IDUs received treatment was 28.7±7.3 years, 
versus the average age of HCV negative IDUs – 25.8 ± 5.3 (p=0.026). 
 
 
 
 
 
 
Figure 20. Average IDUs age at treatment initiation in Prishtina, Kosovo 
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5.2.8 Logistic regression analysis 
 
Logistic regression analysis was used in order to analyze the factors being associated 
with the HCV infection and to predict the presence of antibodies against HCV among 
IDUs. 
Univariate logistic regression analysis showed that factors significantly associated with 
anti-HCV positivity were: 
 
- The age of IDUs  (ОR: 1.111, 95% CI 1.062 – 1.163; p<0.001), more 
precisely the age group from 30 to 39 years (ОR: 2.667, 95% CI 1.146 – 
6.203; p=0.023), and 40 years and older (ОR: 5.939, 95% CI 2.388 – 14.772; 
p<0.001); 
- IDUs being married (ОR: 1.836, 95% CI 1.006 – 3.350; p=0.048); 
- With completed primary education or no formal primary education compared 
to the higher education (ОR: 6.139, 95% CI 2.343 – 16.083; p<0.001), and 
completed secondary education compared to higher education (ОR: 2.528, 
95% CI 1.093 – 5.747; p=0.03);  
- Had a longer history of drug use (ОR: 1.384, 95% CI 1.245 – 1.538; p=0.001); 
- Drug injection of 1 to 3 times per week compared to once (ОR: 2.267, 95% CI 
1.252 – 6.114; p=0.012), drug injection 4 to 6 times per week compared to 
once (ОR: 10.952, 95% CI 1.204 – 9.660; p=0.034), and drug injection of 1 to 
3 times per day compared to once (ОR: 4.537, 95% CI 1.997 – 10.308; 
p<0.001); 
- Drug injection in the so called ‘shooting galleries’ where IDUs gather (ОR: 
2.882, 95% CI 1.499 – 5.540; p=0.002); 
- IDUs who were ever arrested for drug use (ОR: 1.918, 95% CI 1.101 – 3.341; 
p=0.022);  
- IDUs who were ever in prison (ОR: 3.068, 95% CI 1.713 – 5.438; p<0.001). 
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Table 41. Univariate logistic regression model to predict HCV infection 
among IDUs in Prishtina, Kosovo 
Variable N  
Anti-
HCV 
positive 
(%) 
Unadjusted 
OR CI 95% p-value 
Gender           
Female 21 33.3 ref (1)     
Male 183 49.7 1.978 0.763 – 5.128 0.16 
Missing 1         
Age (years)     1.111 1.062 – 1.163 <0.001 
Age (years)           
19–29 37 24.3 ref (1)     
30–39 104 46.2 2.667 1.146 – 6.203 0.023* 
≥ 40 64 65.6 5.939 2.388 – 14.772 <0.001 
Marital status           
Not married 142 43.7 ref (1)     
Married 63 58.7 1.836 1.006 – 3.350 0.048* 
Education           
Higher 35 25.7 ref (1)     
Primary  30 68 6.139 2.343 – 16.083 <0.001 
Secondary  120 46.7 2.528 1.093 – 5.747 0.030* 
Employment           
Employed 61 41 ref (1)     
Unemployed 144 51.4 1.522 0.831 – 2.790 0.174 
Duration of 
drug use (years) 
    1,384 1.245 – 1.538 0.001** 
Duration of 
drug use (years) 
          
5–9 69 33.3 ref(1)     
10–14 52 48.1 1.852 0.884 – 3.878 0.102 
15–19 
45 60 3 1.377 – 6.535 
  
0.006** 
20–24 28 60.7 3.091 1.246 – 7.669   0.015* 
25–29 4 75 6 0.591 – 20.924 0.13 
>30 7 57.1 2.667 0.55 – 12.926 0.223 
Frequency of 
injection            
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Once 67 31.3 ref (1)     
2–3 times 36 27.8 0.842 0.347 – 2.059 0.707 
1–3 times a 
week 43 55.8 2.267 1.252 – 6.114 0.012* 
4–6 times a 
week 6 83.3 10.952 1.204 – 9.660 0.034* 
1–3 times a day 
43 67.4 4.537 1.997 – 10.308 
  
0.001** 
4 or more times 
a day 10 100 4.00E+09 0 0.999 
Place of 
injecting drugs           
At home 161 47.8 ref(1)     
On the street or 
in the park 17 41.2 0.778 0.281 – 2.150 0.628 
In a shooting 
gallery or in 
another place 
where IDUs 
gather 58 67.2 2.882 1.499 – 5.540 0.002** 
Other  18 50 1.091 0.560 – 2.125 0.798 
Drugs           
Heroin           
No 4 25 ref(1)     
Yes 201 48.8 2.854 0.292 – 27.906 0.367 
Cocaine           
No 150  45.3 ref(1)     
Yes 55 54.5 1.409 0.758 – 2.620 0.279 
Heroin and 
cocaine            
No 153  43.1  ref(1)     
Yes 52 63.5 2.289 1.197 – 4.380 0.012* 
Morphine           
No 184  44.6 ref(1)     
Yes 21 76.7 3.894 1.369 – 11.076 0.011* 
Opium           
No  194  47.4 ref(1)     
Yes 11 72.7 3.018 0.777 – 18.262 0.110 
Methadone           
No 62  16.1  ref(1)     
Yes 143 62.2 8.57 4.022 – 18.262 0.001** 
Use of used 
needles/syringes           
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No 181 45.9 ref (1)     
Yes 24 66.7 2.361 0.962 – 5.795 0.061 
Arrested for 
drug use           
No 102 40.2 ref (1)     
Yes 103 56.3 1.918 1.101 – 3.341 0.022* 
Imprisonment           
No 95 33.7 ref (1)     
Yes 110 60.9 3.068 1.713 – 5.438 0.001** 
Sexual 
intercourse           
No 54 44.4 ref (1)     
Yes 149 50.3 1.09 0.582 – 2.043 0.788 
Missing 3         
Sex for money           
No 190 48.2 ref (1)     
Yes 11 63.6 1.265 0.373 – 4.288 0.706 
Missing 4         
Treatment for 
quitting drugs           
No 100 38.9 ref (1)     
Yes 104 57.7 1.272 0.732-2.211 0.394 
Missing 1         
*p<0.05; **p<0.01; OR=odds ratio; CI=confidence interval; 
 
Multivariate logistic regression analysis confirmed that independent significant 
predictors for the presence of anti-HCV among IDUs were: the age of IDUs (p=0.009), 
duration of drug use (p=0.002), the lowest educational level (p=0.039), drug injection in 
the so called 'shooting galleries' where the individuals gather for drug injection 
(p=0.009), and being in prison (p=0.01).  
 
With increase of age by one year, the risk for anti-HCV positivity increased by 8.6% 
(ОR: 1.086, 95% CI 1.021 – 1.156); 
 
The drug addicts with completed primary education or informal primary education 
compared to higher education had a 2.8 times higher risk for anti-HCV positivity  (ОR: 
2.886, 95% CI 1.199 – 8.33); 
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Increase of the duration of drug injection by one year increased the risk for anti-HCV 
positivity by 7.2% (ОR: 1.072, 95% CI 1.025 – 1.121);   
 
Drug users who injected drugs in the so-called 'shooting galleries' had a 2.5 times 
greater risk for anti-HCV positivity compared to IDUs injecting at other places (ОR: 
3.011, 95% CI 1.542 – 5.878);  
 
Being in prison increased the risk of the IDUs for anti-HCV positivity 2.26 times (ОR: 
2.26, 95% CI 1.215 – 4.204). 
 
Table 42. Multivariate logistic regression model to predict HCV 
infection among IDUs in Prishtina 
Variable N  
Anti-
HCV 
positive 
(%) 
Adjusted 
OR CI 95% p-value 
Gender   
 
      
Female 21 33.3 ref (1)     
Male 183 49.7 1.77 0.653 – 4.800 0.260 
Missing 1 
 
      
Age (years) 
    1.086 1.021 – 1.156 0.009** 
Age (years) 
          
19–29 37 24.3 ref (1)     
30–39 104 46.2 2.297 0.873 – 5.331 0.096 
≥ 40 64 65.6 3.221 0.949 – 5.563 0.065 
Marital status 
          
Not married 
142 43.7 ref (1)     
Married 
63 58.7 1.173 0.472 – 2.914 0.730 
Education  
          
higher 35 25.7 ref (1)     
primary  30 68 2.886 1.199 – 8.330 0.039* 
secondary  120 46.7 1.710 0.682 – 4.289 0.253 
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Employment 
          
Employed 61 41 ref (1)     
Unemployed 144 51.4 1.324 0.668 – 2.621 0.420 
Duration of 
drug use (years) 
    1.072 1.025 – 1.121 0.002** 
Duration of 
drug use (years) 
          
5–9 69 33.3 ref (1)     
10–14 52 48.1 1.777 0.810 – 3.898 0-151 
15–19 45 60 2.119 0.924 – 4.863 0.076 
20–24 28 60.7 1.342 0.487 – 3.699 0.569 
25–29 4 75 1.746 0.157 – 19.417 0.650 
>30 7 57.1 0.362 0.056 – 2.344 0.286 
Frequency of 
injection  
          
Once 67 31.3 ref (1)     
2–3 times 36 27.8 0.991 0.393 – 2.499 0.985 
1–3 times a 
week 43 55.8 1.370 0.942 – 5.393 0.620 
4–6 times a 
week 6 83.3 1.070 0.411 – 2.788 0.890 
1–3 times a day 
43 67.4 1.676 0.997 – 9.660 0.820 
4 or more times 
a day 10 100 3.00E+09 0 ***  
Place of 
injecting drugs 
          
At home 161 47.8 ref (1)     
On the street or 
in the park 
17 41.2 0.764 0.273-2.142 0.609 
In a shooting 
gallery or in 
another place 
where IDUs 
gather 
58 67.2 3.011 1.542-5.878 0.001** 
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Other places 18 50 1.098 0.552-2.186 0.820 
Drugs           
Heroin           
No 4 25.0  ref (1)     
Yes 201 48.8 1.711 0.171- 17.158 0.648 
Cocaine           
No 150  45.3  ref (1)     
Yes 55 54.5 1.407 0.728 – 2.719 0.310 
Heroin and 
cocaine            
No 153  43.1  ref (1)     
Yes 52 63.5 1.825 0.920 – 3.619 0.085 
Morphine           
No 184  44.6  ref (1)     
Yes 21 76.7 2.604 0.802 – 8.456 0.110 
Opium           
No  194 47.4  ref (1)     
Yes 11 72.7 1.428 0.318 – 6.405 0.640 
Methadone           
No  62 16.1  ref (1)     
Yes 143 62.2 3.72 0.911 – 10.560 0.140 
Use of used 
needles/syringes 
          
No 181 45.9 ref (1)     
Yes 24 66.7 2.307 0.905 – 5.881 0.080 
Arrested for 
drug use           
No 102 40.2 ref (1)     
Yes 103 56.3 1.679 0.917 – 3.075 0.093 
Imprisonment           
No 95 33.7 ref (1)     
Yes 110 60.9 2.26 1.215 – 4.204 0.010* 
Sexual 
intercourse           
No 54 44.4 ref (1)     
Yes 149 50.3 1.117 0.966 – 1.171 0.737 
Missing 2         
Sex for money           
No 190 48.2 ref (1)     
Yes 11 63.6 1.033 0.294 – 3.625 0.959 
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No 4         
Treatment for 
quitting drugs           
No 100 38.9 ref (1)     
Yes 104 57.7 1.132 0.639 – 2.006 0.672 
Missing 1         
*p<0.05; **p<0.01; *** Not able to be calculated; OR=odds ratio; CI=confidence 
interval 
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5.3 HCV INFECTION AMONG CHRONIC PATIENTS AND 
BLOOD DONORS 
 
Samples of 59 individuals infected with HCV were included in the study, 50 of them 
were from HCV chronic patients at the Infectious Disease Clinic of the University 
Clinical Center of Kosovo, and 9 were from blood donors. Through cross checking of 
cases, it was noticed that three chronic HCV patients were included in the study 
population of dialysis patients.  
 
HCV core region was detected among 31 (62.0 %) HCV chronic patients, and among all 
of them HCV genotype was determined, with the highest frequency of HCV subtype 1b 
– 13/31 (41.9%), followed by subtype 1a – 8/31 (25.8%), subtype 3а – 4/31 (12.9%), 
subtype 4d in 4/31 (12.9%) patients, and subtype 2c in 2/31 (6.5%) chronic HCV 
patients. 
 
In the group of 10 HCV positive blood donors, the HCV genotype was determined in 6 
(66.7%) patients, among whom there were four (66.7%) with subtype 1b and two 
(33.3%) with subtype 1a (Table 43). 
 
Table 43. Distribution of HCV genotypes in HCV chronic patients and blood 
donors 
HCV Genotype Chronic HCV patients  HCV blood donors  
n (%) n (%) 
1a  8 (25.8) 2 (33.3) 
1b 13 (41.9) 4 (66.7) 
3a 4 (12.9)  
4d 4 (12.9)  
2c                  2 (6.5)  
Total 31 6 
 
 - 88 - 
IL28B gene was examined among all 50 HCV chronic patients, in which structure the 
most frequent expression was of the CT genotype – 28/50 (56.0%), followed by CC 
genotype – 19/50 (38.0%),  and ТТ genotype – 3/50 (6.0%).  
 
In the group of  9 HCV positive blood donors, the polymorphism of IL28B could be 
determined in 5 (55.6%) of them, whereas the expression of CC genotype was detected 
in one and the expression of CT genotype in four (Table 44).  
 
Table 44.  Expression of IL28B in chronic patients and blood donors   
IL28B Chronic HCV patients HCV blood donors  
n (%) n (%) 
CC 19 (38.0) 1 (20.0) 
CT 28 (56.0) 4 (80.0) 
TT 3 (6.0)  
Total 50 5 
 
Through cladogram phylogenetic trees of HCV subtypes 1a, 1b, 3a, and 4d, it is 
possible to notice that most sample sequences from the study chronic HCV patients are 
not clustered with each other, with a few minor exceptions.  
 
In fact, out of a total of nine sequences from chronic HCV patients with HCV subtype 
1a, four of them (separately) are inside three different clusters consisted of samples 
from different dialysis centers. Three other sequences from the same group and HCV 
subtype are located inside a cluster of HCV samples from IDUs (Fig.1). 
  
There were 13 sequences of samples with HCV subtype 1b from chronic HCV patients 
for which a cladogram phylogenetic tree shows two triplets inside two clusters with 
aLRT>0.9. Among one of these clusters are also two samples from Gjilan dialysis 
center and two samples from blood donors (Fig.2).  
 
Four sequences from the study chronic HCV patients with HCV subtype 3a are not 
clustered with each other. One sample from this group is located inside a cluster of 12 
samples from IDUs with HCV subtype 3a (Fig.11).  
 - 89 - 
 
Four sample sequences of chronic HCV patients with HCV subtype 4d are not clustered 
with each other and they are placed separately in three different clusters consisted of 
samples from different dialysis centers of Kosovo (Prizren, Prishtina, Mitrovica, Peja, 
Gjakova, Gjilan) (Fig.3).  
 
With regard to sequences from HCV infected blood donors in this study, four samples 
with HCV subtype 1b are placed as paired samples in two different clusters. In one 
cluster with aLRT >0.8 inside cladogram of HCV subtype 1b are placed two sequences 
from two samples from blood donors together with a few control sequences. The second 
pair of samples of blood donors is placed in the cluster with aLRT>0.9 together with 
three samples from chronic HCV patients and two samples from Gjilan dialysis center. 
 
Of two samples of HCV infected blood donors with HCV subtype 1a, one of them is 
placed inside a large cluster of HCV sequences from IDUs.  
 
 
 
5.3.1 Socio-demographic data of chronic HCV patients and anti-HCV 
positive blood donors 
 
A questionnaire on socio-demographic data and possible high risk activities related to 
HCV infection was completed through face-to-face interviews with 42 subjects, 35 of 
them HCV chronic patients and 7 anti-HCV positive blood donors. Among chronic 
HCV patients and blood donors enrolled in the study in 2013 at the Infectious Disease 
Clinic in Prishtina, University Clinical Center of Kosovo (UCCK), 13 (31.0%) were 
female and 29 (69.0%) male, with a mean age of 48.9 ± 13.2 years (minimum age 23 
years, maximum age 69 years). Most subjects were 60–69 years old (13; 31.0%), 
followed by the age group of 39 and younger with 12 (28.6%) subjects. 
 
One third of subjects (12/42; 28.6%) originated from Prishtina, followed by Mitrovica 
with 8 (8/42; 19.0%) subjects, Gjilan with 7 (16.7%), Ferizaj with 6 (14.3%), and 
Prizren and Gjakova with 2 (4.8%) subjects each. As for marital status, most subjects 
were married (35; 83.3%). As for educational level, 16 (38.1%) subjects completed 
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primary education, 15 (35.7%) secondary education, and the lowest percentage of 
subjects had higher level education (11/26.2%). Eighteen (42.9%) subjects were 
unemployed, 11 (26.2%) were housewives, and one was retired (Table 45). 
 
Table 45. Demographic characteristics of chronic HCV patients and anti-HCV 
blood donors 
Variable N (%) 
Gender Female 13 (31.0) 
Male 29 (69.0) 
 
 
Age group 
≤ 39 12 (28.6) 
40 – 49 8 (19.0) 
50 – 59 9 (21.4) 
60 – 69 13 (31.0) 
 
 
 
 
Region 
Prishtina 12 (28.6) 
Mitrovica 8 (19.0) 
Peja 4 (9.5) 
Prizren 2 (4.8) 
Ferizaj 6 (14.3) 
Gjilan 7 (16.7) 
Gjakova 2 (4.8) 
Missing 1 (2.4) 
 
Marital status 
Single 3 (7.1) 
In a relationship 3 (7.1) 
Married 35 (83.3) 
Widow/er 1 (2.4) 
 
Education 
Primary 16 (38.1) 
Secondary  15 (35.7) 
Higher 11 (26.2) 
 
 
 
 
Occupation 
Housewife 11 (26.2) 
Farmer 2 (4.8) 
Physical worker 2 (4.8) 
Engineer 2 (4.8) 
Economist 3 (7.1) 
Health worker 1 (2.4) 
Other 20 (47.6) 
Missing 1 (2.4) 
 
 
Employment 
Unemployment 18 (42.9) 
Employed in public sector 4 (9.5) 
Employed in private sector 18 (42.9) 
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Retired 1 (2.4) 
Missing 1 (2.4) 
 
 
 
 
5.3.2 Knowledge about HCV  
 
Results of this study showed that only 16.7% of chronic HCV patients and blood donors 
infected with HCV had heard about hepatitis C virus prior to their infection. At the time 
of the study, they had more information about the ways of HCV transmission – 33 
(78.6%) responded affirmatively to the question 'Do you know how HCV is 
transmitted?'. Only 4 (9.5%) subjects reported ever having skin jaundice. Five (11.9%) 
HCV positive patients gave family history information about their family members 
being infected with HCV (Table 46). 
    
 
Table 46. Chronic HCV patients’/Anti-HCV blood donor’s knowledge about HCV 
Variable N (%) 
Ever heard about hepatitis C virus Yes 7 (16.7) 
No 34 (81.0) 
Don't  know 1 (2.4) 
Knew how hepatitis C virus is spread Yes 33 (78.6) 
No 8 (19.0) 
Missing 1 (2.4) 
Diagnosed with hepatitis C infection Yes 36 (85.7) 
No 4 (9.5) 
Don't  know 1 (2.4) 
Missing 1 (2.4) 
Ever had skin jaundice Yes 4 (9.5) 
No 37 (88.1) 
Missing 1 (2.4) 
Family members having HCV infection  Yes 5 (11.9) 
No 34 (81.0) 
Don't  know 1 (2.4) 
Missing 2 (4.8) 
 
 - 92 - 
On average, those individuals were diagnosed with HCV 6.6 ± 2.5 years before the 
interviews (data obtained for 35 individuals). The shortest time of having the 
information on diagnosis with HCV infection was 3 years earlier, and the longest 15 
years earlier (Figure 20). 
    
Figure 20.  Time of being diagnosed with HCV infection (year) 
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5.3.3 Risk factors 
 
5.3.3.1 Blood transfusion  
 
Fifteen (35.7%) patients in the study groups received blood transfusion. The University 
Clinical Center of Kosovo in Prishtina was the most frequent medical institution where 
those patients received blood transfusion. Table 47 shows the distribution of patients by 
the number of blood transfusions. The time when those anti-HCV positive patients 
received blood transfusion ranged between 3 and 42 years earlier, the first  blood 
transfusion was received, on average, 13 ± 10.8 years earlier, the median time of the 
first transfusion was 10.5 years (range 5–31).  
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Table 47.  Blood transfusions among chronic HCV positive patients   
Variable N (%) 
Received blood transfusion Yes 15 (35.7) 
No 26 (61.9) 
Missing 1 (2.4) 
Health institution(s) where 
blood transfusions were 
received 
University Clinical Center of 
Kosovo 
7 (46.7) 
Regional hospital   5 (33.3) 
Other 2 (13.3) 
Missing 1 (6.7) 
Number of blood transfusions  One time 5 (33.3) 
Two times 1 (6.7) 
Three times 1 (6.7) 
Four times 1 (6.7) 
3–4 times 1 (6.7) 
Few times 3 (20.0) 
Over ten times 2 (13.3) 
Missing 1 (6.7) 
 
 
5.3.3.2 Dental services  
 
Most patients used dental services (36/42; 85.7%). The type of the dental services and 
the medical institution where those services were provided are given in Table 48.  
 
Table 48. Distribution of dental services among chronic HCV positive patients  
Variable N (%) 
Ever utilized dental services Yes 36 (85.7) 
No 5 (11.9) 
Missing 1 (2.4) 
Type of dental service Filling   3 (8.3) 
Extraction    7 (19.4) 
Filling, Extraction 20 (55.6) 
Prosthetics   2 (5.6) 
Other 3 (8.3) 
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Missing 1 (2.8)  
Medical institution where those 
services were provided 
Family medicine center 3 (8.3) 
Private dentistry center 26 (72.2) 
Family medicine center, 
private dentistry center 
3 (8.3) 
University Clinical 
Center for Dentistry of 
Kosovo 
2 (5.6) 
Other, Germany 1 (2.8) 
Missing 1 (2.8) 
 
5.3.3.3 Surgical interventions  
 
A great part of chronic HCV positive patients underwent surgical interventions (30; 
71.4%). The type of surgical interventions those patients were subjected to and the 
name/type of the medical institution where the surgical interventions took place are 
given in Table 49. Abdominal surgical interventions were most frequent, and most of 
them took place at the University Clinical Center of Kosovo in Prishtina. 
 
Table 49. Distribution of surgical interventions among chronic HCV positive 
patients  
Variable N (%) 
Ever had surgical intervention Yes 30 (71.4) 
No 11 (26.2) 
Missing 1 (2.4) 
Type of surgical intervention Abdominal 9 (30) 
Urological 6 (20) 
Gynecological 1 (3.3) 
Kidney transplantation 1 (3.3) 
Throat 1 (3.3) 
Venous problem 2 (6.7) 
Hydrocele 1 (3.3) 
Extraction of one lung 1 (3.3) 
Nose operation 1 (3.3) 
Biopsy of the neck 1 (3.3) 
Abdominal, Gynecological  1 (3.3) 
Operation on the leg 1 (3.3) 
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Missing 4 (13.3) 
Medical institution where the 
intervention took place 
University Clinical Center of 
Kosovo 
10 (33.3) 
Regional hospital 7 (23.3) 
Private hospital 1 (3.3) 
Other 7 (23.3) 
University Clinical Center of 
Kosovo, Other 
1 (3.3) 
 
 
5.3.3.4 Dialysis  
 
Five patients (11.9%) within the HCV treatment program were also on dialysis, all of 
them started their dialysis in Prishtina, one continued to utilize dialysis services in this 
center, one patient continued dialysis services in Ferizaj and Gjilan, one patient used 
dialysis services in  Mitrovica, one continued in Prizren and one in Gjakova (Table 50). 
It needs to be emphasized that three HCV chronic patients that were enrolled in the 
study within the HCV treatment program were also included in the study on dialysis 
patients. One of them was a patient from Prizren with code KOS-006 within the 
treatment program and with code KOS-303 at dialysis center in Prizren. This patient's 
samples were processed separately at the laboratory, being both of HCV genotype 1a 
and, at the phylogenetic tree, of HCV genotype 1a (Fig. 1), and placed in the same sub-
cluster of samples from Prizren dialysis center. The same situation was with a patient 
from Ferizaj with code KOS-014 within the HCV treatment program and code KOS-
393 at dialysis center of Ferizaj, and finally both samples were placed next to each other 
at the phylogenetic tree of HCV genotype 1 (Fig. 1) at the sub-cluster of samples from 
Ferizaj, Gjilan and Prishtina dialysis center. The third patient, included in the study in 
both groups – within the HCV treatment program and at dialysis centers, was a patient 
with sample code KOS-042 within the treatment program and with code KOS-226 at a 
dialysis center in Mitrovica. In this case, the sample KOS-226 was without detection of 
HCV RNA, but the sample with code KOS-042 was of HCV genotype 1a and, at the 
phylogenetic tree, of HCV genotype 1a (Fig. 1), and was placed inside the cluster of 
samples collected at Mitrovica dialysis center.  
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Table 50. Distribution of chronic HCV positive patients in relation to dialysis 
Variable N (%) 
Ever undergone dialysis Yes 5 (11.9) 
No 35 (83.3) 
Missing 2 (4.8) 
 
 
5.3.3.5 Other risk factors  
 
About half of the patients practiced some of the following risk behaviors: tattoo, ear or 
other body piercing, injected drugs, used shaving kit belonging to somebody else, or 
used somebody else’s tooth brush. It needs to be emphasized that all patients responding 
affirmatively to the question about ear/body piercing were females, which corresponds 
to the local custom of having an ear pierced. Two patients within the HCV treatment 
program were placed in the cluster of samples belonging to IDUs within cladogram of 
HCV genotype 1a (Fig. 1). Of those two patients, one with code KOS-027 was 
interviewed and mentioned having injected drugs. Unfortunately, the second patient 
with code KOS-049 was not reachable for interview. Four (9.5%) HCV positive patients 
had experience as prisoners, and one had hemophilia (Table 51).  
 
Table 51. Distribution of risk behaviors among chronic HCV positive patients  
Variable N (%) 
Ever had a high risk behavior Yes 22 (52.4) 
No 20 (47.6) 
Type of high risk behaviour  Tattoo 1 (4.5) 
Ear or other body piercing 12 (54.5) 
Injected drugs 1 (4.5) 
Used somebody else's shaving kit  1 (4.5) 
Used somebody else's tooth brush  1 (4.5) 
Organ transplantation 2 (9.1) 
Having a sexual partner (other than 
regular/wife/husband) 
1 (4.5) 
Tattoo, ear or other body piercing, 
injected drugs, needlestick injury at 
work, used same toilet with family 
2 (9.1) 
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member 
Tattoo, ear or other body piercing, 
used shaving kit belonging to 
somebody else, etc. 
1 (4.5) 
Ever imprisoned Yes 4 (9.5) 
No 37 (88.1) 
Missing 1 (2.4) 
Diagnosed with hemophilia Yes 1 (2.4) 
No 40 (95.2) 
Missing 1 (2.4) 
 
5.3.4 Treatment 
 
Thirty-four (80.1%) chronic HCV patients received therapy with pegylated interferon 
and ribavirin, 32 (94.12%) patients were administered this therapy at the Clinic for 
Infectious Diseases, University Clinical Center of Kosovo in Prishtina, one was treated 
in Albania and France. Twenty-nine (85.3%) patients completed the treatment, for 3 
patients (8.3%) the treatment was discontinued due to adverse events, for the remaining 
2 patients (5.9%) the reason why this treatment was not completed was not stated. Nine 
(24.1%) of the treated patients had no complaints concerning treatment with pegylated 
interferon/ribavirin. Among the rest of chronic HCV patients undergoing treatment, the 
main complaints are shown in Table 52. 
 
Table 52. Information associated with treatment of chronic HCV positive patients  
Variable N (%) 
Treated with 
interferon/ribavirin 
Yes 34 (80.9) 
No   8 (19.1) 
Place of treatment with 
interferon/ribavirin 
Clinic for Infection Diseases,  UCCK, 
Prishtina 
32 (94.1) 
Albania (2002); France (2005); UCCK 
Prishtina 
1 (2.9) 
Missing 1 (2.9) 
Treatment course with 
interferon/ribavirin 
completed 
Yes 29 (85.3) 
No 3 (8.8) 
Missing 2 (5.9) 
Main complaints related to No complaints 9 (26.5) 
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treatment with 
interferon/ribavirin 
Tiredness 1 (2.9) 
Fever, tiredness   4 (11.8) 
Fever, tiredness, anemia, vomiting 1 (2.9) 
Fever, tiredness, weakness, anemia 1 (2.9) 
Fever, tiredness, itching, exanthemas 1 (2.9) 
Tiredness, weakness, headache, lack of 
sleep, anxiety, hypotension 
1 (2.9) 
Headache, tiredness, pain in legs 1 (2.9) 
Fever, body pain 1 (2.9) 
Fever, thrombocytopenia 1 (2.9) 
Fever, fatigue, thrombocytopenia 1 (2.9) 
Fever, tiredness, body aches 1 (2.9) 
Anemia, leukopenia, sepsis 1 (2.9) 
Fever, pain in legs, headache, tiredness 1 (2.9) 
Tiredness, fever, stomach aches 1 (2.9) 
Cough 1 (2.9) 
Fatigue, weight loss, appetite loss, body 
aches 
1 (2.9) 
Headache, tiredness, dizziness, body pain 1 (2.9) 
Weight loss after treatment 1 (2.9) 
Pain in legs, itching, leukopenia 1 (2.9) 
Missing 3 (8.8) 
 
The distribution of HCV genotypes did not differ significantly between chronic patients 
with and without family history of HCV infection (p=0.13), between chronic patients 
who did not have or had dental interventions (p=0.55), between chronic patients who 
did not have or had a surgical intervention (p=0.89) and risk behaviors such as: tattoo, 
ear or other body piercing, injected drugs, needlestick injury at work, used somebody 
else`s shaving kit, used somebody else`s tooth brush or used the same toilet with a 
family member (p=0.16), with or without experience of being in prison (p=0.13), 
whereas it significantly differed among chronic patients who did not receive and 
received blood transfusion  (p=0.039), and did not undergo hemodialysis  (p=0.023). In 
the group of two patients who had an HCV positive family member, HCV subtype 1a 
was found in one patient, and  HCV subtype 1b in another.  
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In the group of 10 patients who received blood transfusion, HCV subtype 1a was found 
in four, HCV subtype 1b in four, HCV subtype 3a in one, and HCV subtype 2c in one 
patient.   
 
The 1a and 1b HCV subtypes were non-significantly more frequently present in patients 
who used dental services, compared to those who did not – 4/4 (100%); 9/10 (90%) vs 
1/10 (10%), respectively.  
 
In the group of 16 patients who had surgical interventions, HCV subtype 1b was 
detected in 7 (43.7%) patients.  
 
In the group of four patients who underwent dialysis, HCV subtype 1a was found in 
three patients and HCV subtype 4d in one patient. HCV subtype 1a was detected in two 
patients who were imprisoned (Table 53). 
 
Table 53.  HCV genotypes in chronic HCV patients by risk factor 
Variable HCV Genotype  p-value 
1a 
n (%) 
1b 
n (%) 
3а 
n (%) 
4d 
n (%) 
2c  
n (%) 
 
Family members with hepatitis 
C virus 
Yes 1 (50) 1 (50) 0 0 0 0.13 
No 3 (17.6) 8 (47.1) 1 (5.9) 3 
(17.6) 
2 (11.8) 
Ever received blood 
transfusion 
Yes 4 (40) 4 (40) 1 (10) 0 1(10) 0.039* 
No 0 6 (60) 0 3 (30) 1 (10) 
Ever utilized dental services Yes 4 (22.2) 9 (50) 1 (5.6) 2 
(11.1) 
2 (11.1) 0.55 
No 0 1 (50) 0 1(50) 0 
Ever had surgical intervention Yes 3 (18.8) 7 (43.7) 1 (6.3) 3 
(18.7) 
2 (12.5) 0.89 
No 1 (25) 3 (75) 0 0 0 
Ever undergone dialysis Yes 3 (75) 0 0 1 (25) 0 0.023* 
No 1 (6.3) 10 
(62.5) 
1 (6.2) 2 
(12.5) 
2 (12.5) 
Ever had:  tattoo, ear or other 
body piercing, injected drugs, 
needlestick injury at work, used 
somebody else`s shaving kit or 
Yes 1 (11.1) 3 (33.3) 1 
(11.1) 
2 
(22.2) 
2 (22.2) 0.16 
No 7(31.8) 10 
(45.5) 
3 
(13.6) 
2 (9.1) 0 
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tooth brush 
Ever been imprisoned Yes 2 (100) 0 0 0 0 0.13 
No 2 (11.1) 10 
(55.6) 
1 (5.6) 3 
(16.7) 
2 (11.1) 
p (Fisher's exact test, two-tailed test)     *p<0.05   
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6. Discussion 
 
6.1 HCV infection among dialysis patients in Prishtina and overall in 
Kosovo 
 
6.1.1. Anti-HCV prevalence, HCV genotypes and phylogenetic analysis 
 
This is the first study conducted in Kosovo among patients in all seven dialysis centers 
of Kosovo that determined the overall prevalence of HCV infection, the presence of 
HCV genotypes, phylogenetic clustering of HCV viral isolates according to genotype 
and sequencing of HCV NS5B region, and possible association of HCV infection with 
demographic and high risk behaviors/activities. 
 
Results of the study showed a high percentage of anti-HCV positive patients in dialysis 
centers of Kosovo, ranging from 22% at Prishtina dialysis center and going up to 91% 
in Gjakova. In fact, dialysis centers of Kosovo have already been facing high levels of 
HCV infection for many years. Data from this study show the situation in this respect 
has deteriorated (from 42.9% in 2008 to 53.0% in 2013; χ², p=0.0004) (85). 
 
Up to two decades ago, many European countries have been facing high levels of HCV 
infection in hemodialysis units but a progressive reduction of blood transfusions (due to 
the availability of erythropoietin in the late 1980s), followed in the early 1990s by the 
screening of blood donors with increasingly sensitive anti-HCV tests and strict 
application of infection control practices, resulted in a decline of HCV seroprevalence 
among dialysis patients. From 1991 to 2000, anti-HCV prevalence decreased in France 
from 42% to 30%, in Sweden from 16% to 9%, in Italy from 28% to 16%, in Hungary 
from 26% to 15%, in Belgium from 13.5% to 6.8%, and also in the United Kingdom 
from 7% to 3% (86–88). In Croatia, HCV seroprevalence declined from 44% in 1992 
(89) to 23% in 2003 (90). Studies by Atanasova et al. showed a decrease in anti-HCV 
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prevalence from 48% to 14.7% in a hemodialysis unit in Plovdiv, Bulgaria from 2008 to 
2014 (91, 92). 
 
The HCV infection continues to be an issue also in a number of countries neighboring 
Kosovo. High rates of HCV infection have been registered in Skopje, Macedonia, with 
anti-HCV prevalence of 32% (93), and in Bosnia and Herzegovina with 59% (94), 
followed by 26% in Greece (95). Somewhat lower HCV prevalence was noted at Tirana 
dialysis center, Albania, where anti-HCV prevalence was 16.7% (96), followed by 
12.7% in Serbia (97), 7.9% in Turkey in 2011 (98), and from 2.3% to 3.4% at a number 
of hemodialysis centers in Croatia (99, 100).  
 
Sequencing of specific regions of HCV genome for genotyping purposes and 
phylogenetic identification of isolates in clusters as a tool for assisting in identifying 
health care associated HCV infections have been used widely (101, 102).   
 
This study showed that HCV subtypes 1a, 4d, 1b, and 2 were circulating throughout 
Kosovo dialysis centers. The most prevalent was HCV subtype 1a (61.6%), followed by 
subtype 4d (33.2%), 1b (3.6%), and the lowest presence of HCV genotype 2 with only 
1.4%.  
 
In all dialysis centers, including Prishtina, HCV subtype 1a was most frequent, except 
in Peja, at which dialysis center HCV subtype 4d was most prevalent. This distribution 
of HCV subtypes is specific for dialysis centers of Kosovo, since according to results of 
this study, HCV subtypes 1a and 3a were the most prevalent among injecting drug users 
in Prishtina, and HCV subtype 1b was most prevalent among chronic HCV patients and 
blood donors in Kosovo.  
 
Contrary to Kosovo, most studies from the region are placing HCV subtype 1b as most 
frequent among dialysis patients. Among anti-HCV positive hemodialysis patients in 
northwest Croatia, subtype 1b has been detected in 75% of patients and genotype 3 in 
20.8% of patients (103). In a study with approximately 1,000 Turkish patients 
undergoing dialysis in three different regions of Turkey, HCV genotype 1b was most 
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prevalent with 73% (104). Among 61 anti-HCV positive patients at a dialysis unit in 
Tirana, Albania, the predominant HCV subtype was 1b in 25 patients (50%), followed 
by subtypes 2c, 4a, 3a, and 1a in 18%, 14%, 8%, and 6% of cases, respectively (105). 
HCV subtype 1b seems to be most frequent in the Netherlands and France, whereas in 
Italian hemodialysis patients subtypes 2a and 3a predominate (106). HCV genotype 1 
was shown to be most prevalent in hemodialysis patients (89.0%) in Macedonia (107). 
 
Similarly to Kosovo with regard to HCV subtype 1a, in a number of studies in Brazil, 
HCV genotype 1 was shown to be most prevalent (46.7% – 64.9%) among hemodialysis 
patients, followed by genotype 3 (19.0% – 30.6%), and genotype 2 (4.6% – 5.3%). 
HCV genotypes 4, 5, and 6 have not been identified in those studies. Within genotype 1, 
subtype 1a was shown to be most prevalent (74.1%), followed by subtype 1b (11.1%) 
(108, 109). 
  
The final confirmation that HCV infection among dialysis patients in Kosovo should be 
attributed to dialysis services was obtained through phylogenetic analysis of HCV 
isolates of HCV subtypes 1a, 1b, and 4d of dialysis patients. A high degree of 
phylogenetic clustering of HCV subtypes 1a (100%), 1b (63.6%), and 4d (96.4%) 
among dialysis sample sequences from Kosovo, including samples from Prishtina 
dialysis center, clearly indicates that many HCV infections originate within dialysis 
centers.  
 
6.1.2 Contributing factors for HCV spreading in dialysis centers of Kosovo 
 
This study tried to gain an insight into the underlining conditions that might contribute 
to the spread of HCV infection within dialysis centers of Kosovo. Therefore, we 
analyzed different factors, including duration of dialysis, use of blood transfusion and 
issues related to the management of dialysis units, such as staffing with a nephrologist 
and nurses, availability of dialysis machines, premises, anti-HCV testing, supply with 
consumables needed for daily work, etc. 
 
Initially, different anti-HCV prevalences among seven dialysis units in Kosovo 
suggested that specific factors within dialysis centers could have impacted this situation.  
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Multivariate data analysis showed that the main factors contributing to anti-HCV 
positivity were duration of dialysis and utilizing dialysis services in more than one 
dialysis center in Kosovo. Also, patients who had longer history of utilization of dialysis 
services had higher anti-HCV prevalence, ranging from 32% for those with less than 9 
years of utilization of dialysis services in Kosovo and going up to 91% for those with 
20–30 years of experience on dialysis.  
 
According to the staff at dialysis units in Kosovo, the need for transfused blood for 
dialysis patients in Kosovo has also decreased in recent years due to usage of 
erythropoietin. In addition, donated blood used in case of need is mandatorily screened 
for the presence of anti-HCV and HCV antigen at the National Blood Transfusion 
Center of Kosovo (NBTCK). Data from the NBTCK show that in the period 2011–2013 
there were 73,295 blood donations, out of which only 29 (0.04%) resulted as anti-HCV 
positive. These data indicate that blood donation could not be taken as a contributing 
factor in recent HCV infections at dialysis units in Kosovo. Nevertheless, the 
unadjusted Poisson analysis for dialysis patients in Kosovo revealed blood transfusion 
as one of the factors associated with anti-HCV positivity. In addition, both unadjusted 
and adjusted Poisson analyses revealed blood transfusion as one of the significant 
factors associated with anti-HCV positivity among dialysis patients at Prishtina dialysis 
center.  Therefore, this issue needs to be further investigated. 
 
Exploring data on the management of dialysis centers, a number of issues could be seen 
as contributing to high levels of HCV infection at dialysis units in Kosovo. 
 
Staffing is one of the issues. It is an important issue because it is directly related to the 
quality of service provision at dialysis units (110). It was observed that in almost all 
dialysis centers of Kosovo the number of nephrologists (internal disease specialists with 
sub-specialty in nephrology) and nurses was lower than needed in comparison to the 
number of patients/dialysis. Nephrologists in Gjakova, Mitrovica, Peja, and Ferizaj are 
not full-time engaged only at hemodialysis units but they also have to work at other 
internal disease units of the regional hospitals. While in Croatia the regulations for 
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management of dialysis units require having one doctor per 35 dialysis patients (or for 
10–12 dialyses per day), and one nurse per 4 dialysis patients, in Kosovo there is one 
doctor on average per 43 patients (or one doctor per 20 dialyses per day) and 5.5 
dialysis patients per one nurse (111). In addition, there is no infection control nurse and 
renal dialysis technician as working positions in either of the dialysis centers of Kosovo 
(112).  
 
Additionally, sufficient working premises are lacking in dialysis centers and, 
consequently, in a number of them anti-HCV positive and HBsAg positive patients are 
located in the same room with anti-HCV and HBsAg negative patients. An exception to 
this situation is Prishtina dialysis center since it is currently located in the totally new 
premises with sufficient space and staff allocations for HBsAg and anti-HCV positive 
patients.  
 
In most centers in Kosovo, new dialysis patients do not have anti-HCV test results prior 
to admission for dialysis. In those centers where anti-HCV results are available at the 
admission of patients, the quality of testing is unknown. Again, an exception is the 
dialysis center of Prishtina, since in the past the anti-HCV testing was provided to this 
center by the National Centre for Blood Transfusion, located just a few meters from 
Prishtina dialysis center.  Furthermore, in recent years the anti-HCV testing has been 
provided to Prishtina dialysis center by the Department of Microbiology at the National 
Institute of Public Health of Kosovo, again located approximately 100 meters from the 
Prishtina dialysis center.  
 
The disinfection materials were not available at all times during a daily work in some 
dialysis centers (e.g. Gjakova, Prizren, and Gjilan) and when they were available, their 
content (type and concentration) was unknown. There was no written protocol for 
disinfection at dialysis units. It is well known that HCV can remain viable in the 
environment (on equipment, clothing, etc.) for at least 16 hours (113). A more recent 
study found that HCV could maintain infectivity for up to 6 weeks at 4°C and 22°C 
(114). This means that an accidental contact with HCV-contaminated fomites and other 
hospital equipment could be linked with health care associated HCV infections even 
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after prolonged periods following their deposition. Moreover, the HCV infectivity is 
influenced by HCV viral titer, temperature and humidity of the environment. It is 
already known that commercially available antiseptics can reduce the infectivity of 
HCV on surfaces only when used at the recommended concentrations but not when 
further diluted (115, 116).   
 
Most dialysis patients in Kosovo in this study were either unemployed or retired, 
meaning they are a vulnerable group of population also from economic and social 
aspect. The study results showed that dialysis patients did not have accurate knowledge 
about their anti-HCV status or they were reluctant to present verbally their serostatus to 
study investigators. Multivariable analysis among Prishtina dialysis patients revealed 
that lack of knowledge about HCV was significantly associated with anti-HCV 
positivity. In direct interviews with patients, we observed that dialysis patients were 
very much concerned about the risks of HCV infection at dialysis units but since they 
depended on dialysis service, they did not have sufficient 'courage' to bring this issue 
forward to managers of dialysis units or higher health authorities in Kosovo.  
 
Other possible factors, such as possible transmission among family members, surgical 
and dental interventions, tattoos, injecting drugs, piercing, using others' shaving kits, 
imprisonment and having hemophilia, were not found to have played any role in the 
transmission of HCV at dialysis centers of Kosovo. 
 
As for the treatment of HCV infection, only 7.4% of anti-HCV positive dialysis patients 
received treatment. In this group, 66.6% completed the entire course of treatment, which 
is still based only on administration of pegylated interferon and ribavirin. Direct acting 
antivirals for HCV treatment are not available through public health system in Kosovo.  
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6.2 HCV infection among injecting drug users in Prishtina  
 
6.2.1 Anti-HCV prevalence, HCV genotypes and phylogenetic analysis 
 
Almost half (48.3%) of the IDUs in Prishtina Region of Kosovo had antibodies against 
HCV in this study. On the other hand, a situation with HIV infection in this group is 
very good since there were no HIV positive cases, the presence of antibodies against 
Treponema pallidum (cause of syphilis) was very low (2%), and the prevalence of 
HBsAg was 8.8%.   
 
IDUs are the group of population which is affected in high prevalence with HCV 
infection. This problem is especially evident in Eastern and South-Eastern Europe 
where the rate of injecting drug use is almost five times higher than global average 
(117).  
 
HCV antibody levels among national samples of IDUs in 2011–2012 varied from 19 to 
84%, among seven of the 11 European countries with national data reporting a 
prevalence rate over 50% (118).  
 
According to the European Monitoring Center for Drugs and Drug Addiction, report 
from 2016 among European countries with national trend data (2008–2014), statistically 
significant (p<0.05) increases of HCV infection were reported in the following five 
countries: Greece, Latvia, Hungary, Slovenia, and Turkey (119).  
 
High prevalence of HCV infection among IDUs is also present in the countries 
neighboring to Kosovo. The 2014 bio-behavioral study among IDUs in Skopje, 
Macedonia, found that 289 out of 401 IDUs tested had the presence of antibodies 
against HCV, resulting in anti-HCV prevalence of 72.1% (120). According to the 
Behavioral and Biological Surveillance study in Albania conducted in 2011, the 
prevalence of anti-HCV among 200 IDUs in Tirana was estimated to be 28.8% (121). In 
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Serbia, the second cycle of integrated cross-sectional bio-behavioral surveillance survey 
was carried in 2010 among IDUs using respondent-driven sampling methodology. A 
total of 571 IDUs were included in the survey (371 in Belgrade and 200 in Niš). The 
prevalence of hepatitis C infection was 77.4 % in Belgrade and 60.5 % in Niš (122). A 
Behavioral and Biological Surveillance study among IDUs in Bosnia and Herzegovina 
from 2012 revealed anti-HCV prevalence of 43.4% among IDUs in Sarajevo, 22.5% in 
Zenica, 34.9% in Banja Luka, 43.4% in Mostar, and 12% in Bijeljina, with an average 
of 31.2% for the entire Bosnia and Herzegovina (123). A bio-behavioral survey using 
respondent-driven sampling (RDS) in IDUs was conducted in Podgorica, Montenegro, 
in 2013. A total of 402 IDUs were recruited. According to results of that study, HIV 
prevalence was 1.1%, while the prevalence of HCV and HBsAg was 53% and 1.4%, 
respectively (124). 
 
In addition to European countries, and Kosovo neighboring countries specifically, high 
prevalences of HCV infection are recorded worldwide.  
 
A study by Li et al. conducted in a China-Myanmar border city in 2012 found anti-HCV 
prevalence to be 41.5% among 370 recruited IDUs. Participants with HCV infection 
were more likely to be HIV positive, have injected more types of drugs, have shared 
other injection equipment and have unprotected sex with regular sex partners (125).  
 
A respondent-driven sampling (RDS) study was conducted during the period January–
December 2013 among 14,481 IDUs in 15 cities from 11 states in India. Overall 
weighted anti-HCV prevalence was 37.2%. Correlates of HCV infection included 
higher lifetime injection frequency, HIV positivity, and a higher prevalence of persons 
with HIV RNA > 1,000 copies/ml in the community (126).  
 
Among the 407 recruited IDUs in Ottawa, Canada, through a chain-referral method 
(behavioral-biological surveillance study), the HCV prevalence was 60.6% (127).  
 
In addition to showing the prevalence of antibodies to HCV, the present study, for the 
first time in Kosovo and also in the neighboring countries including the Behavioral and 
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Biological Surveillance studies among IDUs, provides information on the distribution of 
HCV genotypes among IDUs and their clustering through phylogenetic analysis.  
 
Almost 2/3 (64.3%) of isolated HCV genotypes in this study belonged to subtype 1a, 
followed by 1/3 (34.3%) belonging to subtype 3a, and only one isolate (1.4%) was 
identified as HCV subtype 2k. There were no other HCV genotypes isolated among 
IDUs in Prishtina Region of Kosovo during the study. Since these are the first data on 
the distribution of HCV genotypes among IDUs in Kosovo, we are not in the position to 
compare data with other in-country similar studies. Nevertheless, it is interesting to 
compare HCV genotypes distributed among IDUs with HCV genotypes among HCV 
positive patients at dialysis units of Kosovo in 2013, among whom also HCV subtype 
1a was more present (with 2/3), followed by subtype 4d (1/3), subtype 1b (3.18%), and 
only one sample with genotype 2 (0.64%). There was no HCV subtype 3a isolated 
among dialysis patients in Kosovo. In addition, among 29 chronic HCV patients at the 
Infectious Disease of the University Clinical Center, Prishtina, Kosovo, in the period 
2012–2013, 44.8% (13/29) had HCV subtype 1b, 27.6% (8/29) subtype 1a, and 13.8% 
(4/29) subtypes 3a and 4d. Among six HCV positive samples taken from blood donors 
in Prishtina, Kosovo, for which HCV genotype was determined, four (66.7%) had HCV 
subtype 1b, and the remaining two (33.3) had subtype 1a.  
 
The study results did not find any significant difference in HCV genotype distribution 
among IDUs in Prishtina Region in relation to drug use and sexual practices. 
 
Many studies worldwide on HCV genotype distribution among IDUs have shown 
subtypes 1a and 3a to be most prevalent.  
 
The molecular epidemiology of HCV was studied among 108 IDUs (who also had HIV 
infection) from 7 European countries (Austria, Italy, the Netherlands, Scotland, Spain, 
Switzerland, and France) by van Asten et al. The most prevalent HCV subtypes were 1a 
(36%) and 3a (33%), but the percentage of genotype 4 was also relatively high, ranging 
from 7% in northern Europe to 24% in southern Europe (78). The distribution of HCV 
genotypes among IDUs in Albania showed that HCV genotype 3 was predominant 
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(85.7%), followed by genotype 1 (9.5%) (128). Genotype 3a was the most prevalent 
type among IDUs in Bulgaria (129). Among IDUs in Hungary, HCV genotype 1 was 
most prevalent with 74.2%, followed by subtype 3a with 22.7%, and genotype 4 with 
3%. This genotype distribution among IDUs was different from the one from general 
population in which HCV subtype 1b is more prevalent and subtype 3a is rarely seen 
(130). The molecular epidemiology study of HCV isolates in Lisbon, Portugal, obtained 
from 124 individuals with HCV presence belonging to IDUs showed that the most 
prevalent subtypes were 1a and 3a; however, genotype 4 viruses (subtypes 4a and 4d) 
were present among 24.6% of IDUs (131).  
 
HCV subtype 1a was most prevalent among 407 IDUs of Ottawa, Canada, with 65.9%, 
followed by subtype 3a (22.5%), 1b and 2b (both with 4.9%), and subtype 2a with 1.6% 
(127).  
 
As part of a comprehensive health care program for people who use drugs in Nepal, 
among 401 IDUs in three regions of Nepal, HCV genotypes were determined in 164 of 
the 168 HCV-RNA positive participants. Out of this number, 66 had HCV genotype 1 
(40.2%) and 98 had genotype 3 (59.8%) (132). 
 
The most prevalent HCV genotypes among IDUs in Croatia are subtype 3a (60.5%) and 
1a (23.7%) (133). 
 
Phylogenetic analysis of HCV subtypes 1a and 3a obtained from IDUs in Prishtina 
Region has revealed significant clustering of samples. High degree phylogenetic 
clustering of HCV subtypes 1a (66.7%) and 3a (71.4%) isolates among IDUs in 
Prishtina Region indicates that many HCV infections originate within networks of this 
group. The fact that this study was implemented using respondent-driven sampling 
could also have contributed to this high percentage of HCV clustering. 
 
Since we have not been in the position to find similar HCV phylogenetic clustering 
information from respondent-driven sampling in the region, a comparison with similar 
studies worldwide has been made.  
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In a study by Jacka et al., among 501 IDUs with HCV subtypes 1a and 3a in Vancouver, 
Canada, 31% (n=156) were in pairs/clusters. This was a longstanding longitudinal 
prospective study covering the period 1996–2012. Factors independently associated 
with phylogenetic clustering included: age <40, human immunodeficiency virus (HIV) 
infection, HCV seroconversion, and recent syringe borrowing (134).  
 
A study by Pilon et al., among 407 recruited IDUs in Ottawa, Canada, found that 38% 
of HCV sequences obtained were associated with clusters. According to the same study, 
the most susceptible IDUs (most at risk by behavior) would have been exposed and 
infected very early in their injecting history leading to the relatively low level of HCV 
phylogenetic clustering observed in the study (124).  
 
According to a longitudinal study by Sacks-Davis et al., with data collected between 
July 2005 and August 2008 in Melbourne, Australia, newly acquired infections (primary 
and reinfection) and new viral strains are more than twice as likely to be in phylogenetic 
clusters than infections present at enrolment that are not classified as newly acquired 
(135).  
 
It needs to be emphasized that the goal of phylogenetic analysis of HCV isolates from 
IDUs in Prishtina Region of Kosovo was not to analyze factors associated with 
clustering. However, this component of analysis is recommended to be taken into 
consideration in further biological and behavioral surveillance studies with IDUs in 
Kosovo.   
 
The single nucleotide polymorphism (SNP) located on chromosome 19, rs12979860, 
located 3 kb upstream of interleukin 28B (IL28B) gene encoding interferon-λ3, has 
been found to be strongly associated with treatment-induced viral clearance in HCV 
infected patients with HCV genotype 1, and has also been found to be associated with a 
three-fold increase in spontaneous clearance of HCV infection independent of 
ethnic/racial background (136–137).  
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In this study, we found that among anti-HCV positive IDUs who were HCV RNA 
negative, the CC IL28B polymorphism was present among 58.6% of them and was 
higher than CT and TT genotype. Among anti-HCV positive IDUs with the presence of 
HCV RNA, the CC IL28B was also higher (43.5%) compared to CT or TT. This 
frequency is in line with the European pattern of this allele distribution (138). However, 
differences in the prevalence of IL28B polymorphism among anti-HCV positive IDUs 
in Prishtina, Kosovo, were not significant, being either HCV RNA positive or negative, 
and between the ones infected with either HCV subtypes 1a or 3a. 
 
 
6.2.2 Factors contributing to HCV spreading among IDUs  
 
Results of this study showed that IDUs of older age had the highest anti-HCV 
prevalence. This is probably due to the fact that older IDUs were injecting drugs for a 
longer period of time and had a higher frequency of drug injection; both of those drug 
use practices were shown to be significant factors for anti-HCV positivity. On the other 
hand, the lowest (24.3%) anti-HCV prevalence was observed among younger IDUs, 
which could be seen as a window of opportunity for prevention of HCV spreading 
among younger IDUs if harm reduction activities are to be implemented. In the 
BIOBSS study on IDUs conducted in Skopje, Macedonia, just like in the Kosovo study, 
specific prevalence by age groups indicated that the risk of HCV infection increases 
with age, where in those aged 18–24 years, the prevalence of HCV was 47.1% 
compared to the age group of 35–39 where the prevalence was 83.6%, and the age 
group of 40–49 years, where the prevalence was 85.9% (120). Similar findings were 
found also in Podgorica, in the Montenegro study with IDUs, where HCV prevalence 
was 31.5% in those younger than 25 years of age and 57.4% among those older than 26 
years (124).   
 
In addition to age and duration of drug use, IDUs with lower level of education and 
those ever imprisoned in their lifetime had more chances to be HCV infected. Having 
lower level of education means also limited opportunities for employment for this group 
of IDUs, and if we add to this a high unemployment rate among general population of 
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Kosovo, it makes this situation even worse for IDUs. It is well known that sharing drug 
injecting equipment, and the associated social and economic situation, are factors that 
contribute to HCV transmission among IDUs (139-141).  
 
The issue of imprisonment and HCV infection has to be further investigated in order to 
gain more information if this is related to drug use inside the prison system or increased 
possibilities for imprisonment due to longer drug use and out of law behavior related to 
drug use.  
 
Study results highlighted the importance the so-called ‘shooting galleries’ have on the 
transmission of HCV infection among IDUs. Anti-HCV positive IDUs who were 
injecting drugs in shooting galleries or other places where IDUs gather were statistically 
significantly more numerous than HCV negative IDUs. It is well known that 
contaminated needles are not the only vehicle for blood-borne HCV transmission; the 
virus remains infective in a liquid, syringes, and on inanimate surfaces for weeks (142, 
143). Therefore, injecting at shooting galleries is often associated with an increased risk 
of infection by blood-borne pathogens (144–146). 
 
Results of this study showed that almost all IDUs reported using a sterile needle/syringe 
for drug injection. On the other hand, 92.6% of IDUs reported that somebody else used 
their needle/syringe. This is an interesting finding since 79.9% of IDUs reported that 
they always (in 100% of drug injections) used a sterile needle/syringe. This could imply 
that the study missed most IDUs injecting drugs with already used needles/syringes or it 
could indicate that IDUs participating in the study were not giving true information. The 
latter could have some rationale based on the fact that most study participants used 
harm reduction services from the NGO Labyrinth, staff of which organization 
conducted the interviews, and IDUs would not like to be seen in front of them as they 
are not following their instructions. Compared to other similar studies in which 
needle/syringe sharing has been associated with a higher risk for HCV infection, in the 
present study this type of drug use pattern did not show any significant difference 
between anti-HCV positive and anti-HCV negative IDUs. For example, in a study by 
Hagan et al., any syringe sharing has been associated with a 3-fold higher risk of HCV 
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infection (145). Needle sharing frequency has been the most important risk factor for 
hepatitis C among IDUs in Croatia. The HCV seroprevalence rate has ranged from 
27.3% in IDUs who answered that they shared needles occasionally to 100% in IDUs 
who always shared needles (p<0.001) (147).  
 
Almost all IDUs reported buying sterile needles/syringes from pharmacies and 2/3 of 
IDUs reported receiving sterile/needles from NGOs, this last figure being significantly 
higher than observed for anti-HCV positive IDUs. In Tallinn, Estonia, those IDUs using 
pharmacies as the main source of sterile needles were shown to have lower odds for 
being infected with HCV, and pharmacy users were more likely to have a regular or 
temporary employment, and were also more likely to have health insurance compared to 
IDUs using NGOs needle/syringe exchange program (148). Considering the fact that 
70% of IDUs in the present study were unemployed, buying sterile needles/syringes for 
this group of people is a real challenge; therefore, a needle/syringe exchange program 
implemented through organizations working on harm reduction is highly important. In 
fact, the needle/syringe exchange program and opioid substitution treatment (OST) 
should be the core interventions for prevention and control of infectious diseases among 
IDUs.  
 
Unfortunately, the harm reduction program for IDUs in Kosovo is limited in its 
experience and scope of coverage. The needle and syringe exchange program was 
initiated in 2009 through a local non-governmental organization Labyrinth by drop-in 
center in Prishtina, followed by two other similar centers in Prizren (second largest 
region in Kosovo) and Gjilan. In 2010, approximately 45,000 needles/syringes were 
distributed by the Labyrinth (149). The average number of needles/syringes distributed 
yearly per injecting drug user through a specialized program was five in the period 
2011/2012. On the other hand, coverage with opioid substitution treatment (with 
methadone) was only 2.1% of IDUs in 2012, when OST was initiated (150).  
 
If we wanted to estimate the number of needed sterile needles/syringes for IDUs, this 
could be calculated based on the number of IDUs in Kosovo (which is approx. 3,000–
5,000) and the number of injections per specific period of time. Based on the data from 
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the present study, approximately half of the IDUs injected drugs at a frequency once a 
day. If we take the number of 3,000 IDUs living in Kosovo (which is the lowest 
estimated number), then we arrive at the number of 547,500 needles/syringes needed for 
one year in case we wanted to cover 100% injections with sterile needles/syringes. The 
average frequency of drug injections for the second half of IDUs in this study was four 
times per month; therefore, similar calculations as above would give us a number of 
72,000 needles/syringes. The total estimated number of needed sterile needles/syringes, 
in order to be always used during each injection of drugs among the lowest estimated 
number of IDUs in Kosovo, per one year, would be 619,500.  
 
Unfortunately, there is no treatment program for HCV infected IDUs in Kosovo at this 
moment; therefore, there are no data on the relationship between IL28B polymorphism 
among IDUs and their treatment outcome. Implementing the HCV treatment program 
for HCV infected IDUs in Kosovo would be a highly challenging activity considering 
the limited financial resources within the health system of Kosovo and the issues related 
to IDUs, such as socio-economic and living conditions, stigmatization and 
marginalization.  
 
Nevertheless, some studies suggest that treatment of chronic HCV infection in the 
current and former IDUs could be successful, and additional benefits of such a treatment 
delivered in a community-based, multidisciplinary, primary care model may extend 
beyond narrowly defined virological outcomes (151).  
 
Some HCV treatment programs among IDUs have shown that the HCV treatment is not 
associated with drug use or used needle and syringe borrowing during follow-up, but is 
associated with decreased ancillary injecting equipment sharing (152).  
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6.3 HCV infection among chronic patients and blood donors in 
Prishtina 
 
6.3.1 HCV genotypes and phylogenetic analysis among chronic HCV patients and 
blood donors 
 
Results of this study showed that the most prevalent HCV genotype among chronic 
HCV patients in Kosovo was subtype 1b with 41.9%, followed by subtype 1a with 
25.8%, and by subtypes 3a and 4d with 12.9% each. Similarly, HCV subtype 1b was 
most prevalent among blood donors with 66.6%, followed by subtype 1a with 33.3%. 
This could indicate that, among general population infected with HCV in Kosovo who 
do not belong to dialysis patients or drug users, the most common is HCV genotype 1 
(67.7% among HCV chronic patients and 100% among blood donors), with HCV 
subtype 1b being more present. To this contributes also the fact that among chronic 
HCV patients from Infectious Disease Clinic, University Clinical Center of Kosovo, at 
the time of this study implementation, there was a small portion of dialysis patients and 
IDUs. This finding is similar to the HCV genotype distribution in Europe, estimated to 
have predominant HCV genotype 1 (64.4%), followed by genotype 3 (25.5%), genotype 
2 (5.5%), and genotype 4 (3.7%) (153).  
 
Through cladogram phylogenetic trees of HCV subtypes 1a, 1b, 3a and 4d, it was 
possible to notice that most sample sequences from the study chronic HCV patients and 
blood donors were not clustered with each other, with a few minor exceptions of limited 
number of samples included in clusters with dialysis patients or IDUs, which could 
indicate that those chronic HCV patients were either dialysis patients or IDUs. 
 
 
6.3.2 Factors contributing to HCV spreading  
 
Since most chronic HCV patients denied having any risk factor attributable to HCV 
infection (excluding ear piercing, which is very common among females in Kosovo), 
were not utilizing dialysis services, or did not have any family members living with 
 - 117 - 
HCV, then it could be speculated that most probably they could have been infected 
through medical interventions such as surgical or dental services, since 71–85% of 
chronic HCV patients used those services.   
 
The HCV treatment program with pegylated interferon and ribavirin started in Kosovo 
in 2011, with very limited number of HCV patients enrolled per year. In fact, for many 
years, worldwide, pegylated interferon and ribavirin have been the main drugs for 
treatment of HCV infection. Through administration of pegylated interferon-alpha 
combined with ribavirin in the treatment of chronic hepatitis C among patients with 
genotypes 1 up to 46% of patients’ experienced sustained virological response, and 
those infected with HCV genotype 2 and 3 experienced even higher responses, with 
rates in excess of 80% (154). 
 
The HCV treatment program at the Infectious Disease Clinic, UCCK, Prishtina, is 
funded by the public funds of Kosovo and is free of charge. Unfortunately, there are no 
published data on treatment success or HCV genotype distribution among this group of 
patients in Kosovo. Results of this study showed that the CC genotype was present 
among 38% of chronic HCV patients in Kosovo. Unfortunately, during the study, we 
did not have the opportunity to cross-check the presence of CC genotype among chronic 
HCV patients with treatment induced viral clearance or spontaneous clearance of HCV 
infection due to lack of data from the Infectious Disease Clinic, UCCK. Furthermore, 
due to insufficient volume of samples (and due to frequent handling of samples), we 
were not in the position to measure the viral load of those patients enrolled in the study.  
 
DAAs are not available yet through public HCV treatment program in Kosovo (not part 
of essential list of drugs of public health system) due to high costs of these drugs and a 
limited budget for pharmaceuticals within the budget of the Ministry of Health.  
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7. Conclusion 
 
This study, for the first time in Kosovo, provides comprehensive data on HCV 
prevalence among dialysis patients and IDUs, combined with HCV genotype 
distribution among these groups of population, adding genotype information of chronic 
HCV patients and blood donors, and their genetic relatedness of HCV isolates through 
phylogenetic analyses and socio-demographic data. 
 
The study reveals that most prevalent HCV genotype among all studied groups (dialysis 
patients in Prishtina and overall in Kosovo, IDUs, chronic HCV patients and blood 
donors) is genotype 1, with subtype 1a being most prevalent among dialysis patients 
and IDUs, and subtype 1b being most prevalent among chronic HCV patients and blood 
donors. HCV subtype 3a is the second most prevalent among IDUs and it is not found 
among dialysis patients or blood donors. The subtype 4d is the second most prevalent 
among dialysis patients in Prishtina and overall in Kosovo, and this subtype is not found 
among IDUs or blood donors. 
 
The phylogenetic trees of HCV subtypes 1a, 1b, 3a, and 4d developed from sample 
sequences of studied groups have provided a significant number of phylogenetic 
clusters, which are mainly related to specific dialysis centers or drug injection.  
 
 
7.1 Hemodialysis 
 
This study highlights high levels of HCV infection at dialysis units in Prishtina and 
overall of Kosovo. Different percentages of anti-HCV prevalence and specific HCV 
subtype distribution in regional dialysis centers of Kosovo, genetic relatedness of HCV 
isolates presented in phylogenetic clusters according to subtype and dialysis centers, 
association of HCV infection with age of dialysis patients, duration of dialysis, change 
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of dialysis centers and blood transfusion, are strong indicators of large HCV 
transmission at dialysis centers of Kosovo.  
 
Prishtina dialysis center is the largest dialysis center in Kosovo, and at the same time 
has the lowest prevalence (22%) of anti-HCV positivity among its patients. This 
situation is probably due to the fact that this dialysis center has larger premises, with 
structural division of these premises and staff specifically for HbsAg and anti-HCV 
positive patients.  Furthermore, being located inside the capital of the country and being 
part of the University Clinical Center of Kosovo, it has possibilities to have better 
access to decision makers, financial and human resources as well as medical and 
laboratory services. 
 
HCV subtypes 1a and 4d are most prevalent among dialysis patients in Prishtina, with 
subtype 1a being very slightly higher. Longer history of dialysis is also one of the main 
factors associated with anti-HCV positivity, similar to all dialysis patients in Kosovo; 
nevertheless, blood transfusion, age and having less knowledge about HCV have been 
shown as factors associated with anti-HCV positivity among dialysis patients in 
Prishtina.  
 
High level of anti-HCV prevalence among dialysis patients in Kosovo in this study is an 
indicator that factors that have impacted decrease of HCV infection at dialysis units in 
Europe and other developed countries in the 1990s have not been implemented entirely 
and/or properly even to date. In contrast to most European countries that have achieved 
to decrease infection with HCV at dialysis units over the past 20–25 years, Kosovo has 
failed in this endeavor. Infection control practices are very much limited at dialysis units 
of Kosovo, the staff, especially nurses, are not educated on infection prevention 
practices. There is lack of laboratory support with regard to HCV testing of patients 
undergoing dialysis, and the one which is provided is not offered at the time needed or 
lacks information on quality control. Except for Prishtina, other dialysis units are 
suffering from lack of sufficient premises and continual supply with daily consumables 
that would be needed for infection prevention. Lack of sufficient number of 
nephrologists, especially in Mitrovica, Gjakova, Ferizaj and Peja, is another important 
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pitfall in this system. Many dialysis patients are not aware of their anti-HCV status and, 
generally, of their rights as patients. Currently, there is a very small percentage of HCV 
infected dialysis patients within the treatment program, which is provided for a limited 
number of people free of charge by the Ministry of Health. 
 
This situation makes as imperative the development and implementation of a special 
HCV prevention and treatment program for dialysis patients in Kosovo. In order to 
initiate the HCV prevention program at dialysis units of Kosovo, including Prishtina 
dialysis center, the following steps could be recommended to be undertaken by the 
Ministry of Health, Hospital and University Service of Kosovo (University Clinical 
Center of Kosovo in Prishtina and Regional Hospital where dialysis centers are placed): 
 
- Infection control practices should be established and strongly implemented in 
all dialysis centers of Kosovo; dialysis staff has to be trained on the 
appropriate infection control practices; sufficient quantities of needed 
consumables should be made available at all times at dialysis units;  
- Regular and timely screening for the presence of antibodies against HCV 
should be available at all times and in all regions of Kosovo. In addition, 
qualitative RT-PCR testing should be introduced in order to detect HCV 
infected cases in which anti-HCV testing would result in a negative test result 
due to initial stage of infection;  
- Sufficient number of health staff should be employed, especially specialists in 
nephrology in Gjakova, Mitrovica, Ferizaj and Peja; 
- There should be infrastructural investments by the government in building 
appropriate and sufficient hemodialysis premises in Kosovo;  
- In addition, the possibility of introducing peritoneal dialysis should be 
investigated;  
- Special attention should be given to education of dialysis patients on HCV 
infection prevention and their rights as patients;  
- The HCV treatment program of Kosovo should expand and include HCV 
positive dialysis patients within the program;  
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- The blood transfusion service should screen donated blood with qualitative 
molecular tests for HCV, replacing current serological testing based on 
antigen/antibody detection, in order to prevent possible transmission of HCV 
to dialysis patients through blood transfusion.  
 
Implementation of these recommendations would require the development of a more 
detailed action plan, with specific timeframe, people to be engaged, and sufficient 
budget. Even in the best case scenario of implementation of above mentioned 
recommendations, it would take considerable time to improve the situation. 
Nevertheless, Kosovo should address this serious health problem, which in fact should 
be one of the main priorities of the health system in Kosovo. Further delays would 
result in additional HCV infections in dialysis patients, increased morbidity and 
mortality among dialysis patients, and increased HCV transmission risk.  
 
 
7.2. Injecting drug users 
 
Almost half of the IDUs in Prishtina Region of Kosovo are infected with HCV. This 
prevalence is within the estimated global HCV prevalence among IDUs. Age of IDUs, 
having longer history of drug injection, lower level of education, drug injection in so-
called ‘shooting galleries’, and ever being in prison are shown to be the main predictors 
of HCV infection among IDUs in Prishtina study. 
 
While HCV subtype 1a is present also among other groups of population with HCV 
infection in Kosovo, genotype 3a is currently associated only with drug use. High 
percentages of HCV isolates from IDUs belonging to either HCV subtypes 1a or 3a 
have shown phylogenetic clustering presenting information on HCV transmission 
within the community of IDUs who live/inject drugs in Prishtina. 
 
Among IDUs who are anti-HCV positive and HCV RNA negative, almost 2/3 have 
presented with IL28B polymorphism CC. In addition, less than half of anti-HCV 
positive IDUs with HCV RNA presence have CC genotype of IL28B polymorphism, 
which in case of inclusion in the current HCV treatment program (with pegylated 
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interferferon and ribavirin) could lead to rapid and sustained virological response and 
impact decreased possibilities of HCV transmission.  
 
In order to prevent further spreading of HCV infection among IDUs in Prishtina and 
overall in Kosovo, there is a need for implementation of a harm reduction program, with 
sufficient quality and scope of coverage, which should include needle exchange 
program, methadone maintenance program and peer education through outreach work. 
Since ‘shooting galleries’ have been shown as one of the sites that contribute to the 
spread of HCV infection, these locations should be targeted as a priority. There should 
be a special focus of HCV prevention activities among younger IDUs, since they have a 
lower rate of HCV infection compared to older groups of IDUs, and this could present a 
window of opportunity. The treatment of HCV infection among IDUs in Kosovo is an 
activity that should be taken into consideration since, in addition to possible health 
benefits from virus clearance, it is also one of the main components of prevention of 
HCV spreading.  
 
  
7.3 Chronic HCV patients and blood donors 
 
The HCV treatment program within the public health system provides treatment to a 
low number of chronic HCV patients due to limited budget. Current treatment protocols 
are based only on pegylated interferon and ribavirin, since DAAs are not available 
through public health funds. Different to dialysis patients and IDUs, HCV subtype 1b is 
shown to be most present among chronic HCV patients and blood donors, providing the 
basis for possibilities of having this genotype more present among general population. 
Since most chronic HCV patients and blood donors deny having any high risk behavior 
that could result in HCV infection, the most possible route of infection could be 
considered to be a medical intervention (mainly dental or surgical). This situation brings 
to attention once again the importance of strict adherence to aseptic techniques in the 
provision of medical services that could pose a risk in transmission of blood-borne 
pathogens.  
 
The Kosovo health system should include into the HCV treatment program the 
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availability of DAAs and should expand in scope of coverage with inclusion of a larger 
number of chronic HCV patients, anti-HCV positive dialysis patients and IDUs.  
 
The WHO Global Health Sector Strategy on viral hepatitis 2016–2021 aims to 
contribute to elimination of viral hepatitis (including HCV) as a major public health 
issue by 2030 through 90% reduction of new infections, 100% of blood donations 
screened in quality assured manner, 90% of injections administered safely, 300 sterile 
needles and syringes provided to each IDU per year, 90% of diagnosed HCV infections 
and 80% of HCV infections treated. The Kosovo health system needs to make 
tremendous efforts in achieving these targets. Nevertheless, with higher commitment of 
health staff, sufficient support from key governmental stakeholders, and involvement of 
positive HCV patients through non-governmental organizations, this situation could be 
improved with activities primarily targeting dialysis patients and IDUs.  
 
 - 124 - 
 
8. Abstract in Croatian 
 
Molekularna epidemiologija HCV-a u Regiji Priština na Kosovu, Xhevat Jakupi, 2018 
 
Cilj: Utvrditi genetsku raznolikost HCV-a među različitim skupinama populacije u  
Prištini, na Kosovu. 
Metode: Učinjena je genotipizacija i sekvenciranje HCV-a na anti-HCV pozitivnim 
uzorcima krvi bolesnika na hemodijalizi, korisnicima droga injektiranjem, darivatelja 
krvi i kroničnih pacijenata zaraženih virusom hepatitisa C. Za bolje razumijevanje 
čimbenika povezanih s HCV infekcijom, korišteni su intervjui kod svih ispitivanih 
skupina.   
Rezultati: Pozitivni anti-HCV nalazi dobiveni su kod 22% bolesnika na hemodijalizi u 
Prištini,  kao prosjek u 53% bolesnika u centrima za hemodijalizu na Kosovu, kao i kod 
48% korisnika droga injektiranjem. HCV genotip 1a bio je najzastupljeniji kod 
bolesnika na hemodijalizi u Prištini (47%) i sveukupno na Kosovu (62%) te među 
korisnicima droga injektiranjem (64%), dok je genotip 1b bio najzastupljeniji među 
kroničnim bolesnicima zaraženim virusom hepatitisa C (42%) i darivateljima krvi 
(67%). Drugi po redu najzastupljeniji genotipovi bili su 3a među korisnicima droga 
injektiranjem (34%) te 4d među bolesnicima na hemodijalizi u Prištini (44%) te 
sveukupno u centrima za hemodijalizu na Kosovu (33%). Filogenetska stabla HCV 
genotipova 1a, 1b, 3a i 4d pokazala su filogenetsko grupiranje uzoraka u klastere s 
obzirom na centre za hemodijalizu i korištenje droga. Dužina perioda na hemodijalizi i 
dobivanje hemodijalize u različitim centrima uočeni su kao čimbenici koji su povezani s 
anti-HCV pozitivnim nalazima među bolesnicima na hemodijalizi na Kosovu, dok su 
specifično za Prištinu, pored već spomenutih, ti čimbenici uključivali i transfuziju krvi, 
dob i znanje o HCV-u među bolesnicima na hemodijalizi, a među korisnicima droga 
injektiranjem to su bili dob, trajanje korištenja droga ubrizgivanjem, niža razina 
obrazovanja, ubrizgavanje droga u nadziranim prostorima (tzv. 'shooting galleries') te 
boravak u zatvoru. 
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Zaključak: Na Kosovu postoji visoka razina HCV infekcija u centru za hemodijalizu u 
Prištini i općenito u centrima za hemodijalizu na Kosovu te kod korisnika droga 
injektiranjem, a najzastupljeniji je HCV genotip 1a. Zbog ovakve situacije ponovno se 
naglašava potreba za strogim pridržavanjem mjera za suzbijanje HCV infekcije u 
centrima za hemodijalizu te provedbu aktivnosti za smanjivanje štete kod korisnika 
droga injektiranjem.    
Ključne riječi: HCV, prevalencija, genotip, hemodijaliza, korisnici droga injektiranjem. 
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9. Abstract in English  
 
Molecular epidemiology of HCV in Prishtina region of Kosovo, Xhevat Jakupi, 2018 
 
Aim: To determine genetic diversity of HCV among different population groups in 
Prishtina, Kosovo. 
Methods: Anti-HCV positive samples of dialysis patients, IDUs, blood donors, and 
chronic HCV patients were HCV genotyped and sequenced. To better understand the 
underlying conditions of HCV infection, interviews were used with all groups.  
Results: Anti-HCV positive findings were observed in 22% of dialysis patients in 
Prishtina, and as average among 53% of patients at dialysis centers of Kosovo, as well 
as in 48% of IDUs. HCV subtype 1a was most prevalent among dialysis patients in 
Prishtina (47%) and overall in Kosovo (62%), and among IDUs (64%), whereas 
genotype 1b was most prevalent among chronic HCV patients (42%) and blood donors 
(67%). The second most prevalent genotypes were 3a among IDUs (34%) and 4d 
among dialysis patients in Prishtina (44%) and overall at dialysis centers of Kosovo 
(33%). Phylogenetic trees of HCV subtypes 1a, 1b, 3a, and 4d showed phylogenetic 
clusters of samples related to dialysis centers or drug use. Duration of dialysis and 
receiving dialysis in different centers were factors associated with anti-HCV positivity 
among Kosovo dialysis patients, whereas specifically for Prishtina, in addition to the 
above, those factors included blood transfusion, age and knowledge about HCV among 
dialysis patients, while among IDUs those were age, duration of drug injection, lower 
educational level, drug injection in shooting galleries, and being in prison. 
Conclusion: High levels of HCV infection at dialysis center in Prishtina and overall at 
Kosovo dialysis centers and among IDUs are present in Kosovo, with HCV subtype 1a 
being most prevalent. This situation reiterates the need for strict adherence to infection 
control practices at dialysis centers and implementation of harm reduction activities 
among IDUs.    
Keywords: HCV, prevalence, genotype, dialysis, IDUs. 
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